Welcome!

Thank you for joining us in Chicago as we celebrate the Thirty Year Anniversary Meeting of the society!
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2500 members from over 45 countries, representing over 10 different disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include basic scientists, anesthesiologists, cardiologists, cardiothoracic surgeons, immunologists, ethicists, nurses, pharmacists, pathologists, perfusionists, pulmonologists, transplant coordinators and tissue engineers. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The Purposes of the Society Are:

To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences.

To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.

To hold scientific meetings featuring presentations and discussions relevant to these disciplines.

To sponsor a scientific journal for the publication of manuscripts related to these disciplines.

To establish and maintain an international registry for heart and lung transplantation.

To award research grants and establish endowments for the study of these disciplines.
SCIENTIFIC PROGRAM COMMITTEE

PROGRAM CHAIR: Hermann Reichenspurner, MD, PhD, University Heart Center Hamburg, Germany,

PRESIDENT: James K. Kirklin, MD, ISHLT President, University of Alabama at Birmingham, AL,

Allen S. Anderson, MD, University of Chicago Medical Center, Chicago, IL
Sharon A. Beer, RN, MSc, Queen Elizabeth Hospital, Birmingham, United Kingdom
Tuvia Ben Gal, MD, Rabin Medical Center, Petah Tikva, Israel
Gerald J. Berry, MD, Stanford University, Stanford, CA
Roberta C. Bogaev, MD, FACC, Texas Heart Institute, Houston, TX
John V. Conte, MD, Johns Hopkins Hospital, Baltimore, MD
John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Duane Davis, MD, Duke University Medical Center, Durham, NC
Daniel F. Dilling, MD, Loyola University Medical Center, Maywood, IL
Giuseppe G. Faggian, MD, University of Verona Medical School, Verona, Italy
Paul W. M. Fedak, MD, PhD, FRCSC, Foothills Medical Center, Calgary, Alberta, Canada
Andrew J. Fisher, FRCP, PhD, Institute of Cellular Medicine, Newcastle Upon Tyne, United Kingdom
Kimberly L. Gandy, MD, PhD, Children's Hospital of Wisconsin, Milwaukee, WI
Allan R. Glanville, MD, FRACP, St. Vincent's Hospital, Darlinghurst, NSW, Australia
Jan F. Gummert, MD, PhD, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany
Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland
Daphne T. Hsu, MD, Children's Hospital at Montefiore, Bronx, NY
Mandeep R. Mehra, MD, JHLT Editor, University of Maryland School of Medicine, Baltimore, MD
Bruno M. Meiser, MD, Herzchirurgische Klinik und Poliklinik, Munchen, Germany
Omar A. Minai, MD, Cleveland Clinic Foundation, Cleveland, OH
Martha L. Mooney, MD, Sentara Norfolk Transplant Center/ EVMS, Norfolk, VA
Michael G. Petty, PhD(c), RN, CCNS, CNS, University of Minnesota Medical Center, Minneapolis, MN
Richard N. Pierson, III, MD, University of Maryland, Baltimore, MD
Heather J. Ross, MD, MHSc, FRCP(c), Toronto General Hospital, Toronto, Ontario, Canada
Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Hamburg, Germany
Randall C. Starling, MD, MPH, The Cleveland Clinic Foundation, Cleveland, OH
Marc A. Stern, MD, Hopital Foch, Suresnes Cedex, France
David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH
Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
Florian M. Wagner, MD, University Hospital Eppendorf, Hamburg, Germany
Marian Zembala, MD, PhD, FESC, Silesian Medical School, Zabrze, Poland
**ABSTRACT REVIEWERS**

Dan Admon, MD, Hadassah University Hospital, Jerusalem, Israel  
Annalisa Angelini, MD, Universita Di Padova, Italy  
Selim M. Arcasoy, MD, Columbia University, New York, NY  
Abbas Ardehali, UCLA School of Medicine, Los Angeles, CA  
James B. Atkinson, MD, PhD, Vanderbilt University Medical Center, Nashville, TN  
Carla C. Baan, PhD, Erasmus MC, Rotterdam, The Netherlands  
David A. Baran, MD, Newark Beth Israel Medical Center, Newark, NJ  
Juergen Behr, MD, University of Munich, Germany  
Christian Benden, MD, University Hospital Zurich, Switzerland  
Alexandria Berg, RN, Children’s Healthcare of Atlanta, GA  
Sangeeta M. Bhorade, MD, University of Chicago, IL  
Emma Birks, MRCP, Harefield Hospital, Harefield, Middlesex, United Kingdom  
Annette Boehler, MD, University Hospital Zurich, Switzerland  
Michael Burch, MD, Great Ormond Street Hospital, London, United Kingdom  
Allen P. Burke, MD, University of Maryland Medical Center, Baltimore, MD  
Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA  
Paul Corris, MB FRCP, Freeman Hospital, Newcastle, United Kingdom  
Maria Rosa Costanzo, MD, FACC, FAHA, Midwest Heart Specialists, Naperville, IL  
Angelika Costard-Jaeckle, MD, University Heart Center Hamburg, Hamburg, Germany  
William G. Cotts, MD, Bluhm Cardiovascular Institute, Northwestern University, Chicago, IL  
Maria G. Crespo Leiro, MD, Unidad de Insuficiencia Cardiaca y Trasplante Cardiaco, La Coruna, Spain  
Lara Danziger-Isakov, MD, MPH, The Cleveland Clinic Foundation, Cleveland, OH  
Tobias Deuse, MD, PhD, University Heart Center Hamburg, Germany  
Annette DeVito Dabbs, RN, PhD, University of Pittsburgh School of Nursing, Pittsburgh, PA  
Fabienne Dobbe, MSc, PhD, University Hospital Leuven, Belgium  
Brooks S. Edwards, MD, Mayo Clinic, Rochester, MN  
Thomas M. Egan, MD, MSC, University of North Carolina School of Medicine, Chapel Hill, NC  
Howard Eisen, MD, Drexel University College of Medicine, Philadelphia, PA  
Aly El Banayosy, MD, Penn State Hershey Medical Center, Hershey, PA  
Okan Elidemir, MD, Texas Children's Hospital, Houston, TX  
Stephan Ensminger, MD, PhD, University of Erlangen-Nurnberg, Erlangen, Germany  
Michiel E. Erasmus, MD, PhD, University Medical Center Groningen, The Netherlands  
Roberto Fiocchi, MD, PhD, Ospedali Riuniti di Bergamo, Italy  
Michael C. Fishbein, MD, UCLA School of Medicine, Los Angeles, CA  
Juliet E. Foweraker, MD, PhD, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom  
Robert Franz, MD, Mayo Clinic, Rochester, MN  
Darren H. Freed, MD, PhD, FRCSC, St. Boniface General Hospital, Winnipeg, Manitoba, Canada  
James P. Gagermeier, MD, Loyola University Medical Center, Chicago, IL  
Edward Garrity, Jr., MD, University of Chicago Medical Center, Chicago, IL  
James F. George, PhD, University of Alabama at Birmingham, AL  
Reda Girgis, MB BCh, Johns Hopkins University, Baltimore, MD  
Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY  
Gonzalo V. Gonzalez-Stawinski, MD, The Cleveland Clinic Foundation, Cleveland, OH  
Kate Gould, FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom  
Cynthia Gries, MD, MSc, University of Washington, Seattle, WA  
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark  
Elizabeth Hammond, MD, LDS Hospital, Salt Lake City, UT  
Ari L. J. Harjula, MD, Helsinki University Central Hospital, Helsinki, Finland  
Ray E. Hershberger, MD, University of Miami Miller School of Medicine, Miami, FL  
Peter M. Hopkins, FRACP, The Prince Charles Hospital, Brisbane, Australia  
Evelyn Horn, MD, Well Cornell Medical Center, New York, NY  
Shahid Husain, MD, MS, Toronto General Hospital, Ontario, Canada  
Martin Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark  
Peter Jaksch, MD, General Hospital Vienna, Austria  
Robert Jaquiss, MD, Arkansas Children’s Hospital, Little Rock, AR  
Valluvan Jeevanandam, MD, University of Chicago Hospitals, Chicago, IL  
Annemarie Kaan, MCN, RN, St. Paul’s Hospital, Vancouver, British Columbia, Canada  
Walter G. Kao, MD, FACC, University of Wisconsin School of Medicine, Madison, WI  
Anne Keogh, MBBS, MD, St. Vincent’s Hospital, Sydney, Australia  
Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Ontario, Canada  
James K. Kirklin, MD, University of Alabama at Birmingham, AL  
Walter Kleperko, MD, University of Vienna, Austria  
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA  
Christiane Kugler, PhD, Hannover Medical School, Hannover, Germany  
Sudhir S. Kushwaha, MD, Mayo Clinic, Rochester, MN  
Hans B. Lehmkuhl, MD, Deutsches Herzzentrum Berlin, Germany
Pascal Leprince, MD, PhD, Hospital Pitie-Salpetriere
Deborah J. Levine, MD, University of Texas Health Science Center, San Antonio, TX
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Alfred Hospital, Melbourne, Australia
Katherine Lietz, MD, PhD, Yale University School of Medicine, New Haven, CT
Jane Maclver, RN, MSc, Toronto General Hospital, Toronto, Ontario, Canada
Donna M. Mancini, MD, New York Presbyterian Hospital, New York, NY
Charles C. Marboe, MD, College of Physicians & Surgeons, New York, NY
Sandra Martin, RN, MSN, University Hospital Leuven, Belgium
Stanley I. Martin, MD, Ohio State University Medical Center, Columbus, OH
Frauke Mattner, MD, Hannover Medical Center, Hannover, Germany
Kenneth McCurry, MD, Cleveland Clinic Foundation, Cleveland, OH
Keith McNeil, FRACP, Metro North Health Service District, Herston, Queensland, Australia
Federica Meloni, MD, PhD, University of Pavia, Italy
Carmelo Milano, MD, Duke University Medical Center, Durham, NC
Henrik Milting, PhD, Erich & Hanna Klessmann Institute, Bad Oeynhausen, Germany
Paul J. Mohacsi, MD, University Hospital, Berne, Switzerland
Jean-Francois Mornex, MD, Hospital Louis Pradel, Lyon, France
Michiel Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany
Jonathan B. Orens, MD, Johns Hopkins University, Baltimore, MD
Robert F. Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA
Elfriede Pahl Schuette, MD, Children's Memorial Hospital, Chicago, IL
Scott M. Palmer, MD, MHS, Duke University, Durham, NC
Myung H. Park, MD, University of Maryland School of Medicine, Baltimore, MD
Si M. Pham, MD, University of Miami/Jackson Memorial Hospital, Miami, FL
Sean P. Pinney, MD, Mount Sinai Medical Center, New York, NY
Christophe Pison, MSC, MD, PHD, CHU de Grenoble, France
Jeffrey L. Platt, MD, University of Michigan, Ann Arbor, MI
J. Eduardo Rame, MD, Penn Heart and Vascular Center, Philadelphia, PA
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Ontario, Canada
Olaf Reinhardt, MD, Stanford University, Stanford, CA
Mauro Rinaldi, MD, IRCCS Policlinico San Matteo, Torino, Italy
Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom
Stuart Russell, MD, Johns Hopkins Hospital, Baltimore, MD
Robert J. Schilz, MD, Case Western Reserve University, Cleveland, OH
Fernanda P. Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Ontario, Canada
Gregory I. Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia
Stuart C. Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO
Gabor B. Szabo, MD, PhD, University of Heidelberg, Germany
Jose Tallaj, MD, University of Alabama at Birmingham, AL
Henry D. Tazelaar, MD, Mayo Clinic, Scottsdale, AZ
Jeffrey J. Teuteberg, MD, University of Pittsburgh/Presbyterian, Pittsburgh, PA
Hendrik Treede, MD, University Heart Center Hamburg, Germany
Vincent G. Valentine, MD, University of Texas Medical Branch, Galveston, TX
Dirk Van Raemdonck, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
Johan Vanhaecke, MD, University Hospital Gasthuisberg, Leuven, Belgium
Erik A. M. Verschuuren, MD, PhD, University Medical Centre, Groningen, The Netherlands
Robert G. Weintraub, MB BS FRAC, Royal Children's Hospital, Parkville, Victoria, Australia
Richard D. Weisel, MD, Toronto General Hospital, Toronto, Ontario, Canada
Lori J. West, MD, DPhil, University of Alberta, Edmonton, Canada
Glen P. Westall, FRACP, PhD, Melbourne, Australia
Connie White-Williams, PhD, University of Alabama at Birmingham, AL
Gayle L. Winters, MD, Brigham & Women's Hospital, Boston, MA
Thorsten Wittwer, MD, PhD, MA, University Hospital of Cologne, Germany
Joseph Woo, MD, University of Pennsylvania Health System, Philadelphia, PA
Roger Yusen, MD, MPH, Washington University School of Medicine, St. Louis, MO
Michael Zakliczynski, MD, Silesian Centre for Heart Disease, Gliwice, Poland
Andreas O. Zuckermann, MD, University of Vienna, Austria
INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION
30th Anniversary Meeting and Scientific Sessions

SCIENTIFIC COUNCIL OPERATING BOARDS

HEART FAILURE AND TRANSPLANT MEDICINE
Maria G. Crespo-Leiro, MD, Chair
Allen Anderson, MD, FACC, Vice-Chair
Maria Rosa Costanzo, MD, Past-Chair
Nicholas R. Banner, FRCP, Standards and Guidelines Workforce Leader
Allen S. Anderson, MD, Education Workforce Leader
Mariano Feccia, MD, Registries and Databases Workforce Leader
David P. Nelson, MD, Communications Workforce Leader

MECHANICAL CIRCULATORY SUPPORT
Emma Birks, MRCP, PhD, Chair
Francis D. Pagani, MD, PhD, Vice-Chair
Stephanie A. Moore, MD, Standards and Guidelines Workforce Leader
Roberta C. Bogaev, MD, FACC, Education Workforce Leader
Jaap Lahpor, MD, PhD, Registries and Databases Workforce Leader
Evgenij V. Potapov, MD, Communications Workforce Leader
Mario C. Deng, MD, Development Liaison

INFECTIOUS DISEASES
Margaret M. Hannan, MD, Chair
Martha L. Mooney, MD, Vice-Chair
Shahid Husain, MD, MS, Past-Chair
Lara Danziger-Isakov, MD, MPH, Standards and Guidelines Workforce Leader
Martha L. Mooney, MD, Education Workforce Leader
Frauke Mattner, MD, Registries and Databases Workforce Leader
Vincent G. Valentine, MD, Communications Workforce Leader
Eric A. M. Verschuuren, MD, PhD, Development Liaison

NURSING, HEALTH SCIENCE AND ALLIED HEALTH
Connie White-Williams, MSN, Chair
Bernice L. Coleman, RN, PhD, Vice-Chair
Annette J. Devito Dabbs, RN, PhD, Past Chair
Michael G. Petty, PhD(c), RN, CCNS, CNS, Standards and Guidelines Workforce Leader
Sharon A. Beer, RN, MSN, Education Workforce Leader
Fabienne Dobbels, PhD, Registries and Databases Workforce Leader
Bronwyn J. Levey, RN, Grad Dip Clin Ep, Communications Workforce Leader
Judy A. Currey, PhD, Grants and Awards Workforce Leader
Kevin Carney, RN, CCTC, Development Liaison

PATHOLOGY AND BASIC SCIENCE
Stephan M. Ensinger, MD, PhD, Chair
Annalisa Angelini, MD, Vice Chair
E. Rene Rodriguez, MD, Past Chair
Carmela D. Tan, MD, Standards and Guidelines Workforce Leader
E. Rene Rodriguez, MD, Education Workforce Leader
Robert F. Padera, MD, PhD, Registries and Databases Workforce Leader
James B. Atkinson, MD, PhD, Communications Workforce Leader

PEDIATRIC TRANSPLANTATION
Christian Benden, MD, Chair
Elfriede Pahl Schuette, MD, Vice-Chair
Michael Burch, MD, Past Chair
Okan Elidemir, MD, Standards and Guidelines Workforce Leader
Daphne Hsu, MD, Education Workforce Leader
Richard E. Chinnock, MD, Registries and Databases Workforce Leader
Anne L. Dipchand, MD, Communications Workforce Leader

PULMONARY ARTERIAL HYPERTENSION
Raymond L. Benza, MD, Chair
Myung Park, MD, Vice-Chair
John P. Scott, MD, Past-Chair
Evelyn Horn, MD, Standards and Guidelines Workforce Leader
Adaani Frost, MD, Registries and Databases Workforce Leader
Deborah J. Levine, MD, Communications Workforce Leader
Srinivas Murali, MD, Development Liaison

PULMONARY TRANSPLANTATION
Geert M. Verleden, MD, PhD, Chair
Lianne G. Singer, MD, FRCP, Vice Chair
David Weill, MD, Vice Chair-Elect/Secretary
Martin R. Zamora, MD, Past Chair
David Weill, MD, Standards and Guidelines Workforce Leader
Christopher H. Wigfield, MD, FRCS, Education Workforce Leader
Shaf Keshavjee, MD, Registries and Databases Workforce Leader
Christine L. Lau, MD, Communications Workforce Leader
Roger D. Yusen, MD, MPH, Quality of Life Workforce Leader
Patrick Evrard, MD, Development Liaison Officer

JUNIOR FACULTY AND TRAINEE COUNCIL
Lorriana E. Leard, MD, Chair
David W. Markham, MD, Vice Chair
Cynthia J. Gries, MD, Past Chair
Susan D. Moffatt-Bruce, MD, PhD, Standards and Guidelines Workforce Leader
Daniel F. Dilling, MD, Education Workforce Leader
Jennifer C. Matthews, MD, Registries and Databases Workforce Leader
Pali D. Shah, MD, Communications Workforce Leader
Arezu, Z. Aliabadi, MD, Development Liaison
INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION
30th Anniversary Meeting and Scientific Sessions

ISHLT COMMITTEES

EDUCATION COMMITTEE
Andrew Fisher, FRCP, PhD, Chair
Daniel F. Dilling, MD, Junior Faculty and Trainee Council Workforce Leader
Allen S. Anderson, MD, FACC, Heart Failure Council Workforce Leader
Sharon A. Beer, RN, MSc, Nursing, Health Science and Allied Health Council Workforce Leader
Martha L. Mooney, MD, Infectious Diseases Council Workforce Leader
Christopher H. Wigfield, MD, FRCS, Pulmonary Transplantation Council Workforce Leader
Daphne Hsu, MD, Pediatric Council Workforce Leader
Omar A. Minai, MD, Pulmonary Hypertension Council Workforce Leader
Roberta C. Bogaev, MD, FACC, Mechanical Circulatory Support Council Workforce Leader
E. Rene Rodriguez, MD, Pathology and Basic Science Council Workforce Leader
Keith McNeil, FRACP, At Large Member
Andreas O. Zuckermann, MD, At Large Member
Beatriz Diaz Molina, MD, At Large Member

COMMUNICATIONS COMMITTEE
Maryl R. Johnson, MD, Chair
Pali D. Shah, MD, Junior Faculty and Trainee Council Workforce Leader
David P. Nelson, MD, Heart Failure Council Workforce Leader
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Nursing, Health Science and Allied Health Council Workforce Leader
Vincent G. Valentine, MD, Infectious Diseases Council Workforce Leader
Christine L. Lau, MD, Pulmonary Transplant Council Workforce Leader
Anne I. Dipchand, MD, Pediatric Council Workforce Leader
Deborah J. Levine, MD, Pulmonary Hypertension Council Workforce Leader
Evgenij V. Potapov, MD, Mechanical Circulatory Support Council Workforce Leader
James B. Atkinson, MD, PhD, Pathology and Basic Science Council Workforce Leader
Nicholas R. Banner, FRCP, Education Committee Representative
David Weill, MD, Standards and Guidelines Committee Representative
David S. Feldman, MD, ISHLT Links Newsletter Editor
Mandeep R. Mehra, MD, Editor, Journal of Heart and Lung Transplantation
Cynthia S. Herrington, MD, At Large Member
Cedric D. Sheffield, MD, At Large Member
Cynthia J. Gries, MD, MSc, At Large Member

GRANTS AND AWARDS COMMITTEE
Duane Davis, MD, Chair
Mark Barr, MD, Past Chair
Lori J. West, MD, DPhil
Carla C. Baan, PhD
Marshall I. Hertz, MD, Reviewer
Bernice L. Coleman, RN, PhD, Reviewer

JHLT EDITORIAL BOARD
Mandeep Mehra, MBBS, FACC, FACP, Editor-in-Chief
Patricia Uber, PharmD, Scientific Managing Editor
Maria Rosa Costanzo, MD, Editor Emeritus 1995-1999
James K. Kirklin, MD, Editor Emeritus 2000-2009

EDITORS OF OFFICE CONSULTANTS:
Jonathan B. Orens, MD
Jayan Parameshwar, FRCP
Richard N. Pierson III, MD

EDITORS OF BOARD CONSULTANTS:
Claus B. Andersen, MD, D.M.Sc
Marcelo Cantarovich, MD
Charles E. Canter, MD
Pablo F. Castro, MD
Richard E. Chinnock, MD
John V. Conte, MD
Paul A. Corris, MB FRCP
Duane Davis, MD
Fabienne Dobblez, MSc, PhD
Howard J. Eisen, MD
Roger W. Evans, PhD
Michael C. Fishbein, MD
Edward R. Garrity, Jr., MD
James F. George, PhD
Alan R. Glanville, MD, FRACP
Kate Gould, FRCPath
Kathleen L. Grady, PhD, APN, FAAN
Shahid Husain, MD, MS
Maryl R. Johnson, MD
Shaf Keshavjee, MD, FRCSC
Jon Kobashigawa, MD
Willem Kop
Bruce McManus, MD, PhD
Bruno M. Meiser, MD
Alan H. Menkis, MD, FRCSC(C)
Leslie W. Miller, MD
Robert F. Padera, MD, PhD, Pathology and
Basic Science Council Workforce Leader
Roger D. Yusen, MD, MPH, Outcomes Specialist
Maria G. Crespo-Leiro, MD, Outcomes Specialist
Leah Edwards, PhD, Thoracic Registry Biostatistician

THORACIC REGISTRY
STEERING COMMITTEE
Marshall I. Hertz, MD, Medical Director
Josef Stehlik, MD, MPH, Associate Medical Director, Heart
Jason D. Christie, MD, Associate Medical Director,
Lung/Heart-Lung
Richard Kirk, MA, FRCP, FRCPCCH,
Associate Medical Director, Pediatric Heart
Paul Aurora, MRCP, PhD, Associate Medical Director,
Pediatric Lung/Heart-Lung
Fabienne Dobbels, PhD, Associate Medical Director, Outcomes
Axel Rahmel, MD, Associate Medical Director, OEO Relations
Leah Edwards, PhD, Associate Medical Director, Biostatistics
Jaime Williamson, SAS Analyst
Kathryn A. Philibin, RN, TII Liaison
Anna Kucheryavaya, Assistant Biostatistician

PROFESSIONAL STANDARDS
AND GUIDELINES COMMITTEE
Maria Rosa Costanzo, MD, Chair
Susan D. Moffatt-Bruce, MD, PhD, Junior Faculty and
Trainee Council Workforce Leader
Nicholas R. Banner, FRCP, Heart Failure Council Workforce Leader
Michael G. Petty, PhD(c), RN, CCNS, CNS, Nursing,
Health Science and Allied Health Council Workforce Leader
Lara Danziger-Isakov, MD, MPH, Infectious Diseases
Council Workforce Leader
David Weill, MD, Pulmonary Transplantation
Council Workforce Leader
Okan ELidemir, MD, Pediatric Council Workforce Leader
Evelyn Horn, MD, Pulmonary Hypertension
Council Workforce Leader
Stephanie A. Moore, MD, Mechanical Circulatory
Support Council Workforce Leader
Carmela D. Tan, MD, Pathology and Basic Science
Council Workforce Leader
Diego H. Delgado, MD, At Large Member
Maria G. Crespo-Leiro, MD, At Large Member
Daniela Pini, MD, At Large Member

REGISTRIES AND DATABASES
COMMITTEE
Marshall I. Hertz, MD, Chair
Jennifer C. Matthews, MD, Junior Faculty and
Trainee Council Workforce Leader
Mariano Feccia, MD, Heart Failure Council Workforce Leader
Fabienne Dobbels, PhD, Nursing, Health Science and
Allied Health Council Workforce Leader
Frauke Mattner, MD, Infectious Diseases Council Workforce Leader
Shaf Keshavjee, MD, Pulmonary Transplantation Workforce Leader
Richard E. Chinnock, MD, Pediatric Council Workforce Leader
Adaani Frost, MD, Pulmonary Hypertension Council
Workforce Leader
Jaap Lahpor, MD, PhD, Mechanical Circulatory Support
Council Workforce Leader

PAST EDITORS
Journal Of Heart And Lung Transplantation
2000-2009 James K. Kirklin, MD
1995-1999 Maria Rosa Costanzo, MD
1986-1994 Michael P. Kaye, MD
1981-1985 Jacques G. Losman, MD

MEDICAL DIRECTORS, THORACIC
ORGAN TRANSPLANT REGISTRY
2001-Present Marshall I. Hertz, MD
1993-2001 Jeffrey D. Hosenpud, MD
1987-1993 Michael P. Kaye, MD
PAST SCIENTIFIC PROGRAM CHAIRS

2009 Paris, France   Randall C. Starling, MD, MPH
2008 Boston, MA      Lori J. West, MD, DPhil
2007 San Francisco, CA  Duane Davis, MD
2006 Madrid, Spain    John Dark, MB, FRCS
2005 Philadelphia, PA  Shaf Keshavjee, MD
2004 San Francisco, CA  Mandeep R. Mehra, MD
2003 Vienna, Austria  Bruce R. Rosengard, MD
2002 Washington, DC  Robert C. Robbins, MD
2001 Vancouver, Canada  David O. Taylor, MD
2000 Osaka, Japan  Jon Kobashigawa, MD
1999 San Francisco, CA  Mark L. Barr, MD
1998 Chicago, IL  James B. Young, MD
1997 London, England  Stephan Schueler, MD
1996 New York, NY  William A. Baumgartner, MD
1995 San Francisco, CA  Leslie W. Miller, MD
1994 Venice, Italy  John Wallwork, MBChB, FRCS
1993 Boca Raton, FL  Maria Rosa Costanzo, MD
1992 San Diego, CA  Eric A. Rose, MD
1991 Paris, France  John B. O’Connell, MD
1990 San Diego, CA  D. Glenn Pennington, MD
1989 Munich, Germany  Bruno Reichart, MD
1988 Los Angeles, CA  John C. Baldwin, MD
1987 New Orleans, LA
1986 New York, NY
1985 Anaheim, CA  Terence A. H. English, FRCS and Hillel Laks, MD
1984 New York, NY  Randall B. Grieppe, MD
1983 New Orleans, LA  Stuart W. Jamieson, MD and Mark E. Thompson, MD
1982 Phoenix, AZ  Michael Kaye, MD and Bernard Gersh, MD
1981 San Francisco, CA  Edward B. Stinson, MD and Michael L. Hess, MD

ISHLT AWARD RECIPIENTS

LIFETIME ACHIEVEMENT AWARD
2004 Sir Magdi Yacoub, MD
1999 Keith Reemtsma, MD
1996 Norman Shumway, MD

LIFETIME SERVICE AWARD
1997 Jacques G. Losman, MD
1996 Michael P. Kaye, MD

PIONEERS IN TRANSPLANTATION LECTURE
2009 Christian E. A. Cabrol, MD
2008 Richard E. Lower, MD
2006 Leonard L. Bailey, MD
2002 Michael DeBakey, MD
Bruce A. Reitz, MD

NORMAN E. SHUMWAY ISHLT CAREER DEVELOPMENT AWARD
2008 Glen Westall, MD, PhD (supported by Roche)
2006 Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)
2004 Allan M. Ramirez, MD (supported by Novartis Pharma)
2002 Anthony Azakie, MD (supported by Roche)
2000 Gordon D. Wu, MD (supported by Roche)

ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANTS
2009 Hua Shen, MD, PhD (supported by Astellas)
Tobias Deuse, MD, PhD (supported by Novartis)
Masahiro Miyajima, MD, PhD (supported by XDx)
Shin Hirayama, MD, PhD (supported by Gilead)
Jonathan Choy, PhD (supported by XDx)
Satoshi Itoh, MD (supported by Transmedics)
Teresa Martinu, MD (supported by Novartis)
Deepti Saini, PhD (supported by XDx)
Matthew J. Weiss, MD (supported by Novartis)

2008-2009 Mandeep R. Mehra, MD
2007-2008 Paul A. Corris, MB FRCP
2006-2007 Robert C. Robbins, MD
2005-2006 Mark L. Barr, MD
2004-2005 Alec Patterson, MD
2003-2004 Jon Kobashigawa, MD
2002-2003 Stephan Schueler, MD
2001-2002 James B. Young, MD
2000-2001 Anne Keogh, MBBS, MD
1999-2000 Robert L. Kormos, MD
1998-1999 Alan Menkis, MD, FRCS(C)
1997-1998 Leslie Miller, MD
1996-1997 William Baumgartner, MD
1995-1996 Sharon Hunt, MD
1994-1995 John Wallwork, FRCS
1993-1994 Eric Rose, MD
1992-1993 John O’Connell, MD
1991-1992 Christian Cabrol, MD
1990-1991 Margaret Billingham, MD
1988-1990 Bruno Reichart, MD
1986-1988 Stuart Jamieson, MD
1984-1986 Terence English, FRCS
1982-1984 Jack Copeland, MD
1981-1982 Michael Hess, MD
2005 Ryan C. Fields, MD (supported by Citron)
Arne Neyrinck, MD (supported by Astellas)
Ahmad Saad, MD (supported by Bevco)
2004 Christian A. Gleimner, MD (supported by Astellas)
Taisoishi Shoji, MD, PhD (supported by Astellas)
Kendall N. Taylor, PhD (supported by Bevco)
Monica Zwierzchonieuska, MD (supported by TK)
2003 Ewourd J. van den Bos, MD (supported by Astellas)
Felix Fernández, MD (supported by Bevco)
2002 Rudiger Hoehbs, MD (supported by Bevco)
2001 Aruna Gsinnson, MD (supported by Bevco)
Marès Vaura, PhD (supported by Bevco)
2000 Richard S. Lee, MD (supported by Novartis)
Christopher H. Wigfield, FRCS (supported by Bevco)
2003 Georgi Yang, MD (supported by Novartis)
Stroma Krovvidi, PhD (supported by Bevco)
Satoshi Saito, MD (supported by Ortho-Biotech)
Sivasai Krovvidi, PhD (supported by Ortho-Biotech)
2004 Christian A. Gleissner, MD (supported by Astellas)
2005 Ryan C. Fields, MD (supported by Chiron)
2006 Thierry T roosters, PhD (supported by Bevco)
2007 Beth D. Kaufman, MD (supported by Novartis)
Cynthia Gries, MD, MSc (supported by Astellas)
2008 ISHLT TRANSPLANT REGISTRY
JUNIOR FACULTY AWARD
2008 Cynthia Graus, MD, MSc.
Santar Halperr, MD, PhD
Josef Stelhik, MD, MPH
2007 Brith D. Kaufman, MD
2008 ISHLT NURSING AND SOCIAL SCIENCES RESEARCH GRANT
2008 Jane MacIver, RN, MS,
Stacey M. Pollock-BarZiv, PhD
2007 ISHLT MEMORIAL FELLOWSHIP GRANT
2007 Thija S. Ikomen, MD (supported by Bevco)
Andrew F. Pierre, MD (supported by Ortho-Biotech)
2005 Frances L. Johnson, MD (supported by Ortho-Biotech)
2004 Jonathan Chen, MD (supported by Bevco)
Alyssa M. Krasinskas, MD (supported by Astellas)
Owen T. Lawrence, MD (supported by Ortho-Biotech)
Anne K. Rainsamen-Sokolowski, MD (supported by Bevco)
2003 Siigrid Sander, MD
2002 Frank D’Ovidio, MD
2001 Peter Blaha, MD
2000 Michael F. Weisbrot, MD
1999 Joerg Koglin, MD
1998 Carla C. Baum, MD
1997 Simon D. Eiref, MD
1996 Moninder S. Bhabra, MD
1995 Elizabeth A. Davis, MD
1994 Michael P. Fischbein, MD
1993 David Marshman, MD
1992 David P . Kapelanski, MD
1991 David P. Kapelanski, MD
1990 Andres J. Duncan, MD
1989 Charles D. Fraser, Jr., MD
1988 Simon D. Eiref, MD
1987 Charles D. Fraser, Jr., MD
1986 Stuart J. Knechtle, MD
1985 Wim Van Der Bij, MD
1984 Hermann Reichenpurner, MD
1983 Robbin G. Cohen, MD

PHILIP K. CAVES AWARD
2009 Howard Huang, MD
2008 Sarah N. Nadig, MD
2007 Heather E. Merry, MD
2006 Gregor Warnecke, MD
2005 Sigrid Sandner, MD
2004 Frank D’Ovidio, MD
2003 M.D. Peterson, MD
2002 Peter Blaha, MD
2001 Alexander S. Krupnick, MD
2000 Michael F. Weisbrot, MD
1999 Joerg Koglin, MD
1998 Carla C. Baum, MD
1997 Simon D. Eiref, MD
1996 Moninder S. Bhabra, MD
1995 Elizabeth A. Davis, MD
1994 John W. Winter, MD
1993 Alain Chapelier, MD
1992 David F. Kapelanski, MD
1991 A. Jimenez, MD
1990 Andotr J. Duncan, MD
1989 A.M. Wood, MD
1988 Charles D. Fraser, Jr., MD
1987 Wim Van Der Bij, MD
1986 Stuart J. Knechtle, MD
1985 Michael A. Breda, MD
1984 Hermann Reichenpurner, MD
1983 Robbin G. Cohen, MD

NURSING AND SOCIAL SCIENCES EXCELLENCE IN RESEARCH AWARD
2009 Connie White-Williams, MSN
2008 Annette DeviVid Dubbs, RN, PhD
2007 Christineau Kugler, PhD
2006 Kathleen L. Grady, PhD, RN
2005 Mary Amanda Dew, PhD

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MSCD PAPER AWARD
2009 Nishant Shah, MD (supported by Thoratec)

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT
2009 Sara D. Borovic, MD (supported by Thoratec)

HIGHLIGHTS OF THE SCIENTIFIC PROGRAM

MECHANICAL CIRCULATORY SUPPORT

The 30th Anniversary Meeting and Scientific Sessions of ISHLT will have a record number of presentations addressing the challenges of patient selection for mechanical circulatory support (MCS), clinical management of the MCS patient and recommendations to reduce adverse events associated with device support. Your colleagues share their experience with some of the most dreaded complications of MCS in a Sunrise Symposium, “VADs Gone Bad Case Presentations,” on Wednesday morning.

The first satellite session on Wednesday morning, “The Ultimate VAD Symposium,” will provide participants with a comprehensive overview of MCS – from patient and device selection to outpatient management. Immediately thereafter, a satellite symposium, “Who Plays God? Ethics in Transplantation and MCS Devices,” will address the ethical issues teams face when patients require transitioning to palliative care. During the Opening Plenary Session on Wednesday afternoon, Dr. James Kirklin will give attendees the most recent update from the INTERMACS registry.

Gender differences in device outcomes and adverse events will be discussed on Thursday morning in the “Battle of the Sexes:” Thursday afternoon’s concurrent session, “Device Disasters: Can We Avoid Them?” will review strategies to address adverse events in LVAD patients. In “Getting Back to the Basics: MCS Devices and the Myocyte,” which will be held on Thursday afternoon, insights can be gleaned regarding the molecular and cellular mechanisms behind patients’ clinical responses to MCS.

Friday morning, the concurrent session, “Cost Effectiveness and Long-Term Outcomes,” addresses the financial impact of advanced technology. Friday afternoon there will be two sentinel concurrent sessions: “The Menu: Which Device When?” and “Expert Consensus Definitions in Cardiopulmonary Transplantation and MCS Infections.”

2005
2004
2003
2002
2001
2000
1999
1998
1997
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
1983
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
2005
2004
2003
2002
2001
2000
1999
1998
1997
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
2005
2004
2003
2002
2001
2000
1999
1998
1997
Saturday morning’s plenary session will conclude with an unprecedented debate by Dr. O.H. Frazier and Dr. Mandeep Mehra: “MCS IS IN, Heart Transplantation is OUT.” Whether you are new to the field of MCS or a seasoned VAD clinician, at this year’s ISHLT meeting you will find stimulating and provocative presentations that will help you enhance the care of patients requiring MCS.

PULMONARY HYPERTENSION
This year, the PH members of the Program Committee have put together a stellar series of seminars that highlight management of advanced PH. On Wednesday, April 21 at 7:00 AM Sunrise Symposium, “Clinical Challenges in the Management of Right Ventricular Failure,” will focus on RV failure management, especially in patients waiting for thoracic transplants. That will be followed with an 8:15 Wednesday Satellite Symposium called “Innovations in Pulmonary Hypertension: Advances in Medical and Surgical Therapies” where the new guidelines including use of combination therapies will be presented. On Thursday April 22 at 10:45 a Concurrent Session titled, “Novel Genomic, Proteomic, and Clinical Risk Markers in Pulmonary Arterial Hypertension” is scheduled. One of the main themes throughout these sessions will be a focus on right ventricular (dys)function, its imaging, its assessment and its management, with presentations from some of the leading authorities in the world. On the whole, this year’s meeting offers a great opportunity to learn more about PH and its management.

INFECTIOUS DISEASE
This year’s Annual Meeting is laced with venues presenting cutting edge developments in transplant and mechanical circulatory support (MCS) related infectious diseases. On Wednesday, Satellite Symposium 6 unfurls the impact of emerging pathogens on the cardiothoracic transplantation center’s every day business by the experts in the field. The Australian experience of the novel SARS-CoV-2 pandemic was described: with a six month head start before the Northern Hemisphere’s tangle with the pandemic influenza virus, they have a lot to tell that we can all learn from.

Management of this and other donor derived infections will be investigated from donor evaluation at the time of transplantation through inadvertent donor transmitted infections in the cardiothoracic transplant recipient. Timely laboratory diagnostics will be examined for donor selection and resources explored that are available to assist in post transplant evaluation of a donor-derived infection. The post transplant presentation, diagnosis and management of geographically restricted infectious diseases will also be explored.

On Thursday, Concurrent Session 21 contains molecular and clinical studies furthering our understanding of the interrelationship between transplant immunology and pathogen and several relevant topics concerning clinical management of transplant and MCS related infections.

Friday’s Concurrent Session 40 should not be missed by anyone involved in clinical research. This session will premier the summary of the “ISHLT Expert Consensus Definitions of Infections in Cardiothoracic Transplantation and Mechanical Circulatory Support Patients.” A panel of workforce members will lead the panel discussion at the end of the presentations for further clarification of these definitions.

On Saturday morning, Sunrise Symposium 7 “Crossing the Lines” puts the definitions of mechanical circulatory support related infectious diseases into the clinical application – learning from the past and going into the future with a unified set of definitions for these infections. “The Expert Consensus Definitions of Infections in Cardiothoracic Transplantation and Mechanical Circulatory Support Patients” will be available for use in future studies to accurately capture the true incidence of infectious diseases in these patients.

PEDIATRIC TRANSPLANTATION
There are several programs of particular interest to the pediatric transplant community. At 7:00 am on Wednesday, April 21, there will be a Sunrise Symposium on “Technical Issues in Mechanical Support in the Pediatric Patient” followed by two Satellite Symposiums with a pediatric focus: “Coronary Vasculopathy from Bench to Bedside” and “Management of the Sensitized Patient.”

On Saturday, April 24, there will be a Sunrise Symposium with case presentations on “Tough Cases in the Management of the Sensitized Patient” and a symposium on “Transplantation in the Pediatric Patient with Cardiomyopathy.” There will be three outstanding oral presentation sessions, a moderated poster session and a general poster session dedicated to pediatric transplantation.

BASIC SCIENCE
One of the most important events of the meeting is the Caves Award session, during which young academic scientists present their “hottest” experimental and clinical research. Another session not to be missed is “Stem Cell Research and Tissue Engineering,” especially the invited presentation by Professor Eschenhagen.

PULMONARY TRANSPLANTATION
The following programs are of interest related to pulmonary transplantation. Satellite Symposium 9 will cover the significance of airways inflammation in lung allograft dysfunction. This symposium discusses the current understanding of airways inflammation and its potential role in the evolution of chronic rejection, but will also highlight new insights and different treatment modalities. Satellite Symposium 4 and 10, which deal with the diagnosis and the management of sensitized patients, will further guide the recent evolution in the role of antibody-mediated rejection. This is only a very small part of the program, but cannot be missed by the attendees who still have questions on these topics.

NURSING, HEALTH SCIENCE AND ALLIED HEALTH
Our 2010 Annual Meeting program has been constructed and designed based on feedback and evaluations from our nursing science, social science and allied health colleagues. We are delighted to report that the nursing and social science content of this year’s meeting is focused on presentations and discussions, balanced between clinical research, outcomes in practice and for the first time, participants will be afforded the opportunity to discuss in case study methodology format, specific care challenges in the heart and lung recipient population.

Please put the following sessions on your calendars as “Not to be Missed!”

Wednesday, April 21st, 7:00-8:00 AM, Sunrise Symposium 5: Clinical Challenges for Nursing and Allied Health: What Would You Do? Case Presentations.

This interactive session is designed to give you a valuable opportunity to interact with other nursing and allied health professionals as we discuss common clinical challenges. Bring your perspective and your questions to this interesting dialogue.

Wednesday, April 21st, 10:30 AM-12:30 PM, Satellite Symposium 12: Transforming Transplant Care Through Evidence Based Practice

In a series of invited presentations, experts in nursing and other allied health fields explore what we know – and what we don’t know – about evidence related to outcomes of our care delivery to transplant and mechanical circulatory support patients. Hear the latest in evidence and join others in considering future directions for research into the care of these unique populations.
A series of interesting abstracts presenters work to fill in some of the gaps in knowledge we face in the post-operative management of thoracic transplant recipients. You won’t want to miss these highly rated summaries of important current research.

**PATHOLOGY**

This year’s Annual Meeting features several landmark and cutting edge developments in the field of pathology as it relates to heart and lung transplantation. Antibody mediated rejection (AMR) (abstracts 92, 94, 95, 97, 111, 179, 220, 317, 319) and the significance of donor specific antibody and B-cells (13, 39, 70, 100, 148, 152, 248, 251, 315, 320, 322, 342, 454, 458, 459, 464) are a major focus this year. Significant advances are also presented in molecular assessments of rejection (32, 43, 98, 120, 174, 178, 245, 449, 452, 453, 461, 481), cellular mechanisms of “chronic” rejection and predictors of survival (21, 25, 37, 96, 339, 340, 451), allograft coronary vasculopathy (38, 51, 93, 149, 213, 247, 450, 488) and PTLD and other malignancies complicating transplantation (44, 199, 362, 363, 400, 401, 523). Lung transplantation pathology is also highlighted (150, 151, 298, 299, 300, 301) with particular focus on bronchiolitis obliterans syndrome (99, 154, 302, 316, 324, 341, 342).

Satellite Symposium 4 will focus on the relationship of rejection episodes to the development of heart allograft vasculopathy, BOS and graft survival. The pathology of AMR, pre and post transplant AMR surveillance, as well as monitoring and diagnosis of AMR will all be discussed. Satellite Symposium 5 will examine cardiac allograft vasculopathy from bench to bedside, exploring the role of innate and adaptive immunity in the pathogenesis of allograft vasculopathy, prevalence, detection and prognosis of allograft vasculopathy in children.

Satellite Symposium 9 will focus on the role of lymphocytic bronchiolitis and airway inflammation in transplanted lungs, as well as the association with rejection and BOS. Satellite Symposium 10 will discuss several aspects of the management of highly sensitized patients, including the ISHLT Consensus Discussion on AMR in heart transplantation, where a summary of results will be presented.

Concurrent Session 6 “AMR Story Continues” will focus in the use of C4d and other new markers for diagnosis of AMR in heart biopsies. The Thursday plenary session will present comparison of gene expression profile and endomyocardial biopsy for surveillance of acute rejection. Concurrent Session 1 will deal with the role of stem cells in basic and translational approaches. Concurrent Session 16 highlights molecular and clinical studies furthering our understanding of the interrelationship between the transplanted or failing heart and gene expression profile markers. Concurrent Session 32 will discuss the mechanisms of inflammation and repair in the lung allograft airway. Concurrent Session 35 will focus on new approaches to the evaluation and treatment of acute rejection, discussing a new C1q assay for prediction of AMR. Concurrent Session 39 will also discuss the molecular mechanisms of organ rejection.

**JUNIOR FACULTY & TRAINEES**

We are excited to have two new and very special offerings at this year’s Annual Meeting. On Thursday April 22 join us at 12:15 PM for the “International Networking Lunch,” where junior faculty and trainees can be mentored on “Getting Your Next Job,” “Balancing Work and Family,” or other topics (pre-registration is required and limited). On Friday, April 23 at 10:45 AM we are excited to see presentations from winners of an abstract competition called “Clinical Case Dilemmas in Thoracic Transplantation” – with tough cases presented to expert discussants. All are welcome to observe or to join in the discussion.

**HEART FAILURE AND TRANSPLANT MEDICINE**

The following sessions should prove to be of particular interest to those engaged in the fields of heart failure and transplant medicine:

- Satellite Symposium 7 (Wednesday, April 21, 10:30-12:30) will be devoted to the ethics of thoracic transplantation.
- Results of several potentially significant clinical trials will be reported at this year’s meeting. In the Plenary Session (Thursday, April 22, 8:30-10:15 AM): the IMAGE trial compares the standard biopsy guided surveillance strategy with a noninvasive approach using gene expression profiling in cardiac transplantation. In Concurrent Session 12 (Thursday, April 22, 10:45-12:15): the TACTAC trial, which compared a tacrolimus alone vs a tacrolimus and MMF regimen for routine immunosuppression in cardiac transplantation, will be presented.
- During the Thursday Plenary Session, a summary of the first ISHLT guidelines for the management of the post transplant patient will be presented.
- There will be a series of sessions on mechanical circulatory support which will provide a comprehensive overview of this rapidly evolving field.

**JUNIOR FACULTY & TRAINEES**

- The first ever ISHLT Academy course (Saturday, April 24 – Sunday, April 25) will follow the conclusion of the Scientific Sessions. This separate registration program is designed to be a comprehensive overview of advanced heart failure and cardiac transplantation for practitioners and trainees alike.
## ISHLT Thursday

<table>
<thead>
<tr>
<th>TIME</th>
<th>INTERNATIONAL BALLROOM</th>
<th>CONTINENTAL A/B</th>
<th>CONTINENTAL B</th>
<th>BOULEVARD ROOM</th>
<th>CONTINENTAL C</th>
<th>WALDORF ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>COUNCIL MEETING ID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td>PLENARY SESSION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>CONCURRENT SESSION 7</td>
<td>CONCURRENT</td>
<td>CONCURRENT</td>
<td>CONCURRENT</td>
<td>CONCURRENT</td>
<td></td>
</tr>
<tr>
<td>10:15 AM</td>
<td>Battle of the Sexes -- Pt Section</td>
<td>SESSION 7</td>
<td>SESSION 8</td>
<td>SESSION 8</td>
<td>SESSION 9</td>
<td></td>
</tr>
<tr>
<td>10:45 AM</td>
<td>CONCURRENT SESSION 12</td>
<td>CONCURRENT SESSION 12</td>
<td>CONCURRENT SESSION 12</td>
<td>CONCURRENT SESSION 12</td>
<td>CONCURRENT SESSION 12</td>
<td></td>
</tr>
<tr>
<td>11:15 AM</td>
<td>CONCURRENT SESSION 13</td>
<td>CONCURRENT SESSION 13</td>
<td>CONCURRENT SESSION 13</td>
<td>CONCURRENT SESSION 13</td>
<td>CONCURRENT SESSION 13</td>
<td></td>
</tr>
<tr>
<td>11:45 AM</td>
<td>CONCURRENT SESSION 14</td>
<td>CONCURRENT SESSION 14</td>
<td>CONCURRENT SESSION 14</td>
<td>CONCURRENT SESSION 14</td>
<td>CONCURRENT SESSION 14</td>
<td></td>
</tr>
<tr>
<td>12:15 PM</td>
<td>CONCURRENT SESSION 19</td>
<td>CONCURRENT SESSION 19</td>
<td>CONCURRENT SESSION 19</td>
<td>CONCURRENT SESSION 19</td>
<td>CONCURRENT SESSION 19</td>
<td></td>
</tr>
<tr>
<td>12:30 PM</td>
<td>CONCURRENT SESSION 20</td>
<td>CONCURRENT SESSION 20</td>
<td>CONCURRENT SESSION 20</td>
<td>CONCURRENT SESSION 20</td>
<td>CONCURRENT SESSION 20</td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>CONCURRENT SESSION 21</td>
<td>CONCURRENT SESSION 21</td>
<td>CONCURRENT SESSION 21</td>
<td>CONCURRENT SESSION 21</td>
<td>CONCURRENT SESSION 21</td>
<td></td>
</tr>
<tr>
<td>1:15 PM</td>
<td>CONCURRENT SESSION 22</td>
<td>CONCURRENT SESSION 22</td>
<td>CONCURRENT SESSION 22</td>
<td>CONCURRENT SESSION 22</td>
<td>CONCURRENT SESSION 22</td>
<td></td>
</tr>
<tr>
<td>1:45 PM</td>
<td>CONCURRENT SESSION 23</td>
<td>CONCURRENT SESSION 23</td>
<td>CONCURRENT SESSION 23</td>
<td>CONCURRENT SESSION 23</td>
<td>CONCURRENT SESSION 23</td>
<td></td>
</tr>
<tr>
<td>2:15 PM</td>
<td>MINI ORAL SESSION 6</td>
<td>MINI ORAL SESSION 6</td>
<td>MINI ORAL SESSION 6</td>
<td>MINI ORAL SESSION 6</td>
<td>MINI ORAL SESSION 6</td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:45 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## ISHLT Friday

### TIME

<table>
<thead>
<tr>
<th>Time</th>
<th>INTERNATIONAL BALLROOM</th>
<th>CONTINENTAL A/B</th>
<th>BOULEVARD ROOM</th>
<th>CONTINENTAL C</th>
<th>WALDORF ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>COUNCIL MEETING</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PULM Tx</td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>COUNCIL MEETING</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PED</td>
</tr>
<tr>
<td>8:15 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>COUNCIL MEETING</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>INRIAN</td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>COUNCIL MEETING</td>
</tr>
<tr>
<td></td>
<td>BUSINESS MEETING</td>
<td></td>
<td></td>
<td></td>
<td>BASIC SCIENCE</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45 AM</td>
<td>CONCURRENT SESSION 25</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cost Effectiveness &amp; Outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CONCURRENT SESSION 26</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Risk of Heart Transplantation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CONCURRENT SESSION 27</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BOS Risk Factors and Prevention</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CONCURRENT SESSION 28</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Making a Better Breath</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CONCURRENT SESSION 29</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PH: Innovative Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CONCURRENT SESSION 30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Cases in Thoracic Tx</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:15 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:15 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PREDIDENT’S GALA RECEPTION – GRAND BALLROOM

### TIME

<table>
<thead>
<tr>
<th>Time</th>
<th>2011 PROGRAM COMMITTEE MEETING</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:15 PM</td>
<td></td>
</tr>
<tr>
<td>2:15 PM</td>
<td></td>
</tr>
<tr>
<td>TIME</td>
<td>INTERNATIONAL BALLROOM</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------</td>
</tr>
<tr>
<td>7:00 AM</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
</tr>
<tr>
<td>8:15 AM</td>
<td></td>
</tr>
<tr>
<td>10:15 AM</td>
<td></td>
</tr>
<tr>
<td>10:30 AM</td>
<td></td>
</tr>
<tr>
<td>12:15 PM</td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
</tr>
<tr>
<td>1:15 PM</td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td></td>
</tr>
<tr>
<td>5:30 PM</td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td></td>
</tr>
</tbody>
</table>

**ISHLT Saturday**

**PLENARY SESSION**

<table>
<thead>
<tr>
<th>COFFEE BREAK</th>
<th>COFFEE BREAK</th>
<th>COFFEE BREAK</th>
<th>COFFEE BREAK</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUNRISE 6 SOL after Lung Tx</td>
<td>SUNRISE 7 Crossing the Lines</td>
<td>SUNRISE 8 Lung Tx Disasters</td>
<td></td>
</tr>
</tbody>
</table>

**COUNCIL REPORTS TO BOARD**

**MASTERS ACADEMY REGISTRATION**

**MASTERS ACADEMY SATURDAY SESSION 1 - 3 2 – 9 PM**

**SUNDAY SESSION 4 - 5 7 AM - NOON**

**ISHLT BOARD OF DIRECTORS MEETING**
THE PRESIDENT'S GALA RECEPTION will be held Friday, April 23rd from 8:00 pm – 10:00 pm inside the beautiful Grand Ballroom of the Chicago Hilton, known to many of us from the famous movie “The Fugitive.”

The talented Marginal Donors, starring our own Heather Ross, MD, will be performing for the crowd. Please be sure to join us for this wonderful event celebrating the Society's 30 years.

One ticket to the Gala Reception is included with each paid registration. Additional tickets may be purchased for $75 each.

ACCREDITATION
This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 28 hours in Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

EDUCATIONAL OBJECTIVES
The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

GOALS
To enable participants to learn about current practices, emerging technologies and medical advances related to heart and lung transplantation and end-stage heart and lung disease; and to provide a forum for participants to engage in discussion, debate and examination regarding the efficacy and applicability of these current practices, emerging technologies and medical advances.

TARGET AUDIENCE
The audience for this program includes physicians, surgeons, scientists, nurses and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.

LEARNING OBJECTIVES
Please refer to the disclosure documents distributed at the registration desk for the learning objectives for this educational activity.
DISCLOSURE

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner/Presenter.

These disclosures have been distributed from the registration desk to all delegates.

Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational. ISHLT will ensure that all conflicts of interest have been resolved in accordance with ACCME requirements for the purpose of eliminating bias in the presentation of educational and scientific content.

SCHEDULE AT A GLANCE

Tuesday,
April 20, 2010

8:00 AM – 8:00 PM
Exhibit Booth Installation/Set-up (Southeast Exhibit Hall)

7:00 AM – 1:00 PM
ISHLT BOARD OF DIRECTORS MEETING (Lake Erie Room)

NOON – 8:00 PM
Poster Mounting (Southwest Exhibit Hall)

2:00 PM – 4:00 PM
EDUCATION COMMITTEE MEETING (PDR-4)

2:00 PM – 6:00 PM
ISHLT/ERS/ATS CLAD MEETING (Joliet)

4:00 PM – 6:00 PM
THORACIC REGISTRY STEERING COMMITTEE MEETING (Continental Foyer Office 2)

4:30 PM – 6:30 PM
COMMUNICATIONS COMMITTEE MEETING (PDR-2)
STANDARDS AND GUIDELINES COMMITTEE MEETING (PDR-4)

5:00 PM – 8:00 PM
Registration Desk Open (8th Street Registration)

5:00 PM – 8:00 PM
Slide Ready Room Open (Grand Tradition)

Wednesday,
April 21, 2010

6:00 AM – 7:00 PM
Registration Desk Open (8th Street Registration)

6:00 AM – 7:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM
CORPORATE COUNCIL BREAKFAST MEETING (PDR-2)
7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 1:
**VADs Gone Bad Case Presentations** (International Ballroom)

SUNRISE SYMPOSIUM 2:
**Clinical Challenges in the Management of Right Ventricular Failure** (Continental A/B)

SUNRISE SYMPOSIUM 3:
**Surgical Approaches for Lung Transplantation – Is There Still a Debate?** (Boulevard)

SUNRISE SYMPOSIUM 4:
**Technical Issues in Mechanical Support in the Pediatric Patient Case Presentations** (Continental C)

SUNRISE SYMPOSIUM 5
**Clinical Challenges for Nursing and Allied Health: What Would You Do? Case Presentations** (Waldorf)

8:00 AM – 10:00 AM
Exhibit Booth Set-up (Southeast Exhibit Hall)
Poster Mounting (Southwest Exhibit Hall)

8:15 AM – 10:15 AM
SATELLITE SYMPOSIUM 1:
**The Ultimate VAD Symposium** (International Ballroom)

SATELLITE SYMPOSIUM 2:
**Innovations in Pulmonary Hypertension: Advances in Medical and Surgical Therapies** (Continental A/B)

SATELLITE SYMPOSIUM 3:
**Getting to Yes – Increasing Lung Donors** (Boulevard)

SATELLITE SYMPOSIUM 4:
**Management of the Sensitized Patient and Antibody Mediated Rejection: Part 1** (Continental C)

SATELLITE SYMPOSIUM 5:
**Cardiac Allograft Vasculopathy: From Bench to Bedside** (Waldorf)

SATELLITE SYMPOSIUM 6:
**Emerging Infectious Diseases: Donor Management Issues and Recipient Sequelae** (Marquette)

9:00 AM – 5:00 PM
Press Office Open (Continental Office Foyer 1)

10:00 AM – 7:45 PM
Exhibit Hall Open (Southeast Exhibit Hall)
Internet Café Open (Southeast Exhibit Hall)
Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:30 AM
Coffee Break (Southeast Exhibit Hall)

10:30 AM – 12:30 PM
SATELLITE SYMPOSIUM 7:
**Who Plays God? Ethics in Transplantation and Mechanical Circulatory Support Devices** (International Ballroom)

SATELLITE SYMPOSIUM 8:
**Universal Issues in Tackling Pulmonary Vascular Disease – Where Do We Stand?** (Continental A/B)

SATELLITE SYMPOSIUM 9:
**The Significance of Airways Inflammation in Lung Allograft Dysfunction** (Boulevard)

SATELLITE SYMPOSIUM 10:
**Management of the Sensitized Patient and Antibody Mediated Rejection: Part 2** (Continental C)

SATELLITE SYMPOSIUM 11:
**The ISHLT Guidelines for Heart Transplant Recipients: Towards an International Consensus** (Waldorf)

SATELLITE SYMPOSIUM 12:
**Transforming Transplant Care Through Evidence-Based Practice** (Marquette)

12:30 PM – 2:30 PM
Lunch Break

12:30 PM – 1:30 PM
**REGISTRIES AND DATABASES COMMITTEE MEETING** (Joliet)

1:00 PM – 2:00 PM
MINI ORAL SESSION 1 (Boulevard)
MINI ORAL SESSION 2 (Continental C)
MINI ORAL SESSION 3 (Waldorf)
MINI ORAL SESSION 4 (Marquette)
MINI ORAL SESSION 5 (PDR-2)

2:30 PM – 4:45 PM
**OPENING PLENARY SESSION** (International Ballroom)

4:45 PM – 5:15 PM
Coffee Break (Southeast Exhibit Hall)

5:15 PM – 6:45 PM
**CONCURRENT SESSION 1:**
**Patients, Pumps and Outcomes** (International Ballroom)
CONCURRENT SESSION 2:  
*Heart Transplant Outcome; Does the Donor Matter?*  
(Continental A/B)

CONCURRENT SESSION 3:  
*Observations on Candidate Selection for Lung Transplant*  
(Boulevard Room)

CONCURRENT SESSION 4:  
*Nursing Science: And Then We Were Done: Patient Experience Following Surgical Interventions for Heart and Lung Failure*  
(Continental C)

CONCURRENT SESSION 5:  
*Improving Donor and Recipient Selection in Pediatric Transplantation*  
(Waldorf)

CONCURRENT SESSION 6:  
*The AMR Story Continues*  
(Marquette)

5:30 PM – 6:30 PM  
PAST PRESIDENT’S COUNCIL MEETING  
(Joliet)

6:45 PM – 7:45 PM  
Exhibit Hall Opening Reception (Southeast Exhibit Hall)  
View Posters (Southwest Exhibit Hall)

**Thursday, April 22, 2010**

7:00 AM – 6:00 PM  
Registration Desk Open (8th Street Registration)

7:00 AM – 7:00 PM  
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM  
MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC COUNCIL MEETING  
(Marquette)

PULMONARY ARTERIAL HYPERTENSION SCIENTIFIC COUNCIL MEETING  
(Joliet)

PATHOLOGY AND BASIC SCIENCE SCIENTIFIC COUNCIL MEETING  
(PDR-2)

INFECTIOUS DISEASE SCIENTIFIC COUNCIL MEETING  
(Waldorf)

8:30 AM – 10:15 AM  
PLENARY SESSION  
(International Ballroom)

9:00 AM – 5:00 PM  
Press Office Open (Continental Office Foyer 1)

10:00 AM – 4:30 PM  
Exhibit Hall Open (Southeast Exhibit Hall)  
Internet Café Open (Southeast Exhibit Hall)  
Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:45 AM  
Coffee Break (Southeast Exhibit Hall)

10:45 AM – 12:15 PM  
CONCURRENT SESSION 7:  
*Battle of the Sexes - PT Selection*  
(International Ballroom)

CONCURRENT SESSION 8:  
*Heart Transplantation Outcome*  
(Continental A/B)

CONCURRENT SESSION 9:  
*Donor Influences on Outcomes After Lung Transplant*  
(Boulevard)

CONCURRENT SESSION 10:  
*Novel Genomic, Proteomic & Clinical Risk Markers in PAH*  
(Continental C)

CONCURRENT SESSION 11:  
*Stem Cells: Basic and Translational Approaches*  
(Waldorf)

CONCURRENT SESSION 12:  
*Immunosuppression After Heart Transplantation: Is Less More?*  
(Marquette)

12:15 PM – 2:15 PM  
Lunch Break

12:15 PM – 2:15 PM  
JUNIOR FACULTY AND TRAINEE COUNCIL MENTOR LUNCH  
(PDR-2) (advance ticket purchase required)

12:30 PM – 2:00 PM  
INTERNATIONAL PEDIATRIC LUNG TRANSPLANT COLLABORATIVE MEETING  
(Joliet)

2:30 PM – 4:00 PM  
CONCURRENT SESSION 13:  
*Device Disasters: Can We Avoid Them?*  
(International Ballroom)

CONCURRENT SESSION 14:  
*Heart Transplantation Post Op Dilemma*  
(Continental A/B)

CONCURRENT SESSION 15:  
*Clinical Investigation in Acute and Chronic Rejection After Lung Transplantation*  
(Boulevard)

CONCURRENT SESSION 16:  
*Every Breath I Take is Now Better*  
(Continental C)

CONCURRENT SESSION 17:  
*Quality of Life and Social Sciences: Have We Done the Right Thing?: Assessing Quality of Life Following Cardiothoracic Transplantation*  
(Waldorf)
CONCURRENT SESSION 18:
Tissue Gene Regulation and Protection From Injury (Marquette)

4:00 PM – 4:30 PM
Coffee Break (Southeast Exhibit Hall)

4:30 PM – 6:00 PM
CONCURRENT SESSION 19:
Clinical Heart Transplantation and Immunology
(International Ballroom)

CONCURRENT SESSION 20:
Getting Back to the Basics: MCSD and the Myocyte
(Continental A/B)

CONCURRENT SESSION 21:
From Bench to Bedside Update in Transplant Infections
(Boulevard)

CONCURRENT SESSION 22:
Immunosuppression After Lung Transplantation: From Mouse
to Man (Continental C)

CONCURRENT SESSION 23:
Pediatric Transplantation in Unique Patient Populations
(Waldorf)

CONCURRENT SESSION 24:
Heart Failure: Prognostication and Outcomes (Marquette)

6:00 PM – 7:00 PM
PULMONARY TRANSPLANTATION COUNCIL QUALITY
OF LIFE WORKFORCE MEETING (Joliet)
JUNIOR FACULTY AND TRAINEE COUNCIL MEETING
(PDR-2)

6:00 PM – 7:00 PM
MINI ORAL SESSION 6 (Boulevard)
MINI ORAL SESSION 7 (Continental C)
MINI ORAL SESSION 8 (Waldorf)
MINI ORAL SESSION 9 (Marquette)

Friday,
April 23, 2010

7:00 AM – 6:00 PM
Registration Desk Open (8th Street Registration)

7:00 AM – 6:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM
PULMONARY TRANSPLANTATION SCIENTIFIC COUNCIL
MEETING (Waldorf)

HEART FAILURE AND TRANSPLANT MEDICINE
SCIENTIFIC COUNCIL MEETING (Marquette)

PEDIATRIC TRANSPLANTATION SCIENTIFIC COUNCIL
MEETING (Joliet)

NURSING, HEALTH SCIENCE, AND ALLIED HEALTH
SCIENTIFIC COUNCIL MEETING (PDR-2)

BASIC SCIENCE SCIENTIFIC COUNCIL MEETING
(tentative) (PDR-4)

8:15 AM – 10:15 AM
PLENARY SESSION
(International Ballroom)

9:00 AM – 5:00 PM
Press Office Open (Continental Office Foyer 1)

10:00 AM – 4:30 PM
Exhibit Hall Open (Southeast Exhibit Hall)
Internet Café Open (Southeast Exhibit Hall)
Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:45 AM
ANNUAL BUSINESS MEETING
(International Ballroom)

ISHLT Members Only

10:15 AM – 10:45 AM
Coffee Break (Southeast Exhibit Hall)

10:45 AM – 12:15 PM
CONCURRENT SESSION 25:
Cost Effectiveness and Long-Term Outcomes
(International Ballroom)

CONCURRENT SESSION 26:
Assessing the Risk of Heart Transplantation
(Continental A/B)

CONCURRENT SESSION 27:
Bronchiolitis Obliterans Syndrome (BOS): Risk Factors
and Prevention (Boulevard)

CONCURRENT SESSION 28:
Making a Better Breath (Continental C)

CONCURRENT SESSION 29:
Pulmonary Hypertension; Innovative Therapy (Waldorf)

CONCURRENT SESSION 30:
Clinical Case Dilemmas in Thoracic Transplantation
(Marquette)

6:00 PM – 7:00 PM
PULMONARY TRANSPLANTATION COUNCIL QUALITY
OF LIFE WORKFORCE MEETING (Joliet)
JUNIOR FACULTY AND TRAINEE COUNCIL MEETING
(PDR-2)

JHLT EDITORIAL BOARD LUNCHEON MEETING
(Joliet Room)

12:30 PM – 2:00 PM
JHLT EDITORIAL BOARD LUNCHEON MEETING
(Joliet Room)
Saturday, April 24, 2010

7:00 AM – 10:30 AM
Registration Desk Open (8th Street Registration)

7:00 AM – 9:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 6:
Linking Outcomes and Quality of Life After Lung Transplant
(Boulevard)

SUNRISE SYMPOSIUM 7:
Crossing the Lines (Continental C)

SUNRISE SYMPOSIUM 8:
Disasters Early After Lung Transplant (Waldorf)

SUNRISE SYMPOSIUM 9:
Tough Cases in the Management of the Sensitized Patient Case Presentations (Marquette)

8:00 AM – 10:15 AM
PLENARY SESSION/AWARDS PRESENTATIONS
(Continental A/B)

9:00 AM – 12:00 Noon
Press Office Open (Continental Office Foyer 1)

10:15 AM – 10:30 AM
Coffee Break (Registration Area)

10:30 AM – 12:00 Noon
CONCURRENT SESSION 42:
Blood, Clots and Antibodies (Continental A/B)

CONCURRENT SESSION 43:
Lung Transplantation Complications (Boulevard Room)

CONCURRENT SESSION 44:
Late Complications Post Heart Transplantation (Continental C)

CONCURRENT SESSION 45:
Transplantation for Pediatric Cardiomyopathies (Waldorf)

CONCURRENT SESSION 46:
What’s Hot! Best Abstracts from Mechanical Circulatory Support, Heart Transplantation, Lung Transplantation (Marquette)

4:00 PM – 4:30 PM
Coffee Break (Southeast Exhibit Hall)

4:30 PM – 11:59 PM
Exhibit Hall/Poster Hall Strike
(Southeast/Southwest Exhibit Halls)

4:30 PM – 6:00 PM
CONCURRENT SESSION 37:
Heart Transplantation Clinical Challenges (Continental A/B)

CONCURRENT SESSION 38:
Lung Transplant for Interstitial Lung Disease (Boulevard)

CONCURRENT SESSION 39:
Molecular Mechanisms of Organ Rejection (Continental C)

CONCURRENT SESSION 40:
Expert Consensus Definitions in Cardiopulmonary Transplantation and Mechanical Circulatory Support Infections (Waldorf)

CONCURRENT SESSION 41:
Philip K. Caves Award Candidate Presentations (Marquette)

6:00 PM – 7:00 PM
NEW ISHLT BOARD MEMBER ORIENTATION MEETING (PDR-4)

8:00 PM – 10:00 PM
GALA ANNIVERSARY RECEPTION (Grand Ballroom)

7:00 AM – 9:00 PM
Slide Ready Room Open (Grand Tradition)

8:00 AM – 10:15 AM
PLENARY SESSION/AWARDS PRESENTATIONS
(Continental A/B)

9:00 AM – 12:00 Noon
Press Office Open (Continental Office Foyer 1)

10:15 AM – 10:30 AM
Coffee Break (Registration Area)

10:30 AM – 12:00 Noon
CONCURRENT SESSION 42:
Blood, Clots and Antibodies (Continental A/B)

CONCURRENT SESSION 43:
Lung Transplantation Complications (Boulevard Room)

CONCURRENT SESSION 44:
Late Complications Post Heart Transplantation (Continental C)

CONCURRENT SESSION 45:
Transplantation for Pediatric Cardiomyopathies (Waldorf)

CONCURRENT SESSION 46:
What’s Hot! Best Abstracts from Mechanical Circulatory Support, Heart Transplantation, Lung Transplantation (Marquette)

12:15 PM – 1:15 PM
COUNCIL REPORTS TO THE MEMBERSHIP AND BOARD (Continental C)

1:30 PM – 5:30 PM
ISHLT BOARD OF DIRECTORS MEETING (Lake Erie Room)
The International Society for Heart and Lung Transplantation is Most Grateful for the Educational Grants and Support of:

GOLD LEVEL PARTNER
ASTELLAS

SILVER LEVEL PARTNERS
GILEAD
GENENTECH
NOVARTIS
XDX

BRONZE LEVEL PARTNER
UNITED THERAPEUTICS

CORPORATE LEVEL PARTNER
GENZYME

Toward this 30th Anniversary Meeting and Scientific Sessions.
All meetings and activities will take place at the Hilton Chicago unless otherwise specified. All papers will be presented in English.

Wednesday, April 21, 2010

6:00 AM – 7:00 PM
Registration Desk Open (8th Street Registration)

6:00 AM – 7:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM
CORPORATE COUNCIL BREAKFAST MEETING (PDR-2)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 1:
VADs Gone Bad Case Presentations (International Ballroom)
CHAIRS: O. HOWARD FRAZIER, MD AND JOSEPH G. ROGERS, MD
7:00 AM Suicide Case, Nicholas G. Smedira, MD, Cleveland Clinic Foundation, Cleveland, OH
7:15 AM RV Failure Case, Renzo Cecere, MD, Royal Victoria Hospital, Montreal, Quebec, Canada
7:30 AM Stroke Case, Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD
7:45 AM Infection Case, Martin Strueber, MD, Hannover Medical School, Hannover, Germany

Tuesday, April 20, 2010

8:00 AM – 8:00 PM
Exhibit Booth Installation/Set-up (Southeast Exhibit Hall)

7:00 AM – 1:00 PM
ISHLT BOARD OF DIRECTORS MEETING (Lake Erie Room)

NOON – 8:00 PM
Poster Mounting (Southwest Exhibit Hall)

2:00 PM – 4:00 PM
EDUCATION COMMITTEE MEETING (PDR-4)

2:00 PM – 6:00 PM
ISHLT/ERS/ATS CLAD MEETING (Joliet)

4:00 PM – 6:00 PM
THORACIC REGISTRY STEERING COMMITTEE MEETING (Continental Foyer Office 2)

4:30 PM – 6:30 PM
COMMUNICATIONS COMMITTEE MEETING (PDR-2)
STANDARDS AND GUIDELINES COMMITTEE MEETING (PDR-4)

5:00 PM – 8:00 PM
Registration Desk Open (8th Street Registration)

5:00 PM – 8:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 2:
Clinical Challenges in the Management of Right Ventricular Failure (Continental A/B)
CHAIRS: EVELYN HORN, MD AND SRINIVAS MURALI, MD
This session will cover the clinical challenges associated with right ventricular failure from pathophysiology, diagnosis, and treatment considerations in RV failure associated with secondary PH in patients with pulmonary and cardiac disorders. Specific focus will be placed on management of RV dysfunction in lung transplant and heart transplant candidates.

7:00 AM Assessment of RV Function: Why is it Important and How Do You Do It?, Mardi Gomberg Maitland, MD, MSc, University of Chicago, Chicago, IL
7:20 AM Optimal Timing for Lung Transplant and the Implications of LAS in Pulmonary Arterial Hypertension – Is It Ever Too Late? Adaani Frost, MD, Baylor University, Houston, TX
7:40 AM Pulmonary Hypertension Therapies and VAD Support: Do They Improve Candidacy for Heart Transplant Candidates?, Teresa De Marco, MD, FACC, University of California, San Francisco, CA
7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 3:
Surgical Approaches for Lung Transplantation – Is There Still a Debate? (Boulevard)
CHAIRS: THOMAS K. WADDELL, MD, PHD AND REHDA SOUILAMAS, MD, PHD
7:00 AM Clamshell With Tricks, Duane Davis, MD, Duke University, Durham, NC
7:16 AM Sternal Sparing Clamshell, Bryan F. Meyers, MD, Washington University School of Medicine, St. Louis, MO
7:32 AM Sternalotomy With Tricks, John Dark, MD, FRCS, Freeman Hospital, Newcastle, United Kingdom
7:42 AM Antero-Axillary Approach, Yoshiya Toyoda, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 4:
Technical Issues in Mechanical Support in the Pediatric Patient Case Presentations (Continental C)
CHAIRS: DAVID MORALES, MD AND VICTOR O. MORELL, MD
7:00 AM MCS in the Pediatric Patient with Aortic Insufficiency, Kimberly L. Gandy, MD, PhD, Children’s Hospital of Wisconsin, Milwaukee, WI
7:12 AM Destination Therapy in a Patient with Potential Persistent Tumor Burden, Kirk R. Kanter, MD, Emory University, Atlanta, GA
7:24 AM MCS of the Single Ventricle Population, Bennett Pearce, MD, University of Alabama at Birmingham, AL
7:36 AM MCS in the Failing Fontan, Kristine Guleserian, MD, Children’s Medical Center, Dallas, TX
7:48 AM MCS in the Single Ventricle Patient after Bidirectional Glen, Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 5:
Clinical Challenges for Nursing and Allied Health: What Would You Do? Case Presentations (Waldorf)
CHAIRS: ANNEMARIE KAAN, MCN, RN AND MICHAEL G. PETTY, PHD(C), RN, CCNS, CNS
Health care practitioners consistently report in our educational survey difficulty translating clinical research outcomes into practice. In this session, through a case-study methodology, participants will be offered the opportunity to discuss with experienced healthcare professionals the application of such learning to specific care challenges.

7:00 AM VAD Candidate with Psychosocial Warning Signs that Coping with a VAD May be a Challenge: Lack of Caregiver, Lack of Resources, Non-adherence, Accepted as a Device Candidate as a Bridge to Decision, Daniela Roefe, RN, Heart Center NW, Bad Oeynhausen, Germany
7:20 AM Pediatric Patient Whose Parents have been Non-adherent Presents as an Adult for Re-transplant, Corby D’Amico, RN, MN, Emory University Hospital, Atlanta, GA
7:40 AM Patients Revisiting the Dark Side: Resumption of Drug, Alcohol, Tobacco Abuse after Transplant: How Does the Caregiving Nurse Cope?, Christine Hartley, MS, NP, Stanford University Medical Center, Palo Alto, CA

8:00 AM – 10:00 AM
Exhibit Booth Set-up (Southeast Exhibit Hall)
Poster Mounting (Southwest Exhibit Hall)

8:15 AM – 10:15 AM
SATELLITE SYMPOSIUM 1:
The Ultimate VAD Symposium (International Ballroom)
CHAIRS: JAMES W. LONG, MD, PHD AND GEORGE M. WIESELTHALER, MD
This session will provide the participant with an overview of mechanical circulatory support from patient and device selection, RV function assessment and management, bridge to recovery – role of clenbuterol, bridge to candidacy in the morbidly obese, destination therapy in the elderly, and management of the VAD recipient with hypertension.
8:15 AM Which Device for Which Patient, Michiel Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany
8:35 AM RV Failure: Prediction, Prevention and Treatment, Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Ontario, Canada
8:55 AM Clenbuterol: Myth or Magic?, Francis D. Pagani, MD, PhD, University of Michigan Hospital, Ann Arbor, MI
9:10 AM VADs: Are They the Ultimate Weight Loss Machines? Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
9:25 AM VAD: Are You Ever Too Old?, Thomas Krabatsch, MD, PhD, German Heart Institute, Berlin, Germany
9:40 AM Continuous Flow Devices: What Is Hypertension?, Randall C. Starling, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH
9:55 AM Panel Discussion
8:15 AM – 10:15 AM

SATELLITE SYMPOSIUM 2:
Innovations in Pulmonary Hypertension: Advances in Medical and Surgical Therapies (Continental A/B)

CHAIRS: MYUNG H. PARK, MD AND OMAR MINAI, MD

This session will focus on the most current up-to-date innovations in diagnosis, management, and research in pulmonary arterial hypertension (PAH). In 2009, the ACCF/AHA Executive Summary and report from the 4th World Symposium were published. This session will feature highlights from those meetings and present updates on the current guidelines in combination therapy, surgical therapy and upcoming new treatments in PAH.

8:15 AM New Mandates From The ACCF/AHA Expert Consensus and 4th World Symposium On Pulmonary Hypertension, Valerie McLaughlin, MD, University of Michigan, Ann Arbor, MI

8:30 AM Combination Therapy in Pulmonary Hypertension: Do We Have the Evidence for it and Is it the Best Approach? Jean-Luc Vachiery, MD, Erasme University Hospital-ULB, Brussels, Belgium

8:45 AM Risk Modeling in Pulmonary Arterial Hypertension – Are the Current Approaches Adequate? Robert P. Franz, MD, Mayo Clinic, Rochester, MN

9:00 AM New Therapies on the Horizon in Pulmonary Arterial Hypertension – Going Beyond the Three Pathways, Paul A. Corris, MB FRCP, Freeman Hospital, Newcastle, United Kingdom

9:15 AM Beyond Medical Therapy – Surgical and Cellular Options for Pulmonary Hypertension, Robert J. Schilz, MD, Case Western Reserve University, Cleveland, OH

8:15 AM – 10:15 AM

SATELLITE SYMPOSIUM 3:
Getting to Yes – Increasing Lung Donors (Boulevard)

CHAIRS: DIRK VAN RAEMDONCK, MD, PHD AND BARTLEY P. GRIFFITH, MD

Donor lung utilization is still unacceptably low and varies enormously between regions. Current donor utilization is only 15-20% of existing donors. This session will examine possible approaches (clinical as well as investigational) to improve organ availability.

8:15 AM Introduction - What are the Barriers? Where are the Opportunities? Duane Davis, MD, Duke University, Durham, NC

8:20 AM How To Optimize Donor Lung Procurement, Charles W. Hoopes, MD, University of California San Francisco, CA

8:40 AM Transplant Program Donor Management – Increasing the Donor Pool, Gregory I. Snell, FRACP, MBBS, Alfred Hospital, Melbourne, Australia

9:00 AM DCD Donors, Robert B. Love, MD, Loyola University Medical Center, Maywood, IL

9:20 AM State of the Art Ex Vivo Lung Perfusion, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Ontario, Canada

9:40 AM Resuscitation of the Donor Lung, Florian M. Wagner, MD, University Heart Center Hamburg Eppendorf, Hamburg, Germany

8:15 AM – 10:15 AM

SATELLITE SYMPOSIUM 4:
Management of the Sensitized Patient and Antibody Mediated Rejection: Part 1 (Continental C)

CHAIRS: NANCY L. REINSMOEN, PHD AND STEVEN D. ZANGWILL, MD

Several reports have demonstrated that pre-transplant sensitization to HLA antigens leads to a decrease in graft survival, an increase in rejection episodes, and the development of cardiac allograft vasculopathy (CAV) after heart transplantation and bronchiolitis obliterative syndrome (BOS) after lung transplantation. Further, the percentage of sensitized thoracic organ candidates receiving transplants is far less than nonsensitized patients leading to increased time on the waitlists and increased death on the waitlists. This session is designed to address the assessment and impact of HLA specific antibodies in thoracic organ transplantation. New cutting edge technologies allow for the identification of donor antigens to be avoided to decrease the donor pool for these sensitized patients. UNOS is implementing a calculated PRA to screen donors with unacceptable antigens and to indicate what percentage of the donor pool would be expected to be incompatible for a given patient. Other desensitization therapies are being used to decrease the strength and breadth of the antibody load again to increase the donor pool. Post-transplant monitoring strategies are being utilized to identify patients at risk for immune complications and allow for therapeutic intervention. Several investigators are studying the pathology and clinical implication of donor HLA specific antibodies and efficacy of treatment. This program will attempt to address these issues relevant to thoracic transplantation.

8:15 AM Biology of Antibody Mediated Rejection, Elaine F. Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA

8:35 AM Techniques for Pre- and Post-Transplant Antibody Surveillance, Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

9:05 AM The Crossmatch: How to do it and how to Interpret it, Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, UT

9:25 AM Post-Op Monitoring and Diagnosis of Antibody Mediated Rejection, Margaret M. Burke, FRCPATH, Harefield Hospital, Harefield, Middlesex, United Kingdom

9:45 AM Access for Sensitized Patients – A National Algorithm, Lori J. West, MD, DPhil, University of Alberta, Edmonton, Canada

10:05 AM Panel Discussion
8:15 AM – 10:15 AM
SATELLITE SYMPOSIUM 5:
Cardiac Allograft Vasculopathy: From Bench to Bedside
(Waldorf)

CHAIRS: JEFFREY L. PLATT, MD AND
HANNAH A. VALANTINE, MD

Despite the availability of new immunosuppressive therapies, graft vasculopathy remains a leading cause of graft loss following cardiac transplantation. This symposium is designed to bring together researchers from all perspectives to develop new approaches to the treatment of this problem. This session will educate the basic scientist, translational researcher and clinician about the pathophysiology, clinical manifestations, treatment and outcomes of graft vasculopathy in the heart transplant recipient.

8:15 AM  The Role of Innate Immunity in the Development of Allograft Vasculopathy, Timothy D. Lee, PhD, Dalhousie University Halifax, Nova Scotia

8:30 AM  Adaptive Immunity in Allograft Vasculopathy, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

8:45 AM  Prevalence, Detection, and Prognosis of Graft Vasculopathy in Children, Elfriede Pahl Schuette, MD, Children's Memorial Hospital, Chicago, IL

9:00 AM  Non-Angiographic Imaging Modalities for the Diagnosis of Graft Vasculopathy, Jignesh Patel, MD, PhD, Cedars-Sinai Heart Institute, Beverly Hills, CA

9:15 AM  How to Treat Graft Vasculopathy: Medical and Catheter Based Therapies, Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, PA

9:30 AM  Retransplantation: The Ultimate Treatment, Clifford Chin, MD, Stanford University, Palo Alto, CA

9:45 AM  Panel Discussion

8:15 AM – 10:15 AM
SATELLITE SYMPOSIUM 6:
Emerging Infectious Diseases: Donor Management Issues and Recipient Sequelae (Marquette)

CHAIRS: KATE GOULD, FRCPATH AND
STANLEY I. MARTIN, MD

The recent pandemic influenza and the SARS outbreak experience provide a natural “springboard” to discuss 1) the unfolding of an emerging pathogen threatening cardiothoracic transplant activities concerning donor, recipient, transplant teams and community; 2) donor management issues to identify the risks/testing- and its limitations; 3) resources available, should donor transmitted infection be suspected: UNOS/CDC-donor derived infection advisory board, etc.; 4) how a donor- derived infection presents post transplantation and how to diagnose and manage the recipient.

8:15 AM  Novel 2009 Influenza H1N1Influenza Pandemic as a Model for an Emerging Infection’s Impact on Cardiothoracic Transplant Centers: The Australian Experience, Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

8:35 AM  Donor Derived Infections: Clinical Relevance and How to Avoid It – Evaluation and Management at Time of Donation. The SARS Experience, Atul Humar, MD, University of Alberta, Edmonton, Canada

8:55 AM  Donor Derived Infections: Resources to Sort Out the Answers, Michael G. Ison, MD, MS, UNOS, DTAC, Northwestern University, Chicago, IL

9:15 AM  Donor Infections: Diagnostic Testing and Management to Minimize Risk, Paolo A. Grossi, MD, PhD, University of Insubria, Varese, Italy

9:40 AM  Transmission of Tropical or Geographically Restricted Infections During Solid Organ Transplantation: Clinical Presentation, Diagnostic Testing, and Outcome, Patricia Munoz, MD, Hospital General Universitario Gregorio Maranón, Madrid, Spain

10:00 AM  Panel Discussion

9:00 AM – 5:00 PM
Press Office Open (Continental Foyer Office 1)

10:00 AM – 7:45 PM
Exhibit Hall Open (Southeast Exhibit Hall)

Internet Café Open (Southeast Exhibit Hall)

Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 12:30 PM
SATELLITE SYMPOSIUM 7:
Who Plays God? Ethics in Transplantation and Mechanical Circulatory Support Devices (International Ballroom)

CHAIRS: HEATHER J. ROSS, MD, MHSC, FRCP(C) AND
HANS B. LEHMKUHL, MD

This session will provide an overview of the major ethical issues that come into daily practice.

10:30 AM  Re-Transplantation, Maryl R. Johnson, MD, University of Wisconsin, Madison, WI

10:45 AM  Multiorgan Transplant - One for You, Two or Three for Me, Mark Siegler, MD, University of Chicago, IL

11:00 AM  End of Life/ Palliative Care After Organ Transplantation, Savitri E. Fedson, MD, University of Chicago Hospitals, Chicago, IL

11:15 AM  When Do I Turn the VAD Off?, Jane Maclver, RN, MSc, Toronto General Hospital, Toronto, Ontario, Canada
WEDNESDAY

11:30 AM When to Say No – Does It Keep You up at Night?, Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA

11:45 AM Mechanical Circulatory Support Devices +/- Transplant in Congenital Heart Patients - Yes Or No?, Beth D. Kaufman, MD, Children's Hospital of Philadelphia, PA

12:00 PM Panel Discussion

10:30 AM – 12:30 PM SATellite SYmposium 10: Management of the Sensitized Patient and Antibody Mediated Rejection: Part 2 (Continental C)
CHAIRS: J. DAVID VEGA, MD AND UWE SCHULZ, MD

Several reports have demonstrated that pre-transplant sensitization to HLA antigens leads to decreased graft survival, an increase in rejection episodes, and the development of cardiac allograft vasculopathy (CAV) after heart transplantation and bronchiolitis obliterans syndrome (BOS) after lung transplantation. Further, the percentage of sensitized thoracic organ candidates receiving transplants is far less than nonsensitized patients leading to increased time on the waitlists and increased death on the waitlists. This proposed session is designed to address the assessment and impact of HLA specific antibodies in thoracic organ transplantation. New cutting edge technologies allow for the identification of donor antigens to be avoided to increase the donor pool for these sensitized patients. UNOS is implementing a calculated PRA to screen donors with unacceptable antigens and to indicate what percentage of the donor pool would be expected to be incompatible for a given patient. Other desensitization therapies are being used to decrease the strength and breadth of the antibody load again to increase the donor pool. Post-transplant monitoring strategies are being utilized to identify patients at risk for immune complications and allow for therapeutic intervention. Several investigators are studying the pathology and clinical implication of donor HLA specific antibodies and efficacy of treatment. This program will address these issues relevant to thoracic transplantation.

10:30 AM The Pathology of Airways Inflammation in the Transplanted Lung, Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom

10:55 AM Is Airways Inflammation a Form of Acute Rejection, Martin P. Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark

11:15 AM Airways Inflammation as a Risk Factor for Bronchiolitis Obliterans Syndrome (BOS), Allan R. Glanville, MD, FRACP, Sydney, Australia

11:35 AM Treating Airways Inflammation in the Lung Allograft, Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

11:55 AM Panel Discussion

10:30 AM – 12:30 PM SATellite SYmposium 8: Universal Issues in Tackling Pulmonary Vascular Disease – Where Do We Stand? (Continental A/B)
CHAIRS: RAYMOND L. BENZA, MD AND DEBORAH J. LEVINE, MD

This session will cover key topics discussing diagnosis and management of a secondary PH commonly seen in clinical practice such as PH associated with lung disease, chronic thromboembolic disease and congenital heart disease, as well as the current “hot” topic of exercise and PH.

10:30 AM Report From the REVEAL Registry – What Constitutes the “Real” World Pulmonary Hypertension Patient Population? Harrison W. Farber, MD, Boston University School of Medicine, Boston, MA

10:50 AM Significance of Pulmonary Hypertension in Parenchymal Lung Disease – Implications and Treatment, Reda Girgis, MB BCh, Johns Hopkins University, Baltimore, MD

11:10 AM Chronic Thromboembolic Pulmonary Hypertension – When Does Medical Therapy Have a Place?, Marion Delcroix, MD, University Hospital Leuven, Belgium

11:30 AM Congenital Heart Disease and Pulmonary Hypertension, Curt J. Daniels, MD, Ohio State University, Columbus, OH

11:50 AM Exercise and Pulmonary Hypertension – How Far Can We Push Our Patients?, Ronald J. Oudiz, MD, LA Biomedical Research Institute, Torrance, CA

10:30 AM – 12:30 PM SATellite SYmposium 9: The Significance of Airways Inflammation in Lung Allograft Dysfunction (Boulevard)
CHAIRS: ANDREW J. FISHER, FRCP, PHD AND SANGEETA M. BHORADE, MD

Airway inflammation is widely recognized in patients developing lung allograft dysfunction, however the role this plays in the pathogenesis of Bronchiolitis Obliterans Syndrome and the best approach to its management remains unclear. Better understanding of lymphocytic bronchiolitis has been identified by the ISHLT pulmonary council educational survey as a key area for improved understanding. This session will explore the pathology of airway inflammation in the transplanted lung, examine any association between airway inflammation and acute and chronic rejection and discuss the evidence to support approaches to management.

10:30 AM The Pathology of Airways Inflammation in the Transplanted Lung, Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom

10:55 AM Is Airways Inflammation a Form of Acute Rejection, Martin P. Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark

11:15 AM Airways Inflammation as a Risk Factor for Bronchiolitis Obliterans Syndrome (BOS), Allan R. Glanville, MD, FRACP, Sydney, Australia

11:35 AM Treating Airways Inflammation in the Lung Allograft, Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

11:55 AM Panel Discussion
There is little information addressing evidence-based nursing and allied health care in MCSD and transplant patients. A gap exists between the evidence that supports transplant nursing and allied health care and daily care of the transplant patient. This symposium will present definitions, the gaps in the literature, and current evidence-based nursing and allied health practice in transplantation. It will also foster audience dialogue on these topics.

10:30 AM Best Practice in Transplant Care: A Road More or Less Traveled, Connie White-Williams, PhD, University of Alabama at Birmingham, AL

10:40 AM Lung Transplantation: Evidence Based Nursing Practice: Are We There Yet? Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, Ontario, Canada

10:55 AM Care Management in the Pediatric Transplant Patient: Where is the Evidence?, Karen C. Uzark, PhD, Children’s Hospital Heart Center, Cincinnati, OH

11:10 AM Evidence Based Practice of Self-Care Management in the Adult Mechanical Circulatory Support and Transplant Patient: Is Your Transplant Program Evidence Based?, Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL

11:25 AM Mechanical Circulatory Support Infection Control Guidelines: The Disconnect of Science and Practice, Anne E. Dierlam, RN, Berlin Heart GmbH, Berlin, Germany

11:40 AM Transitioning the VAD Patient to Independence: Concept vs. Reality, Annemarie Kaan, MCN, RN, St. Paul’s Hospital, Vancouver, British Columbia, Canada

11:55 AM Professional Development and Contributions of the VAD Coordinator, Michael A. Sobieski, II, RN, CCP, University Cardiothoracic Surgical Associates, Louisville, KY

12:10 AM Panel Discussion

10:30 AM – 12:30 PM SATELLITE SYMPOSIUM 11: The ISHLT Guidelines for Heart Transplant Recipients: Towards an International Consensus (Waldorf)

CHAIRS: JAMES K. KIRKLIN, MD AND MANDEEP R. MEHRA, MD

Currently there are no published consensus practice guidelines addressing the care of heart transplant recipients. ISHLT has just completed development of such a set of guidelines. This session is intended to share with the ISHLT membership the key consensus recommendations for the care of heart transplant recipients, including early post-operative care, Immunosuppression and long term care.

10:30 AM Introduction and Overview of the Process, Maria Rosa Costanzo, MD, FACC, FAHA, Midwest Heart Specialists, Naperville, IL

10:40 AM Perioperative Care of Heart Transplant Recipients: Report From Task Force 1, Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, Ontario, Canada

11:00 AM Immunosuppression: Report From Task Force 2, David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH

11:20 AM Long Term Care for Transplant Recipients: Report From Task Force 3, Sharon A. Hunt, MD, Stanford University Medical Center, Palo Alto, CA

11:40 AM Closing Remarks from Panel

11:45 AM Moderated Panel Discussion

10:30 AM – 12:30 PM SATELLITE SYMPOSIUM 12: Transforming Transplant Care Through Evidence-Based Practice (Marquette)

CHAIRS: LINDA OHLER, MSN, FAAN AND DANIELA ROEFE, RN

Currently there are no published consensus practice guidelines addressing the care of heart transplant recipients. ISHLT has just completed development of such a set of guidelines. This session is intended to share with the ISHLT membership the key consensus recommendations for the care of heart transplant recipients, including early post-operative care, Immunosuppression and long term care.
1:05 PM  (2) Echocardiographic and Hemodynamic Changes during Interruption of Left Ventricular Assist Device May Predict Outcomes after Weaning from the Device; S. Saito,1 G. Matsumiya,1 Y. Sakata,2 T. Sakaguchi,1 S. Miyagawa,1 Y. Yoshikawa,1 T. Yamauchi,1 T. Kuratani,1 Y. Sawa,1 Osaka University Graduate School of Medicine, Suita, Osaka, Japan; 2Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

1:10 PM  (3) Tricuspid Valve Repair at the Time of Left Ventricular Assist Device Implantation: Is It Warranted?; D. Saeed,1 S. Shalli,1 T. Kidambi,1 I. Mikari,1 C. Malaisrie,1 R. Lee,1 W.G. Cotts,1 P.M. McCarthy,1 E.C. McGee,1 Northwestern Memorial Hospital, Chicago; 2Northwestern Memorial Hospital, Chicago; 3Northwestern Memorial Hospital, Chicago.

1:15 PM  (4) Less Frequency of Aortic Valve Opening and Continuous Flow Device Are Risk Factors for Late Onset of Aortic Regurgitation in Patients with Left Ventricular Assist Device; M. Hatano,1 K. Kinugawa,1 T. Shiga,1 A. Yao,1 Y. Hirata,1 T. Nishimura,1 S. Kyo,1 M. Ono,1 R. Nagai,1 The University of Tokyo, Tokyo, Japan; 2The University of Tokyo, Tokyo, Japan; 3The University of Tokyo, Tokyo, Japan.

1:20 PM  (5) Gastrointestinal Bleeding Complications in Continuous Flow LVAD Patients – Is It Device Specific?; I.-W. Wang,1 T. Guthrie,1 G.A. Ewald,2 E.M. Geltman,2 S. Joseph,1 N. Moazami,1 1Washington University School of Medicine, Saint Louis, MO; 2Washington University School of Medicine, Saint Louis, MO.

1:25 PM  (6) Neurological Adverse Events (NAEs) and Proposed Mechanisms in a Single Center Experience with Continuous-Flow Left Ventricular Assist Devices (LVADs); C.M. Halley,1 G.V. Gonzalez-Stawinski,2 E.C. Chu,1 P.M. Eckman,1 N.S. Smedira,1 R.C. Starling,1 M.M. Mountsi,1 Cleveland Clinic Foundation, Cleveland, OH; 2Cleveland Clinic Foundation, Cleveland, OH.

1:30 PM  (7) The Columbia Experience with the Levitronix CentriMag as a Rescue Device in High Risk Patients; B. Worku,1 H. Takayama, D. Van Patten, P. Pak, Y. Naka. Columbia University, New York, NY.

1:35 PM  (8) Development of Aortic Insufficiency in Patients Supported with a HeartMate II Left Ventricular Assist Device (LVAD); S.-W. Pak,2 N. Uriel,1 H. Takayama,2 B. Kachniarz,2 L.K. Murray,2 D. Mancini,1 Y. Naka,1 U.P. Jorde,1 Columbia University, New York, NY; 2Columbia University, New York, NY.

1:40 PM  (9) Use of Mechanical Support Devices in Patients with Mechanical Mitral Valve Prosthesis; A. Goda,1 H. Takayama,2 S.-W. Pak,2 J. Ulrich,1 D. Mancini,1 Y. Naka,2 Columbia University, New York, NY; 2Columbia University, New York, NY.

1:45 PM  (10) Dynamic Occlusion of the Inflow Cannula by Multimodality Cardiac Imaging Heralds Serious Adverse Events in Patients with a Continuous Flow Left Ventricular Assist Device; J. Goerbig-Campbell,1 R.M. Weiss, A. Guha, F.L. Johnson. University of Iowa, Iowa City.

1:50 PM  (11) Quality of Life in HeartMate II LVAD Patients; Destination Therapy Compared to Post Transplant Bridge to Transplant Therapy at 1 Year; J.M. Aho,3 E.A. Ziemia,1 M.J. Schnaus,2 K. Liao,1 M.R. Pritzker,2 M.M. Colvin-Adams,2 R. John,1 1University of Minnesota, Minneapolis, MN; 2University of Minnesota, Minneapolis, MN; 3Chicago Medical School, Chicago, IL; 4University of Minnesota, Minneapolis, MN; 5University of Minnesota, Minneapolis, MN.

1:55 PM  (12) Delayed Sternal Closure Following LVAD Implantation Is a Safe Alternative to Primary Sternal Closure; I.-W. Wang,1 T. Guthrie,1 G.A. Ewald,2 E.M. Geltman,2 S. Joseph,1 N. Moazami,1 Washington University School of Medicine, Saint Louis, MO; Washington University School of Medicine, Saint Louis, MO.

1:00 PM – 2:00 PM MINI ORAL SESSION 2 (Continental C)

CHAIRS: UGOLINO LIVI, MD AND THORSTEN WAHLERS, MD

1:00 PM  (13) Computational Analysis of the Single Antigen Beads Used in Solid Phase Assays for the Detection of Anti-HLA Antibodies; O.E. Pajaro,1 J.K. Kirklin, J.F. George. University of Alabama at Birmingham, Birmingham, AL.

1:05 PM  (14) PVRI <9 W.U. x m2 Does Not Predict Early Postoperative Mortality in Pediatric Cardiac Transplantation for Cardiomyopathy; P. Chiu,1 M.J. Russo,1 R.R. Davies,1 L.J. Addonizio,1 M.E. Richmond,1 J.M. Chen,2 Columbia University, College of Physicians and Surgeons, New York, NY; 2Weill Medical College of Cornell University, New York, NY.


1:15 PM  (16) Dynamics in Lipid Profile Subfractions in Patients Undergoing Cardiac Transplantation; F.H. Cheema,1 T. Khawaja,2 K.J. Schaefler,2 V.K. Topkara,2 S. Yaman,2 A. Chokshi,1 G. Magda,2 M. Argenziano,2 Y. Naka,1 P.C. Schulze,1 Columbia University Medical Center, New York, NY; 2Columbia University Medical Center, New York, NY.

1:25 PM (18) Efficacy Outcome in De-Novo HTxR: Comparison of 6 Immunosuppressive (IS) Regimens (ISR); H.I. Eisen, J.F. Delgado, G. Junge, A. Karpov, H. Lehmkuhl, C. Pellegrini, J. Kobashigawa, H. Schwende, A. Zuckermann, Drexel University College of Medicine, Philadelphia; Madrid Hospital, Madrid, Spain; Novartis Pharma, Basel, Switzerland; Deutsches Herzzentrum Berlin, Berlin, Germany; Policlinico S. Matteo–IRCCS Università degli Studi di Pavia, Pavia, Italy; Cedars-Sinai Heart Institute, Los Angeles, CA; Medical University of Vienna, Vienna, Austria.

1:30 PM (19) Use of Sildenafil for Prevention of Right Heart Failure in Heart Transplant Recipients with Pulmonary Hypertension; H. Bedanova, M. Orban, J. Ondrasek, E.D. Petrikovits, L. Spinarova, P. Nemec, Center of Cardiovascular and Transplant Surgery, Brno, Czech Republic; Cardiocenter Vysochina, Jihlava, Czech Republic; 31st Department of Internal Medicine-Car dioangiology, Brno, Czech Republic.

1:35 PM (20) Heart Transplant Survival at Age 70 and Older Similar to Younger Patients; D. Daneshvar, A. Phan, L. Czer, M. De Robertis, J. Mirocha, E. Schwarz, R.M. Kass, S. Simisir, A. Trento, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA.

1:40 PM (21) Repetitive Episodes of Rejection Is Associated with Reduction of mRNA Expression of Myocardial Sarcoplasmic Reticulum Ca2+-ATPase and Ryanodine Receptor-2 in Transplanted Hearts; T.S. Kato, K. Hashimura, Y. Sata, H. Ueda, T. Nakatani, T. Shishido, K. Komamura, National Cardiovascular Center, Osaka, Japan; National Cardiovascular Center, Osaka, Japan; National Cardiovascular Center, Osaka, Japan; Takeda Pharmaceutical Company Limited, Osaka, Japan; National Cardiovascular Center, Osaka.

1:45 PM (22) Obesity Is Not a Risk Factor for Heart Transplantation; B. Sarayvupoglu, T. Horai, P. Bonde, C.A. Bermudez, J.K. Bhama, S. Tabata, N. Shigemura, R.N. Ramani, M.A. Simon, J.J. Teuteberg, M.A. Mathier, D.M. McNamara, R.L. Kormos, Y. Toyoda. Heart, Lung & Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.


1:55 PM (24) Use of Ventricular Assist Device as a Bridge to Simultaneous Heart and Kidney Transplantation; R. Yanagida, A. Ruzza, Vespignani, L. Czer, E. Schwarz, S. Simisir, S. Jordan, J.L. Cohen, A. Trento, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Medical University of Vienna, Vienna, Austria.

1:00 PM – 2:00 PM
MINI ORAL SESSION 3 (Waldorf)

CHAIRS: PETER JAKSCH, MD AND ALFRED E. WOOD, FRCSI

1:00 PM (25) Donor Specific Antibody (DSA) as a Time Orthotropic Heart Transplantation with Donor Heart Transplant Survival at Age 70 and Older Use of Ventricular Assist Device as a Bridge to Use of Sildenafil for Prevention of Right Heart Lung Transplantation as Treatment for Pulmonary Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Centre Experience; C. Fegbeutel, I. Kropivnitskaya, G. Wärnecke, J. Gottlieb; S. Fischer, M. Strueber, A. Haverich, A.R. Simon. Hannover Medical School, Hannover, Germany; Hannover Medical School, Hannover, Germany.

1:05 PM (26) Novalung Enables Protective Ventilation in Primary Graft Dysfunction; C.P. Searl, T.A. Butt, A. Samuel, N. Wrightson, A.J. Fisher, J.H. Dark. Freeman Hospital, Newcastle upon Tyne, United Kingdom.

1:10 PM (27) Lung Transplantation as Treatment for Pulmonary Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Centre Experience; C. Hui, L.E. Leard, R.F. Boettger. Medical University of Vienna, Vienna, Austria.


1:20 PM (29) Elevations in Troponin-I (Tn-I) Following Lung Transplantation Predict Survival; R. Celis, J.D. Estep, C. Orrego, L. Semones, R. Kasevan, H. Seetharamaju, G.P. Noon, M. Loebe, G. Torre. TMH, Houston, TX; UTMH, Galveston, TX; Baylor College of Medicine, Houston, TX.


1:30 PM (31) Outcome of Lung Transplant Candidates on Mechanical Ventilation or Extracorporeal Support; J. Gottlieb, A.R. Simon, J. Hadem, M. Dierich, O. Wiesner, M. Strueber, T. Welte. Hannover Medical School, Hannover, Germany; Hannover Medical School, Hannover, Germany; Hannover Medical School, Hannover, Germany.
1:35 PM  (32) Role of ImmuKnow Assay Following Lung Transplantation; M.R. Morrell, E.P. Trulock, R.R. Hachem. Washington University/Barnes-Jewish Hospital, St. Louis, MO.

1:40 PM  (33) A Single-Centre Experience with the Use of Posaconazole for Invasive Fungal Infections in Lung and Heart-Lung Transplant Recipients; B.J.H. Ng, P.M.A. Hopkins, F.D. Kermeen, D.C. Chambers. The Prince Charles Hospital, Chermside, QLD, Australia.


1:50 PM  (35) The Australian Experience with Combined Heart-Lung-Liver Transplantation; A. Fieng, K.D. McNeil, F.D. Kermeen, D.C. Chambers, K. Stuart, J. Fawcett, R. Tam, G.J. Hart, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia; The Princess Alexandra Hospital, Brisbane, QLD, Australia; The Princess Alexandra Hospital, Brisbane, QLD, Australia; Townsville Base Hospital, Townsville, QLD, Australia.


1:00 PM – 2:00 PM
MINI ORAL SESSION 4 (Marquette)

CHAIRS: RICHARD D. WEISEL, MD AND ANDREAS O. ZUCKERMANN, MD

1:00 PM  (37) Recipient Cytokine Levels Are Associated with Early Allograft Dysfunction in Human Lung Transplantation; J.G. Allen, M.T. Lee, G.J. Arnaoutakis, C.A. Merlo, Barbara Detrick, PhD, D(ABMLI), A.S. Shah. Johns Hopkins Medical Institutions, Baltimore, MD; Immunology Laboratory/ Cytokine Laboratory Department of Pathology Johns Hopkins Medical Institutions, Baltimore, MD.

1:05 PM  (38) Preservation Enhances Rat Cardiac Allograft Vasculopathy by Advancing Innate Immune and Dendritic Cell Activation, and Inducing IL-17 Production; S.O. Syrjala, R. Krebs, R. Tiuminen, M.A. Keranen, A.I. Nykanen, K.B. Lemstrom. Haartman Institute, University of Helsinki, Helsinki, Finland.


1:20 PM  (41) Results of a Randomized Phase 2 Trial of ALN-RSV01, an RNAi Therapeutic, Lung Transplant (LTX) Patients Infected with Respiratory Syncytial Virus (RSV); M.R. Zamora, M. Budev, M. Rolfe, J. Gottlieb, J. DeVincenzo, C. Cehelsky, G. Albert, J. Gollob, S. Nochur, A. Vaishnaw, A. Glanville, University of Colorado Health Sciences Center, Aurora, CO; Cleveland Clinic, Cleveland, OH; Tampa General Hospital, Tampa, FL; Klinik für Pneumonologie Medizinische Hochschule, Hannover, Germany; University of Tennessee Center for Health Sciences, Memphis, TN; Alnylam Pharmaceuticals, Cambridge, MA; St. Vincent’s Hospital, Darlinghurst, NSW, Australia.


1:30 PM  (43) Prognostic Value of Immune Cell Function Assay on Biopsy Results and Infection in Cardiac Transplant Patients; R. Dancel, C. Wiesen, P. Chang. University of North Carolina, Chapel Hill, NC.


1:55 PM  (48) The Adverse Effects of Sirolimus in Heart Transplant Patients: Is It Worth It?: M. Kittleson, J. Patel, J. Moriguchi, A. Moradzadeh, M. Kawano, S. Davis, A. Ardehali, J. Kobashigawa. 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

2:00 PM  (49) Pulmonary Artery Hypertension: Heart Failure and ACE Inhibition; E.M. Bader, R. Zolty. 1Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; 2Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

1:00 PM – 2:00 PM MINI ORAL SESSION 5 (PDR-2)

CHAIRS: JOSE A. TALLAJ, MD AND DEBRA L. ISAAC, MD

1:00 PM  (50) Everolimus (Certican) after Heart Transplantation: 2 Years’ Single Center Follow-Up in Calcineurin Inhibitor-Free Immunosuppression; M.A. Engelen, H. Welp, J.R. Sindermann, S. Amler, J. Stypmann. 1University Hospital of Muenster, Muenster, Germany; 2University Hospital Muenster, Muenster, Germany; 3University Hospital Muenster, Muenster, Germany.

1:05 PM  (51) Identifying PKC Epsilon as a Target Molecule To Control Intimal Hyperplasia; T. Deuse, T. Koyanagi, H. Reichenspurner, R.C. Robbins, D. Mochly-Rosen, S. Schrepefer. 1University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, CA; 3Stanford University School of Medicine, Stanford, CA.

1:10 PM  (52) Sirolimus as Primary Immunosuppression Is Associated with Improved Renal Function and Survival Compared with Calcineurin Inhibitors in Stable Cardiac Transplant Recipients; M.A. Al-Omari, E. Raichlin, N.L. Pereira, B.S. Edwards, A.L. Clavell, R.J. Rodeheffer, R.P. Frantz, J.A. Schirger, S.S. Kushwaha. Mayo Clinic, Rochester, MN.


1:20 PM  (54) Balancing Volume in Advanced Heart Failure before Heart Transplant: Mismatch between Right and Left Filling Pressures; P. Campbell, M.H. Drazner, M. Kato, N. Lakdawala, A. Nohria, L.W. Stevenson. 1Brigham and Women's Hospital, Boston, MA; 2University of Texas, Southwest Medical Center, Dallas, TX.

1:25 PM  (55) Scintigraphic Heart Retention and Annular Plane Systolic Excursion Predict Outcome in Patients with Senile Systemic Amyloidosis; A.V. Kristen, S. Haufe, P. Schnabel, C. Rocken, S. Hardt, K. Altland, H.A. Katus, T.J. Dengler. 1University of Heidelberg, Heidelberg, Germany; 2University of Heidelberg, Heidelberg, Germany; 3University of Heidelberg, Heidelberg, Germany; 4University of Kiel, Kiel, Germany; 5University of Giessen, Giessen, Germany.

1:30 PM  (56) Characteristics of Patients Receiving Ventricular Assist Devices as a Bridge to Cardiac Transplant Candidacy; S. Emani, L.B. Louis, A. Hasan, C. Sai-Sudhakar, B. Sun. 1The Ohio State University, Columbus, OH; 2The Ohio State University, Columbus, OH.

1:35 PM  (57) Influence of Pulsatile and Non-Pulsatile Perfusion on Kidney Function; H.A. Welp, B. Naafz, P.B. Persson, S.R. Jurgen, H.H. Scheld, A. Hoffmeier. 1University Hospital Münster, Münster, NRW, Germany; 2Fee University of Berlin, Berlin, Germany.

1:40 PM  (58) Thyroid Deficiency Is Common in Advanced Heart Failure and Associated with Increased Operative Mortality after Assist Device Implantation; N. Uriel, S.W. Pak, P. Colombo, R. Song, D. Mancini, Y. Naka, U.P. Jorde. 1Columbia University, New York, NY; 2Columbia University, New York, NY.

1:45 PM  (59) Nesiritide Worsens Renal Insufficiency in Patients with Right Ventricular Failure Due to Pulmonary Hypertension; I. Kelesidis, P. Velankar, R. Chaudhari, R. Zolty. Albert Einstein College of Medicine, Bronx, NY.

1:50 PM  (60) Impact of Pre-Transplant Pulmonary Hypertension on Post-Transplant Outcomes in IPF; S.C. Mathai, R.E. Girgis, A. Shah, P.M. Hassoun, J.F. McDyer, J.B. Orens, C.A. Merlo. 1Johns Hopkins University School of Medicine, Baltimore, MD; 2Johns Hopkins University School of Medicine, Baltimore, MD.

1:55 PM  (61) Correlation of Right Heart Catheterization (RHC) Parameters and Functional Tests after 16 Weeks of Bosentan-Based Therapy in Patients with Pulmonary Arterial Hypertension (PAH): The COM-PASS-3 Study; F. Torres, S. Murali, F.J. Soto, H. Gupta, M.H. Park, N. Frey, R.L. Benza. 1University of Texas Southwestern Medical Center, Dallas, TX; 2Allegheny General Hospital, Pittsburgh, PA; 3Prevea Health, Sheboygan, WI; 4University of Alabama at Birmingham, Birmingham, AL; 5University of Maryland School of Medicine, Baltimore, MD; 6Actelion Pharmaceuticals US, Inc., South San Francisco, CA.
2:30 PM – 4:45 PM
OPENING PLENARY SESSION
(International Ballroom)

CHAIRS: JAMES K. KIRKLIN, MD AND
HERMANN REICHENSPRUNER, MD, PHD

2:30 PM President's Welcome, James K. Kirklin, MD, University of Alabama at Birmingham, AL

2:35 PM Program Chair's Report, Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Germany

2:50 PM ISHLT International Thoracic Registry Report, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN

3:20 PM INTERMACS Report, James K. Kirklin, MD, University of Alabama at Birmingham, AL

3:30 PM INVITED LECTURE, The Evolution of Lung Transplantation, Alec Patterson, Washington University School of Medicine, St. Louis, MO

3:50 PM In Memoriam of Recently Deceased ISHLT Members, James K. Kirklin, MD, University of Alabama at Birmingham, AL

3:55 PM Margaret E. Billingham, MD Memoriam/Lifetime Achievement Award Lecture, Dr. John Billingham and Bruce A. Reitz, MD, Stanford University, CA

4:20 PM Presidential Address, James K. Kirklin, MD, University of Alabama at Birmingham, AL

4:45 PM – 5:15 PM
Coffee Break (Southeast Exhibit Hall)

5:15 PM – 6:45 PM
CONCURRENT SESSION 1:
Patients, Pumps and Outcomes (International Ballroom)

CHAIRS: KATHERINE LIETZ, MD, PHD AND
ALY EL BANAYOSY, MD

5:15 PM (62) Strategies for LVAD Therapy in INTERMACS: Intent Rate v. Event Rate; JJ Teuteberg, G.C. Stewart, M. Jessup, R.L. Kormos, B. Sun, O.H. Frazier, D.C. Naftel, L.W. Stevenson. Brigham and Women's Hospital, Boston, MA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pennsylvania, Philadelphia, PA; Ohio State University Medical Center, Columbus, OH; Texas Heart Institute, Houston, TX; University of Alabama at Birmingham, Birmingham, AL.

5:30 PM (63) INTERMACS Profiles of Nutrition and Organ Function in Relation to Outcomes; M. Liszkowski, J.J. Teuteberg, S.L. Myers, J.G. Rogers, R. Starling, D.D. Ascheim, L.W. Stevenson. Brigham and Women's Hospital, Boston, MA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Alabama at Birmingham, Birmingham, AL; University of Virginia, Charlottesville, VA.

6:30 PM – 8:00 PM
CONCURRENT SESSION 2:
Patients, Pumps and Outcomes (Continental A/B)

CHAIRS: ROBERTO FIOCCI, MD, PHD AND KEITH D. AARONSON, MD

5:15 PM (64) Rapidly Changing Characteristics of Patients Receiving Mechanically Assisted Circulatory Support in INTERMACS; F.D. Pagani, D.C. Naftel, K.D. Aaronson, M.K. Parides, D.J. Farrar, S.V. Pamboukian, J.K. Kirklin. University of Michigan, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Mount Sinai School of Medicine, New York, NY; Thoratec Corporation, Pleasanton, CA.

6:00 PM (65) Changing Patterns and Regional Differences in the Use of Ventricular Assist Devices as a Bridge-to-Transplant: An Analysis of UNOS Data; F. Kamdar, R. John. University of Minnesota, Minneapolis, MN.

6:15 PM (66) Destination Therapy: Improving Outcomes with Continuous Flow LVADs; M.S. Slaughter, J.G. Rogers, L. Blue, A.J. Lodge, A.J. Tatooles, G. Bhat, C.A. Milano. University of Louisville, Louisville, KY; Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC; Advocate Christ Medical Center, Oak Lawn, IL; Advocate Christ Medical Center, Oak Lawn, IL; University of Louisville, Louisville, KY; Duke University Medical Center, Durham, NC.

5:15 PM – 6:45 PM
CONCURRENT SESSION 2:
Patients, Pumps and Outcomes (Continental A/B)

CHAIRS: ROBERTO FIOCCI, MD, PHD AND KEITH D. AARONSON, MD


Effect of High Frequency Chest Wall Oscillation Versus Chest Physiotherapy on Lung Function Post-Lung Transplant: A Pilot Study; T. Marcarian, M. Ila- 

A High-Intensity Exercise Program Decreases Self-Reported Anxiety in Cardiac Transplant Recipients: A Randomized Study; S.B. Christensen,1 C.H. Dall,2 T. Hermann,3 E. Prescott,4 F. Gustafsson.1 1Rigshospitalet, Copenhagen, Denmark; 2Bispebjerg Hospital, Copenhagen, Denmark.

Concurrent Session 5: Improving Donor and Recipient Selection in Pediatric Transplantation (Waldorf)

CHAIRS: LORI J. WEST, MD, DPHIL AND ERFRIEDE PAHL SCHUETTE, MD

Outcomes of Children Implanted with Ventricular Assist Device Therapy: Analysis of the Interagency Registry for Mechanical Circulatory Support (INTERMACS); E.D. Blume,1 D.N. Rosenthal,2 J.M. Chen,3 C.S.D. Almond,1 P.D. Wearden,4 D.C. Naftel,5 J.K. Kirklin,6 1Children's Hospital, Boston, MA; 2Stanford University Medical Center, Palo Alto, CA; 3Morgan Stanley Children's Hospital of New York-Presbyterian, New York, NY; 4Children's Hospital of Pittsburgh, Pittsburgh, PA; 5University of Alabama at Birmingham, Birmingham, AL.

Influence of the New Heart Allocation System on Pediatric Waitlist and Post-Transplant Survival; A. Iribarne,7 M.J. Russo,8 R.R. Davies,9 H. Takayama,2 J.M. Quaegebeur,1 J.A. Kobashigawa,2 M.C. Fishbein,1 E.F. Reed.1 1Children's Hospital, Boston, MA; 2Stanford University Medical Center, Palo Alto, CA; 3Morgan Stanley Children's Hospital of New York-Presbyterian, New York, NY; 4Children's Hospital of New York-Presbyterian, New York, NY.


A Novel Approach to Size-Matching for Pediatric Heart Transplantation. Can We Do Better?; W.A. Zuckerman,1 M.E. Richmond,1 R.K. Singh,1 J.M. Chen,2 K. Altmann,1 L.J. Addonizio.1 1New York Presbyterian Hospital/Columbia University Medical Center, New York, NY; 2New York Presbyterian Hospital/Columbia University Medical Center, New York, NY.

Body Mass Index and Its Impact on Outcome in Children after Lung Transplantation: An Analysis of the ISHLT Pediatric Lung Transplant Registry; C. Benden,1 D.A. Ridout,2 S.C. Sweet,3 A. Boehler.1 1University Hospital Zurich, Zurich, Switzerland; 2University of Child Health, London, United Kingdom; 3Washington University School of Medicine, St. Louis, MO.

Validation of a Risk Prediction Model for In-hospital Mortality Following Pediatric Heart Transplantation; C.S. Almond,1 K. Gauvreau,1 C. Canter,4 G.E. Piercey,1 T.P. Singh.1 1Children's Hospital Boston, Boston, MA; 3St. Louis Children's Hospital, St. Louis, MO.

Clinical Risk-Prediction of a Novel Thrombo- sis/Activation (TA) Score to Prognosticate Long-Term Cardiac Allograft Vasculopathy (CAV) in Heart Transplant Patients; C.A. Labarrere,1 J.R. Woods,1 J.W. Hardin,2 G.L. Campana,1 M.A. Ortiz,3 B.R. Jaeger,4 B. Reichart,4 L.A. Baldridge,5 J.M. Bonnin,6 A. Currin,6 S.K. Cosgrove,6 P.C. Kirlin,7 J.A. O'Donnell,7 D.A. Hormuth,8 T.C. Wozniak.6 1Clarian Health Partners, Indianapolis, IN; 2University of South Carolina, Columbia, SC; 3Dr Stein und Kollegen, Monchengladbach, Germany; 4Ludwig-Maximilians-Universitat, Munchen, Germany; 5Indiana University School of Medicine, Indianapolis, IN; 6Clarian Health Partners, Indianapolis, IN; 7Krannef Institute of Cardiology, Indianapolis, IN.

Phosphoproteomic Analysis of Cardiac Allograft Biopsies Reveals Novel Markers of Antibody Mediated Rejection; C. Lai,1 J. Wei,1 F. Li,1 Q. Zhang,1 D. Gjertson,1 J.A. Kobashigawa,2 M.C. Fishbein,1 E.F. Reed.1 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

C4d Methodology and Interpretation in Biopsy Diagnosis of Cardiac Antibody-Mediated Rejection: A European Survey from the Transplant Working Group of the Association for European Cardiovascular Pathology (AECVP); M. Burke,1 C. Andersen,2 M. Ashworth,3 F. Black,4 P. Bruneval,5 G. De Maglio,6 H.
Doran,7 M. Fedrigo,6 M. Goddard,9 M. Gonzalez-Cuesta,10 R. Gouveia,11 S. Hoyer,12 M. Kment,13 S. Lantuejoulé,14 O. Leone,15 F. Lopez-Rubio,16 N. Monset,17 D. Neil,18 F. Paraf,19 J. Pardo,20 A. Raisanen-Sokolowski,21 J. Ramirez,22 D. Rassl,23 F. Reinhold,14 S. Rotman,22 S. Stewart,2 B. Weynand,2 F. Yilmaz,28 G. Thiene,9 A. Angelini,8 1Harefield Hospital, London, United Kingdom; 2Rigshospitalet, Copenhagen, Denmark; 3Hôpital de Santa Cruz, Lisbon, Portugal; 4University Hospital, Aarhus, Denmark; 5Institute for Clinical and Experimental Medicine, Prague, Czech Republic; 6University Hospital A Michallon, Grenoble, France; 7S. Orsola-Malpighi, Bologna, Italy; 8University Hospital Reine Sofia, Cordoba, Spain; 9Lund University Hospital, Lund, Sweden; 10Queen Elizabeth University Hospital, Birmingham, United Kingdom; 11Centre Hospitalier Universitaire Dupuytren, Limoges, France; 20University of Navarra, Pamplona, Spain; 23Helsinki University Central Hospital, Helsinki, Finland; 24Hospital Clinic, Barcelona, Spain; 25Papworth Hospital, Cambridge, United Kingdom; 26University Hospital, Oslo, Norway; 27Institut Universitaire de Pathologie, Lausanne, Switzerland; 28Papworth Hospital, Cambridge, United Kingdom; 29Cliniques Universitaires St Luc, Brussels, Belgium; 30University of Ege, Izmir, Turkey; 31University of Padua, Padua, Italy; 32University of Padua, Padua, Italy.

6:15 PM  (96) **C4d in Heart Transplant Biopsies Does Not Appear to Represent Poor Outcome**  
C. Lai,1 J. Patel,2 M. Fishbein,1 M. Kittleson,2 M. Share,2 S. Davis,2 M. Kawano,3 J. Moriguchi,4 A. Ardehali,1 J. Kobashigawa.2  
1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2 Cedars-Sinai Heart Institute, Los Angeles, CA; 3 Cedars-Sinai Medical Center, Los Angeles, CA.

6:30 PM  (97) **What Are the Best Antibody Predictors of AMR Resulting in Cardiac Death?**  

5:30 PM – 6:30 PM  
PAST PRESIDENT’S COUNCIL MEETING (Joliet)

6:45 PM – 7:45 PM  
EXHIBIT HALL OPENING RECEPTION  
(Southeast Exhibit Hall)

VIEW POSTERS (Southwest Exhibit Hall)

**Thursday, April 22, 2010**

7:00 AM – 6:00 PM  
Registration Desk Open (4th Street Registration)

7:00 AM – 7:00 PM  
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM  
MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC COUNCIL MEETING (Marquette)

PULMONARY ARTERIAL HYPERTENSION SCIENTIFIC COUNCIL MEETING (Joliet)

PATHOLOGY AND BASIC SCIENCE SCIENTIFIC COUNCIL MEETING (PDR-2)

INFECTIOUS DISEASE SCIENTIFIC COUNCIL MEETING (Waldorf)

8:30 AM – 10:15 AM  
PLENARY SESSION  
(International Ballroom)

CHAIRS:  
Mandeep R. Mehra, MD and John Wallwork, FRCS

8:30 AM  INVITED LECTURE, The 2010 ISHLT Post Heart Transplantation Guidelines, Maria Rosa Costanzo, MD, FACC, FAHA, Midwest Heart Specialists, Naperville, IL

8:45 AM (98) FEATURED ABSTRACT Comparison of Gene Expression Profiling and Endomyocardial Biopsy for Surveillance of Acute Cardiac Cellular Rejection: Results from the IMAGE Trial  
M.X. Pham,4 A.G. Kfoury,5 A. Raisanen-Sokolowski,21 J. Ramírez,22 D. Rassl,2 F. Reinhold,14 S. Rotman,22 S. Stewart,2 B. Weynand,2 F. Yilmaz,28 G. Thiene,9 A. Angelini,8 1Harefield Hospital, London, United Kingdom; 2Rigshospitalet, Copenhagen, Denmark; 3Hôpital de Santa Cruz, Lisbon, Portugal; 4University Hospital Aarhus, Denmark; 5Institute for Clinical and Experimental Medicine, Prague, Czech Republic; 6University Hospital A Michallon, Grenoble, France; 7S. Orsola-Malpighi, Bologna, Italy; 8University Hospital Reine Sofia, Cordoba, Spain; 9Lund University Hospital, Lund, Sweden; 10Queen Elizabeth University Hospital, Birmingham, United Kingdom; 11Centre Hospitalier Universitaire Dupuytren, Limoges, France; 20University of Navarra, Pamplona, Spain; 23Helsinki University Central Hospital, Helsinki, Finland; 24Hospital Clinic, Barcelona, Spain; 25Papworth Hospital, Cambridge, United Kingdom; 26University Hospital, Oslo, Norway; 27Institut Universitaire de Pathologie, Lausanne, Switzerland; 28Papworth Hospital, Cambridge, United Kingdom; 29Cliniques Universitaires St Luc, Brussels, Belgium; 30University of Ege, Izmir, Turkey; 31University of Padua, Padua, Italy; 32University of Padua, Padua, Italy.

8:55 AM INVITED DISCUSSANT, Jayan Parameshwar, FRCP, Papworth Hospital, Cambridge, United Kingdom
9:00 AM  (99) FEATURED ABSTRACT  Risk of Bronchiolitis Obliterans Syndrome Is Twice as High in Cyclosporine Treated Patients in Comparison to Tacrolimus 3 Years after Lung Transplantation: Results of a Prospective Randomized International Trial of 248 Patients; H. Treede, A. Glanville, W. Klepetko, R. Lama, C. Bravo, M. Estenne, J.-D. Aubert, C. Aboyoun, H. Reichenspurner. 1 University Heart Center Hamburg, Hamburg, Germany; 2 St. Vincent's Hospital, Sydney, NSW, Australia; 3 University Hospital Vienna, Vienna, Austria; 4 University Hospital Reina Sofia, Cordoba, Spain; 5 Hospital Vall d’Hebron, Barcelona, Spain; 6 Erasme University Hospital, Brussels, Belgium; 7 University Hospital Lausanne, Lausanne, Switzerland.

9:10 AM  INVITED DISCUSSANT, Paul A. Corris, MB FRCP, Freeman Hospital, Newcastle, United Kingdom

9:15 AM  INVITED LECTURE,  Prospect of Xenotransplantation, Bruno Reichart, MD, University of Munich/Grosshadern, Munich Germany


9:45 AM  INVITED DISCUSSANT, Steven A. Webber, MB, ChB, Children's Hospital of Pittsburgh, Pittsburgh, PA

9:50 AM  (101) FEATURED ABSTRACT  Are Recipients from Heart Donors Listed as Homeless at Increased Risk for Poor Outcome after Heart Transplantation?; D. Lockhart, L. Doering, C. Burch, S. Montgomery, A. Velleca, J. Patel, M. Kittleson, S. Davis, M. Kawano, Z. Goldstein, A. Moradzadeh, J. Moriguchi, A. Ardehali, J. Kobashigawa. 1 David Geffen School of Medicine at UCLA, Los Angeles, CA; 2 Cedars-Sinai Heart Institute, Los Angeles, CA.

10:00 AM  INVITED DISCUSSANT, Duane Davis, MD, Duke University, Durham, NC

9:00 AM – 5:00 PM  Press Office Open (Continental Foyer Office 1)

10:00 AM – 4:30 PM  Exhibit Hall Open (Southeast Exhibit Hall)

9:00 AM – 5:00 PM

10:00 AM – 4:30 PM

10:00 AM – 4:30 PM

10:15 AM – 10:45 AM  Coffee Break (Southeast Exhibit Hall)

10:45 AM – 12:15 PM

CONCURRENT SESSION 7:  Battle of the Sexes – PT Selection (International Ballroom)

CHAIRS: ROBERTA C. BOGAEV, MD, FACC AND ERIK A. M. VERSCHUUREN, MD, PHD


11:00 AM  (103) Sex Differences in Usage of Mechanical Circulatory Support and Pre-Implant Baseline Characteristics Using the INTERMACS Database; K. O’Callaghan, M. Camacho, T. Martin, K.L. Lockard, M.A. Miller, J.B. Young. 1 Food and Drug Administration, Silver Springs, MD; 2 Newark Beth Israel Medical Center, Newark, NJ; 3 University of Pittsburgh Medical Center, Pittsburgh, PA; 4 National Heart Lung and Blood Institute, Bethesda, MD; 5 Cleveland Clinic Foundation, Cleveland, OH.

11:15 AM  (104) Survival after Implant of a Left Ventricular Assist Device: Is It the Device or Is It the Patient?; J.G. Rogers, F.D. Pagani, J.K. Kirklin, D.C. Naftel, R.J. Morris, W.P. Dembitsky, M.S. Blood, J.B. Young. 1 Duke University Medical Center, Durham, NC; 2 University of Michigan Medical Center, Ann Arbor, MI; 3 University of Alabama at Birmingham, Birmingham, AL; 4 University of Pennsylvania, Philadelphia, PA; 5 Sharp Memorial Hospital, San Diego, CA; 6 Cleveland Clinic Foundation, Cleveland, OH.

11:30 AM  (105) Decreased Survival after Bi-VAD Implant: Is It the Bi-VAD or the Patient?; J. Cleveland, T.B. Reece, D.C. Naftel, J.F. Antaki, M.A. Murray, J.K. Kirklin, R.L. Kormos. 1 University of Colorado at Denver, Aurora, CO; 2 University of Alabama at Birmingham, Birmingham, AL; 3 University of Pennsylvania, Philadelphia, PA; 4 Sharp Memorial Hospital, San Diego, CA; 5 Cleveland Clinic Foundation, Cleveland, OH.

11:45 AM  (106) Equivalent Outcomes of Ventricular Assist Device (VAD) Patients by Gender in the Modern Era of Mechanical Support; E.A. Genovese, M.A. Dew, J.J. Teuteberg, C.A. Bermudez, D.M. McNamara, S. Winowich, A. Weimer, R.L. Kormos. 1 University of Pittsburgh School of Medicine, Pittsburgh, PA; 2 University of Pittsburgh School of Medicine, Pittsburgh, PA; 3 University of Pittsburgh Medical Center, Pittsburgh, PA; 4 University of Pittsburgh Medical Center, Pittsburgh, PA.

12:00 PM  (107) Sex-Specific Differences in Outcome and Adverse Events with Primary Left Ventricular Assist Device Support Using the INTERMACS Database; E.M. Hsich, D.C. Naftel, S.L. Myers, K.L. Grady, D. Schumil, K.L. Ulisney, J.B. Young. 1 Cleveland

THURSDAY
10:45 AM – 12:15 PM
CONCURRENT SESSION 8:
Heart Transplantation Outcome (Continental A/B)
CHAIRS: GIUSEPPE FAGGIAN, MD AND RANDALL C. STARLING, MD, MPH


11:15 AM (110) Outcomes after Heart Transplantation for Chemotherapy-Induced Cardiomyopathy: Results from a Multi-Center Registry; B.W. Hardaway, A.Y. Kucheryavaya, L.B. Edwards, J. Stehlík, D.O. Taylor. 1Cleveland Clinic, Cleveland, OH; 2United Network for Organ Sharing, Richmond, VA; 3University of Utah, Salt Lake City, UT.


12:00 PM (113) Impact of 1 Year Creatinine on Long-Term Survival after Cardiac Transplantation; A.Z. Aliabadi, S.L. Mahr, D. Dunkler, M. Groemer, F.A. Eskandary, D. Zimpfer, M. Grimm, G. Laufer, A.O. Zuckermann. Medical University of Vienna, Vienna, Austria.

10:45 AM – 12:15 PM
CONCURRENT SESSION 9:
Donor Influences on Outcomes After Lung Transplant (Continental A/B)
CHAIRS: STEPHEN C. CLARK, MD AND DUANE DAVIS, MD

10:45 AM (114) The Role of Chronic Alcohol Abuse in the Development of Primary Graft Dysfunction (PGD) in Lung Transplant (LTx) Recipients; A. Pelaez, N. Shah, S.D. Force, E.C. Lawrence, A.M. Ramirez, D.C. Neuhaus, R.O. Mitchell, D.M. Guidot. 1Emory University School of Medicine, Atlanta, GA; 2Emory University School of Medicine, Atlanta, GA; 3Emory University School of Medicine, Atlanta, GA.

11:00 AM (115) Successful Lung Transplant Outcomes with “High Risk Donors”; S. Novosad, S.M. Palmer, R.D. Davis, S. Lin, D.W. Zaas. 1Duke University, Durham, NC; 2Duke University, Durham, NC.

11:15 AM (116) Lung Transplantation with Lungs from Donors 55 Years or Older; T. Horai, N. Shigemura, P. Bonde, B. Sarayyupoglu, S. Tabata, J. Pilewski, M. Crespo, B. Johnson, P. George, M. Morrell, R.L. Kormos, J.K. Bhma, S. Gilbert, C.A. Bermudez, Y. Toyoda. 1University of Pittsburgh Medical Center, Pittsburgh, PA; 2University of Pittsburgh Medical Center, Pittsburgh, PA.

11:30 AM (117) Postoperative Results in Lung Transplantation with Donors 60 Years and Older; J. Lopez, A. Jaregui, J. Sole, M. Deu, O. Ajanguren, J. Rosado, J. Teixidor, L. Tenorio, V. Monforte, M. Canela. 1Hospital Vall d’Hebron, Barcelona, Spain; 2Hospital Vall d’Hebron, Barcelona, Spain; 3Hospital Vall d’Hebron, Barcelona, Spain.

11:45 AM (118) Donation after Cardiac Death (DCD) Lung Allografts Have a Low Incidence of Primary Graft Dysfunction (PGD) after Transplantation (LTx); C.H. Wigfield, J.W. Smith, C.G. Alex, A. D’Allesandro, R.B. Love. 1Loyola University Medical Center, Maywood, Chicago, IL; 2Loyola University Medical Center, Maywood, Chicago, IL; 3University of Wisconsin Hospitals and Clinics, Madison, WI.

12:00 PM (119) Long Term Pulmonary Graft Function in Pediatric Recipients after Living-Donor Lobar Lung Transplantation; M. Yamane, S. Toyooka, T. Oto, Y. Sano, S. Miyoshi. Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

10:45 AM – 12:15 PM
CONCURRENT SESSION 10:
Novel Genomic, Proteomic & Clinical Risk Markers in PAH (Continental C)
CHAIRS: JUERGEN BEHR, MD AND KEITH MCNEIL, FRACP
10:45 AM (120) Gene Expression Signature in the Explanted Lung Is a Better Predictor of Primary Graft Dysfunction after Lung Transplantation than Pulmonary Artery Pressures in Patients with Pulmonary Fibrosis; M. Mura,1,2 M. Anraku,1,2 Z. Yun,1 C. Chaparro,1 K. McRae,1 M. Liu,1 M. Hutcheon,1 T.K. Waddell,1,2 L.G. Singer,2 J.T. Granton,3 S. Keshavjee,1,2 M. de Perrot,1,2 1Latner Thoracic Surgery Research Laboratories, Toronto, ON, Canada; 2Toronto Lung Transplant Program, Toronto, ON, Canada; 3Pulmonary Hypertension Program, Toronto, ON, Canada.

11:00 AM (121) Soluble ST2 Is Associated with Right Heart Failure and Is Independently Predictive of Event Free Survival in Pulmonary Arterial Hypertension; J.E. Rame,1 D. McGlothlin,2 A.H.B. Wu,3 J.O. Hernandez,2 E. Kobashigawa,2 T. De Marco.2 1University of Pennsylvania, Philadelphia, PA; 2University of California San Francisco, San Francisco, CA; 3University of California San Francisco School of Medicine, San Francisco, CA.

11:15 AM (122) Therapy-Related Shifts in NT-proBNP Correlate with Changes in 6MWD and cMRI Parameters in Bosentan-Treated Patients with PAH: The COMPASS-3 Study; M.H. Park,1 S. Murali,2 E.J. Soto,3 F. Torres,4 H. Gupta,5 N. Frey,6 R.L. Benza,2 1University of Maryland School of Medicine, Baltimore, MD; 2Allegheny General Hospital, Pittsburgh, PA; 3Prevea Health, Sheboygan, WI; 4University of Texas Southwestern Medical Center, Dallas, TX; 5University of Alabama at Birmingham, Birmingham, AL; 6Actelion Pharmaceuticals US, Inc., South San Francisco, CA.

11:30 AM (123) Association between Serial 6-Minute Walk Distance (6MWD) Assessments and the REVEAL Pulmonary Arterial Hypertension (PAH) Risk Score Calculator; R.L. Benza,1 D.P. Miller,2 R.P. Frantz,3 A.J. Foreman,2 H.W. Farber,4 A.E. Frost,5 R.J. Barst,6 C.G. Elliott,7,8 M.D. McGoon.3 1Allegheny General Hospital, Pittsburgh, PA; 2ICON Clinical Research, San Francisco, CA; 3Mayo Clinic, Rochester, MN; 4Boston University Medical Center, Boston, MA; 5Baylor College of Medicine, Houston, TX; 6Columbia University College of Physicians and Surgeons, New York, NY; 7Intermountain Medical Center, Murray, UT; 8University of Utah, Salt Lake City, UT.


12:00 PM (125) RV Function Is Essential for Accurate Estimation of Right Ventricular Systolic Pressure by Transthoracic Doppler Echocardiography; A.L. Rieth, V. Mitrovic. Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.

10:45 AM – 12:15 PM CONCURRENT SESSION 11: Stem Cells: Basic and Translational Approaches (Waldorf)

CHAIRS: JOSEPH WOO, MD AND TERRENCE M. YAU, MD, MSC

10:45 AM (126) Withdrawn

11:00 AM (127) Tolerance Induction with Stem and Progenitor Cells: Potential Role for Regulatory T Cells; L. Sun,1,2 K. Trapp,1,3 E. Inagaki,1,2 J. Domen,1,2,3 K. Gandy,1,2 1Children's Research Institute, Milwaukee, WI; 2Children's Hospital of Wisconsin (Herma Heart Center), Milwaukee, WI; 3Medical College of Wisconsin, Milwaukee, WI.

11:15 AM (128) Immunogenicity of Fetal Mesenchymal Stem Cells from the Umbilical Cord Line for Regenerative Therapies; K.R. Tang-Quan,1,2 M.V.V. Kolb,1 T. Deuse,1,2 N. Philipp,3 M. Kay,3 R.C. Robbins,2 H. Reichenspurner,1 S. Schrepefer.1,2 1University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, CA; 3Stanford University, Stanford, CA.

11:30 AM (129) Autologous Bone Marrow Cell Implantation Attenuates Left Ventricular Remodeling and Improves Heart Function in Porcine Myocardial Infarction: An Echocardiographic, Six-Month Angiographic, and Molecular-Cellular Study; E.Y. Lee,1 H.-K. Yip,2 C.-K. Sun,3 J.-J. Sheu,1 L.-T. Chang,4 C.-M. Yuen,5 C.-H. Yen,6 C.-H. Chiang,7 S.-F. Ko,8 S.-N. Pei,9 S. Chua,9 A.A. Youssef,10 C.-J. Wu,1 Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Kaohsiung, Taiwan; Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; Meiho Institute of Technology, Pingtung, Taiwan; Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; National Pingtung University of Science and Technology, Pingtung, Taiwan; National Pingtung University of Science and Technology, Pingtung, Taiwan; Chang Gung Memorial Hospital-Kaohsiung Medical, Kaohsiung, Taiwan; Chang Gung Memorial Hospital-Kaohsiung Medical, Kaohsiung, Taiwan; Suez Canal University Hospital, Ismailia, Egypt.

11:45 AM (130) Circulating Mesenchymal Stem Cells Are Associated with Cardiac Allograft Vasculopathy; S. Aharinejad,1,2 M. Salama,1,2 O. Andrukhova,2 A. Thomas,2 S. Rodler,1 A. Zuckermann,1 G. Laufar,1 M. Grimm.1 1Medical University of Vienna, Vienna, Austria; 2Medical University of Vienna, Vienna, Austria.
12:00 PM (131) Changes in Gene Expression and Improvement in Perioperative Outcomes after Orthotropic Cardiac Xenotransplantation; C.G.A. McGregor,1,2 M. Vlasin,1 R.C. Walker,1 H.D. Tazelaar,1 K. Chandrasekaran,1 B.A. Boilson,1 G.W. Byrne,1,2 1 Mayo Clinic, Rochester, MN; 2University College London, London, United Kingdom.

10:45 AM – 12:15 PM
CONCURRENT SESSION 12:
Immunosuppression After Heart Transplantation: Is Less More?
(Marquette)

CHAIRS: BRUNO M. MEISER, MD AND ALLEN S. ANDERSON, MD, FACC

10:45 AM (132) Everolimus Introduction with CNI Minimization Significantly Improves Renal Function in Thoracic Transplant Recipients: A Scandinavian Multicenter, Randomized Study; L. Gullestad,1 B. Rundqvist,2 S.A. Mortensen,3 H. Eiskjaer, G.C. Riise,2 L. Mared,3 O. Bjortuft,4 B. Ekmechag,5 K. Jansson,7 S. Simonsen,1 E. Gude,1 H. Fagertun,6 D. Solbu,6 M. Iversen,6 1 Oslo University Hospital, Rikshospitalet, Oslo, Norway; 2Sahlgrenska University Hospital, Gothenburg, Sweden; 3Rigshospitalet, Copenhagen, Denmark; 4Aarhus University Hospital, Aarhus, Denmark; 5University of Lund, Lund, Sweden; 6Oslo University Hospital, Rikshospitalet, Oslo, Norway; 7University Hospital Linköping, Linköping, Sweden.

11:00 AM (133) Tacrolimus in Combination, Tacrolimus Alone Compared: 5 Year Results of the TICTAC Trial; D.A. Baran,1 M.J. Zucker,1 M.E. Goldschmidt,1 J. Prevost-Fernandez,1 C. Carr,1 S. Pardi,1 V. Hou,1 M. Binetti,1 M.G. San Agustin,1 J. Ebuenga,1 A. Gass,2 M. Camacho.1 1 Newark Beth Israel Medical Center, Newark, NJ; 2Westchester Medical Center, Westchester, NY.

11:15 AM (134) A Randomized Study Using Humanized Monoclonal Antibody Against Cd52 (Campath-1H) and Tacrolimus in Heart Transplant Recipients; S.M. Pham,1 B.M. Bednar,1 A. Panos,1 E.J. Bauerlein,2 F. Jimenez,2 E. Rosenkranz,1 M. Ricci,1 P. Rusconi,1 S. Chaparro,2 M.A. Aycart,1 R. Hershberger.1 1 University of Miami, Miami, FL; 2University of Miami, Miami, FL; 3University of Miami, Miami, FL.

11:30 AM (135) Experimental Transplantation: Novel Immunosuppression Using the JAK3-Inhibitor R348; T. Deuse,1,2 E. Masuda,3 V. Taylor,4 G. Park,4 D. Carroll,3 H. Reichenspurner,1 J. Velotta,2 R. Robbins,2 S. Schrepfer,1,2 1 University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, CA; 3Rigel, San Francisco, CA.

11:45 AM (136) Effect of Everolimus Introduction and Calcineurin Inhibitor Reduction on Graft Vasculopathy in Heart Transplant Recipients; S. Arora,1 B. Wennenblom,7 B. Rundqvist,7 H. Eiskjaer,3 H.E. Botker,5 S.-A. Mortensen,4 K. Saunameki,4 B. Ekmechag,5 K. Jansson,9 S. Simonsen,1 E. Gude,1 K. Endresen,1 D. Solbu,7 L. Gullestad.1 1 Oslo University Hospital, Oslo, Norway; 2Sahlgrenska University Hospital, Gothenburg, Sweden; 3Skei University Hospital, Aarhus, Denmark; 4Rigshospitalet, Copenhagen, Denmark; 5Lund Hospital, Lund, Sweden; 6Heart Center University Hospital, Linköping, Sweden; 7Novartis Norge AS, Oslo, Norway.

12:15 PM – 2:15 PM
Lunch Break

12:15 PM – 2:15 PM
JUNIOR FACULTY AND TRAINEE COUNCIL MENTOR LUNCHEON (PDR-2) (advance ticket purchase required)

12:30 PM – 2:00 PM
INTERNATIONAL PEDIATRIC LUNG TRANSPLANT COLLABORATIVE MEETING (Joliet)

2:30 PM – 4:00 PM
CONCURRENT SESSION 13:
Device Disasters: Can We Avoid Them? (International Ballroom)

CHAIRS: JAN F. GUMMERT, MD, PHD AND FINN GUSTAFSSON, MD, PHD

2:30 PM (138) Neurocognitive Evaluation of Destination Therapy Patients Receiving Continuous Flow Left Ventricular Assist Devices; R.J. Petrucci,1 J.G. Rogers,2 L. Blue,2 C.T. Gallagher,3 S.D. Russell,2 D. Dorduno,4 B.E. Jaski,5 S. Chillcott,1 B.C. Sun,6 T.L. Yanssens,6 A.J. Tatooles,3 L. Koundakjian,7 D.J. Farrar,7 M.S. Slaughter.8 1 Drexel University College of Medicine, Philadelphia, PA; 2 Duke University, Durham, NC; 3 Advocate Christ Medical Center, Oak Lawn, IL; 4 Johns Hopkins University Medical Center, Baltimore, MD; 5 Sharp Memorial Hospital, San Diego, CA; 6 Ohio State University, Columbus, OH; 7 Thoratec Corporation, Inc., Pleasanton, CA; 8 University of Louisville, Louisville, KY.

2:45 PM (139) Reducing Adverse Neurological Events in LVAD Patients: Pulsatile vs. Continuous Flow; S.J. Park,1 D.C. Naftef,2 M.S. Slaughter,3 M.A. Sobieski,3 L.L. Staley,4 J.A. Tallaj,2 J.T. Baldwin,3 J.K. Kirklin.1 1 Mayo Clinic, Rochester, MN; 2University of Alabama at Birmingham, Birmingham, AL; 3University of Louisville, Louisville, KY; 4 Mayo Clinic, Phoenix, AZ; 5 National Heart, Lung and Blood Institute, Bethesda, MD.
3:00 PM (140) Standardized Psychosocial Evaluation Prior to LVAD May Predict Mortality and Length of Stay; P.M. Eckman,1,2 G.V. Gonzalez-Stawinski,1 K. Kendall,1 D. Racicki,1 W. Tang,1 R.C. Starling,1 M.M. Mountis,1 Cleveland Clinic Foundation, Cleveland, OH; 2University of Minnesota, Minneapolis, MN.

3:15 PM (141) Infection during Mechanical Circulatory Support: Can We Really Expect a Better Outlook with Continuous Flow Technology; C.A. Milano,1 D.C. Naftel,1 R.F. Padera,1 R.C. Starling,1 D.M. McNamara,1 S.V. Pamboukian,2 S.L. Myers,2 R.L. Kormos,3 Duke University Medical Center, Durham, NC; 2University of Alabama at Birmingham, Birmingham, AL; 3Brigham and Women’s Hospital, Boston, MA; 4Cleveland Clinic, Cleveland, OH; 5University of Pittsburgh Medical, Pittsburgh, PA.

3:30 PM (142) Lead Fractures in Left Ventricular Assist Devices – A Multi-Institutional Experience; Y. Ravi,1 R. John,2 C. Salerno,1 Y. Tamara,1 S. Wissman,1 M. Firstenberg,1 B. Sun,1 L. Louis,1 C.B. Sai Sudhakar,1 The Ohio State University Medical Center, Columbus, OH; 2University of Minnesota, Minneapolis, MN; 3St. Vincent’s Hospital, Indianapolis, OH.

3:45 PM (143) Pump Replacement for LVAD Failure Can Be Done Safely and Is Associated with Low Mortality; N. Moazami,1 B. Sun,2 C. Milano,1 R. John,1 J. Conte,3 R. Adamson,4 F. Pagani,7 O.H. Frazier,8 D. Farrar,9 M. Slaughter,10 1Washington University School of Medicine, St. Louis, MO; 2Ohio State University, Columbus, OH; 3Duke University Medical Center, Durham, NC; 4University of Minnesota, Minneapolis, MN; 5Johns Hopkins University, Baltimore, MD; 6Sharp Memorial Hospital, San Diego, CA; 7University of Michigan, Ann Arbor, MI; 8Texas Heart Institute, Houston, TX; 9Thoratec Corporation, Pleasanton, CA; 10University of Louisville, Louisville, KY.

2:30 PM – 4:00 PM
CONCURRENT SESSION 14:
Heart Transplantation Post Op Dilemma (Continental A/B)
CHAIRS: BROOKS S. EDWARDS, MD AND DONALD S. ESMORE, MBBS, FRACS

2:30 PM (144) The Association between Cytomegalovirus Immune Globulin (CMVIG) Use and Long-Term Recipient and Graft Survival in Pediatric and Adult Heart Transplantation Recipients; D.R. Snydman,1 G.E. Bergman,2 J. Vensak,2 1Tufts Medical Center, Tufts University School of Medicine, Boston, MA; 2CSL Behring, King of Prussia, PA.

2:45 PM (145) Does a Normal Angiogram Further from Heart Transplantation Confer Less Chance To Develop CAV? Should We Still Do Annual Angiograms Late after Transplantation?; J. Patel,1 M. Kittleson,2 B. Azarbal,2 A. Hage,2 M. Kawano,2 S. Davis,2 J. Moriguchi,1 A. Ardehali,1 J. Kobashigawa,2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

85

3:00 PM (146) High-Intensity Aerobic Exercise Improves Forearm Flow Mediated Dilatation and Blood Pressure Control Late after Cardiac Transplantation; T. Hermann,1 C.H. Dall,2 S. Christensen,1 S. Boesgaard,1 F. Gustafsson,1 Rigshospitalet, Copenhagen, Denmark; 2Bispebjerg Hospital, Copenhagen, Denmark.

3:15 PM (147) Safety and Efficacy of High Dose vs. LDL-Driven Adjustments of Fluvastatin in Heart Transplant Recipients: A Randomized, IVUS-Based Study; L. Potena, F. Grigioni, F. Fabbri, G. Magnani, P. Ortolani, M. Masetti, F. Fallani, F. Coccolo, A. Russo, A. Branzi. University of Bologna, Bologna, Italy.

3:30 PM (148) Are Circulating Antibodies Necessary To Make a Diagnosis of Antibody-Mediated Rejection?; J. Patel,1 M. Kittleson,2 Q. Zhang,1 E. Reed,1 M. Kawano,1 S. Davis,1 M. Cecka,1 C. Burch,1 A. Velleca,1 E. Stimpson,2 J. Moriguchi,1 A. Ardehali,1 J. Kobashigawa,2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

3:45 PM (149) Combinatorial Biomarkers of Cardiac Allograft Vasculopathy; D. Lin,1 G. Cohen Freue,2 Z. Holland,1 M. Sasaki,1 N. Opushneva,1 C. Imai,4 A. Ignaszewski,4 A. Mui,1 J. Wilson-McManus,2 R. Balshaw,1 R.T. Ng,1 PA. Keown,1 R. McMaster,2 B.M. McManus,1 1The University of British Columbia, Vancouver, BC, Canada; 2The University of British Columbia, Vancouver, BC, Canada; 3The University of British Columbia, Vancouver, BC, Canada; 4The University of British Columbia, Vancouver, BC, Canada.

2:30 PM – 4:00 PM
CONCURRENT SESSION 15:
Clinical Investigation in Acute and Chronic Rejection After Lung Transplantation (Boulevard)
CHAIRS: SCOTT M. PALMER, MD, MHS AND JONATHAN B. ORENS, MD

2:30 PM (150) Flow Cytometric Parameters of CD8 Lavage Cells in Detection of Acute Cellular Rejection in Lung Transplant; D.C. Neujahr,1 A. Mohammed,2 O. Ulukpo,1 A. Pelaez,1 A. Ramirez,1 E.C. Lawrence,1 S.D. Force,1 A.A. Gal,4 C.P. Larsen,3 A.D. Kirk,3 1Emory University School of Medicine, Atlanta, GA; 2Emory University School of Medicine, Atlanta, GA; 3Emory University School of Medicine, Atlanta, GA; 4Emory University School of Medicine, Atlanta, GA.
2:45 PM (151) SaLUTaRy: Survey of Lung Transplant Rejection; L.O. Gordon,1 S. Bhorade,2 W.T. Vigneswaran,3 P.J. McShane,4 E.R. Garrity,2 A.N. Husain,1 1The University of Chicago, Chicago, IL; 2The University of Chicago, Chicago, IL; 3University of Wisconsin Solution in High Risk Lung Transplant Recipients; 4University of Pittsburgh School of Medicine, Pittsburgh, PA.

3:00 PM (158) Prevention of Primary Graft Dysfunction in Lung Transplantation by N-Acetylcysteine after Prolonged Cold Ischemia; I. Inci, B. Erne, S. Arni, J. Wolfgang, S. Hillinger, B. Leskosek, W. Weder. University Hospital, Zurich, Switzerland.

3:15 PM (159) Transcriptional Signatures in Donor Lungs before and after Transplantation: A Functional Pathway Analysis of Donation after Cardiac Death (DCD) vs. Donation after Brain Death (DBD); C.H. Kang,1 M. Anraku,1 M. Cypel,2 J. Yeung,2 S. Gharib,1 A. Pierre,2 M. de Perrot,2 T. Waddell,2 M. Liu,2 S. Keshavjee,2,1 Seoul National University Hospital/University Health Network, Seoul, Republic of Korea; 2Toronto General Hospital, Toronto, ON, Canada; 3University of Washington, Seattle, WA.

3:30 PM (160) Evaluation of the Lung Allocation Score in High Urgent and Urgent Lung Transplant Candidates in Eurotransplant; J.M. Smits,1 G.D. Nossent,2 A.O. Rahmel,1 G. Lauffer,1 J. Gottlieb.1 Eurotransplant, Leiden, Netherlands; 2UMCG, Groningen, Netherlands; 3University Hospital, Vienna, Austria; 4Hannover Medical School, Hannover, Germany.

3:45 PM (161) Initial Topical Cooling Followed by Backtable Celsior Flush Perfusion Provides Excellent Early Lung Function in Porcine Single Lung Transplantation after 24 Hours of Cold Ischemia; B. Gohrbandt,1 M. Avasar,1 G. Warnecke,1 S.P. Sommer,2 A. Haverich,1 M. Strueber,1 Hannover Medical School, Hannover, Germany; 2University Hospital of Wuerzburg, Wuerzburg, Germany.

2:30 PM – 4:00 PM
CONCURRENT SESSION 17:
Quality of Life and Social Sciences: Have We Done the Right Thing?: Assessing Quality of Life Following Cardiothoracic Transplantation (Waldorf)

CHAIRS: BRONWYN J. LEVVEY, RN AND CORBY L. D’AMICO, RN, MN

2:30 PM (162) The Obligation To Say Thank-You; J. Poole,1 M. Shildrick,2 P. Mckeever,3 H. Ross,4 O. Mauthner,4 E. De Luca,4 S. Abbey,3 1Ryersson University, Toronto, ON, Canada; 2Queen’s University Belfast, Belfast, Ireland; 3Bloorview Kids Rehab, Toronto, ON, Canada; 4University Health Network–Toronto General Hospital, Toronto, ON, Canada; 5University Health Network–Toronto General Hospital, Toronto, ON, Canada.

2:45 PM (163) Predictors and Outcomes Associated with Quality of Life (QOL) in Family Caregivers to Cardiothoracic Transplant Recipients; M.A. Dew,1 L. Myaskovsky,2 A.J. DeVito Dabbs,3 A.F. DiMartini,4 Y. Toyoda,5 R. Zomak,6 R.L. Kormos,1 1University of Pittsburgh School of Medicine, Pittsburgh, PA; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3University of Pittsburgh School of Nursing, Pittsburgh, PA.
3:00 PM (164) The Relationships among Satisfaction with Heart Transplant on Quality of Life (QOL) Outcome 5 to 10 Years after Heart Transplantation (HTT); C. White-Williams,¹ K.L. Grady,² E. Wang,³ D.C. Naftel,¹ J.K. Kirklin,³ S. Myers,³ B. Rybarczyk,⁷ J.B. Young,⁶ J. Czerr,⁷ D. Pelegri,⁸ J. Kobashigawa,¹¹ J. Chair,¹² A. Heroux,¹³ R. Higgins,¹⁴ ¹University of Alabama at Birmingham, Birmingham, AL; ²Northwestern Memorial Hospital, Chicago, IL; ³Northwestern Memorial Hospital, Chicago, IL; ⁴University of Alabama at Birmingham, Birmingham, AL; ⁵University of Alabama at Birmingham, Birmingham, AL; ⁶University of Alabama at Birmingham, Birmingham, AL; ⁷Virgina Commonwealth University, Richmond, VA; ⁸The Cleveland Clinic, Cleveland, OH; ⁹The Cleveland Clinic, Cleveland, OH; ¹⁰The Cleveland Clinic, Cleveland, OH; ¹¹Cedars-Sinai Heart Institute, Los Angeles, CA; ¹²UCLA Medical Center, Los Angeles, CA; ¹³Cedars-Sinai Heart Institute, Los Angeles, CA; ¹⁴Rush University Medical Center, Chicago, IL.

3:15 PM (165) Pre-Transplant Smoking in Heart Transplant Patients: A Marker for Long Term Outcome; E. Moreno,¹ A. Velleca,² C. Burch,¹ J. Patel,² M. Kittleson,² M. Kawano,² S. Davis,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa,² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.


2:30 PM – 4:00 PM

CONCURRENT SESSION 18:
Tissue Gene Regulation and Protection From Injury (Marquette)

CHAIRS: STEPHAN M. ENSMINGER, MD, PHD AND MICHAEL P. FISCHBEIN, MD

2:30 PM (168) A Novel Model for the Focused Study of Functional and Genomic Recovery from Decompensated Heart Failure; N.M. Andersen,¹ R. Tang,¹ W.E. Stansfield,¹ M. Rojas,¹ C.H. Selzman,¹ University of North Carolina, Chapel Hill, NC; ²University of Utah, Salt Lake City, UT.

2:45 PM (169) Connective Tissue Growth Factor Gene Expression in the Failing Human Heart; N. Patel,¹ T. Kim,¹ A. McElligott,¹ K.K. Henderson,² B. Pavlovic-Surjanec,² A.L. Heroux,² A.M. Samarel,¹ Loyola University Medical Center, Maywood, IL; ³Loyola University Medical Center, Maywood, IL; ⁴Loyola University Chicago, Maywood, IL.

3:00 PM (170) Hypoxia Inducible Factor-1 Preconditioning Protects Transplanted Hearts Against Ischemia-Reperfusion Injury through Effects on Remote Tissues; M.A.I. Keranen,¹ R. Tuominen,¹ R. Krebs,¹ L.A. Flippin,² M. Arend,² A.I. Nykanen,¹ K.B. Lemstrom,¹ ² ¹University of Helsinki, Helsinki, Finland; ²FibroGen Inc., San Francisco, CA; ³Helsinki University Central Hospital, Helsinki, Finland.

3:15 PM (171) Nebulized Nitrite Protects Rat Lung Grafts from Ischemia-Reperfusion Injury; T. Okamoto,¹ X. Tang,¹ S.C. Erzurum,¹ C. Farver,³ M.T. Gladwin,⁴ K.R. McCurry,¹ ² ¹Lerner Research Institute Cleveland Clinic, Cleveland, OH; ²Cleveland Clinic, Cleveland, OH; ³Cleveland Clinic, Cleveland, OH; ⁴University of Pittsburgh, Pittsburgh, PA.


4:00 PM – 4:30 PM
Coffee Break (Southeast Exhibit Hall)

4:30 PM – 6:00 PM

CONCURRENT SESSION 19:
Clinical Heart Transplantation and Immunology (International Ballroom)

CHAIRS: ADRIAN B. VAN BAKEL, MD, PHD AND MAURO RINALDI, MD

4:30 PM (174) The Use of Gene Expression Profiling Post Heart Transplant in the Real World: The Mid America Experience; A. Kao,¹ K. St Clair,¹ S.L. Lawhorn,¹ A. Magalski,¹ T.L. Stevens,¹ A.M. Borkon,² ¹Mid America Heart Institute, Kansas City, MO; ²Mid America Heart Institute, Kansas City, MO.

4:45 PM (175) Highly Sensitized LVAD Patients Can Be Safely Transplanted with Non-Crossmatched Hearts Using Plasmapheresis and Alemtuzumab: A Contemporaneous Case-Control Series; S.D. Lick, K.K. Kislingbury, A.C. Kollar, N.A. Barbagelata, M.M. Koerner, V.G. Valentine. University of Texas, Medical Branch, Galveston, TX.
5:00 PM  (176) Accommodation after Heart Transplantation: Does It Exist?; M. Kittleton, 1 J. Patel, 2 E. Reed, 1 D. Gjertson, 1 M. Kawano, 2 S. Davis, 2 C. Burch, 1 A. Velleca, 2 E. Stimpson, 2 J. Moriguchi, 2 A. Ardehali, 1 J. Kobashigawa, 1 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

5:15 PM  (177) Normalization of Heart Failure Genomic Markers after Transplantation; Z. Hollander, 1 D. Lin, 1 R. Ng, 1 J. Wilson-McManus, 1 A. Ignaszewski, 1 R. Balshaw, 1 R. McMaster, 1 P. Keown, 1 B. McManus, 1 1The University of British Columbia, Vancouver, BC, Canada; 2PROOF Centre of Excellence, Vancouver, BC, Canada; 3The University of British Columbia, Vancouver, BC, Canada; 4The University of British Columbia, Vancouver, BC, Canada; 5The University of British Columbia, Vancouver, BC, Canada.

5:30 PM  (178) Frequency of Gene Expression Profiling Use in Lieu of Endomyocardial Biopsy Post Heart Transplant Increases with Familiarity: The Mid America Experience; A. Kao, 1 K. St Clair, 1 S.L. Lawhorn, 1 A. Magalski, 1 T.L. Stevens, 1 A.M. Borkon, 2 1Mid America Heart Institute, Kansas City, MO; 2University of Bologna, Bologna, Italy.

5:45 PM  (179) Interplay between Graft-Function and Intra-vascular Deposition of C4d in Heart Transplant Recipients; F. Fabbri, 1 T. Ionico, 1 L. Potena, 1 P. Prestinenzi, 1 G. Magnani, 1 M. Masetti, 1 O. Leone, 2 F. Fallani, 1 F. Coccolo, 1 F. Grigioni, 1 A. Branzi, 1 1Cardiovascular Department, University of Bologna, Bologna, Italy; 2Pathology Department, University of Bologna, Bologna, Italy.

4:30 PM – 6:00 PM
CONCURRENT SESSION 20: Getting Back to the Basics: MCSD and the Myocyte (Continental A/B)

CHAIRS: PAUL W. M. FEDAK, MD, PHD, FRCS AND PASCAL LEPRINCE, MD, PHD

4:30 PM  (180) The Time-Course of Unloading-Induced Cardiac Improvement in Patients with Chronic Non-Ischemic Cardiomyopathy Predicts the Outcome after Weaning from Ventricular Assist Devices; M. Dandel, 1 Y. Weng, 1 H. Siniawski, 1 T. Krabatsch, 1 H.B. Lehmkuhl, 1 E. Potapov, 1 C. Knosalla, 1 H.B. Lehmkuhl, 1 T. Ionico, 1 L. Potena, 1 1Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; 2Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany.

4:45 PM  (181) Plasma Galectin 3 Is Increased in Terminal Heart Failure Patients and Is Elevated in Patients Not Surviving Mechanical Circulatory Support; G. Erkilet, 1 S. Schulte-Eistrup, 2 M. Morshuis, 2 B. Bohms, 1 D. Roefè, 1 J. Gummert, 2 H. Milting, 1 1Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; 2Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany.

5:00 PM  (182) Regulation of Collagen and Prolyl-4-Hydroxylase during Ventricular Assist Device (VAD) Support: Collagen Regulation during VAD-Support Depends on the Degree of Remodeling at the Time of VAD-Implantation; A. Gærtner, 1 A. Kassner, 1 S. Schulte-Eistrup, 1 M. Morshuis, 2 A. El-Banayosy, 1 J. Gummert, 2 H. Milting, 1 1Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; 2Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany.

5:15 PM  (183) The Role of Cathepsin K in Extra Cellular Matrix Remodeling in Patients with End Stage Heart Failure; P. van der Weide, 1 A.H. Bruggink, 1 D.F. van Wichen, 1 J. van Kuik, 1 N. de Jonge, 2 J.R. Lahpor, 2 M.E.I. Schipper, 1 R.A. de Weger, 1 1University Medical Center, Utrecht, Netherlands; 2University Medical Center, Utrecht, Netherlands.

5:30 PM  (184) Myocardial Recovery Is Associated with Low Levels of Circulating MMP8 at LVAD Implantation; J. Beale, 1 R.S. George, 1,2 J. Smith, 1 A. Khaghani, 1 M.H. Yacoub, 2 E.J. Birks, 1,2 P. Barton, 1 1Imperial College, Harefield, Middlesex, United Kingdom; 2Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

5:45 PM  (185) Myocardial Recovery from Advanced Heart Failure Using the Heartmate II LVAD Combined with Drug Therapy: Results from a Prospective Study; E.J. Birks, 1,2 R.S. George, 1,2 M. Hedger, 1 A. Firouzi, 1 T. Bahrami, 1 M. Amrani, 1 M.H. Yacoub, 2 G. Dreyfus, 1 A. Khaghani, 1 1Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; 2Imperial College, Harefield, Middlesex, United Kingdom.

4:30 PM – 6:00 PM
CONCURRENT SESSION 21: From Bench to Bedside Update in Transplant Infections (Boulevard)

CHAIRS: MARGARET M. HANNAN, MD AND MARTHA L. MOONEY, MD

4:30 PM  (186) CD8+ pp65-Specific T Cell Responses and T-Bet Levels Predict Relapsing Viremia Following Primary CMV Infection in Lung Transplant Recipients; M.R. Pipeling, 1 E.R. John, 1 N. Lechtzin, 1 E. Reed, 1 R.S. George, 1,2 J. Smith, 1 A. Firouzi, 1 T. Bahrami, 1 M. Amrani, 1 M.H. Yacoub, 2 G. Dreyfus, 1 A. Khaghani, 1 1Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; 2Imperial College, Harefield, Middlesex, United Kingdom.

4:45 PM  (187) CMV Reactivation within the Lung Allograft Is Associated with Bronchiolitis Obliterans Syndrome Following Lung Transplantation; M.A. Paraskeva, 1 B. Levvey, 1 A. Griffiths, 1 M. Bailey, 2 T.C. Kotsimbos, 1 G.I. Snell, 1 1 Alfred Hospital, Melbourne, Vic, Australia; 2School Public Health & Preventive Medicine, Monash University Alfred, Melbourne, Vic, Australia.
5:00 PM (188) Development of Cytomegalovirus (CMV) Infection during Ongoing Valganciclovir Therapy; L. Patel,2 M. Kirkeslon,2 B. Kubak,1 M. Kawano,2 S. Davis,2 J. Moriguchi,2 A. Ardehali,1 J. Kobashigawa,2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

5:15 PM (195) Omental Stromal Cells (OSC) Abrogate Acute Lung Injury Associated with Allogenic Transplant in Absence of Immunosuppression; R.K. Braun,1 A.A. Martin,1 P. Sethupathi,1 M.G. Medina,1 W. Jungrathmayr,2 C.H. Wigfield,1 M. Ishishima,1 R.B. Love,1 1Loyola University Medical Center, Maywood, IL; 2University Hospital Zurich, Zurich, Switzerland; 3Loyola University Medical Center, Maywood, IL.

5:30 PM (196) Identifying the Potassium Channel KCa3.1 as a New Therapeutic Target to Prevent Chronic Airway Allograft Rejection; X. Hua,1 D. Meyberg,1 T. Deuse,1,2 H. Wulff,1 R. Kohler,1 H. Reichenspurner,1 S. Schrepper,1,2 1University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, CA; 3University of California, Davis, Davis; 4Centrum for Internal Medicine, Marburg, Germany.

5:45 PM (197) Side Effects in a Calcineurin Inhibitor- Everolimus Based Immunosuppressive Regime in Lung Transplanted Recipients; B. Zweytick,1 B. Ghanim,2 J. Sillipp, M. Winter, P. Jaksh, W. Klepetko,1 Medical University of Vienna, Vienna, Austria.

4:30 PM – 6:00 PM CONCURRENT SESSION 23: Pediatric Transplantation in Unique Patient Populations (Waldorf)

CHAIRS: STUART C. SWEET, MD, PHD AND MATTHEW J. FENTON, MRCPCH

5:00 PM (200) Center-Specific Outcomes for Pediatric Heart Transplantation: Do Past Outcomes Predict Future Performance? W.T. Mahle, K.R. Kanter, R.N. Vincent. Children's Healthcare of Atlanta, Atlanta, GA.
5:15 PM  (201) Lung Transplantation in Children after Hematopoietic Stem-Cell Transplantation; S. Yousef,¹ C. Benden,¹ T. Frisgold,² G. Westall,¹ S. Goldfarb,³ M. Ballman,¹ P. Aurora,⁶ G. Doherty,⁶ D. Boyer,⁷ G. Visner,¹ M. Woo,¹² M.G. Michaels,⁹ S.C. Sweet,¹⁰ M.G. Schecter,¹ G.B. Mallory,¹ O. Elidemir,² University of Miami, Miami, FL; ²Baylor College of Medicine, Houston, TX; ³University Hospital Zurich, Zurich, Switzerland; ⁴Children’s Hospital of Philadelphia, Philadelphia, PA; ⁵Hannover Medical School, Hannover, Germany; ⁶Great Ormond Street Hospital, London, United Kingdom; ⁷Harvard University, Boston, MA; ⁸University of Vienna, Vienna, Austria; ⁹Children’s Hospital of Pittsburgh, Pittsburgh, PA; ¹⁰Washington University, St. Louis, MO; ¹¹Alfred Hospital and Monash University, Melbourne, Vic, Australia.

5:30 PM  (202) Outcomes of Heart Transplantation for Patients with Systemic Muscular Disorders; N. Cain,¹ J. Teuteberg,² B. Feingold,¹ S. Miller,¹ E. Quivers,¹ V. Morell,¹ P. Wearden,¹ R. Kormos,² Y. Toyoda,² D. McNamara,² C. Chrysoostomou,¹ V. Gerard,¹ S. Webber.¹ Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²UPMC Presbyterian, Pittsburgh, PA.

5:45 PM  (203) Comparison of Risk Factors and Outcomes for Pediatric Patients Listed for Heart Transplantation after Bidirectional Glenn and after Fontan: A Multi-Institutional Study; J.R. Kovach,¹ E.D. Blume,⁶ D.C. Naftel,² F.B. Pearce,³ M.T. Foushee,² E.R. Edens,¹ J.H. Shuhaiber,¹ F. Fynn-Thompson,¹ J.K. Kirklin,² S.D. Zangwill.¹ Medical College of Wisconsin, Milwaukee, WI; ³University of Alabama at Birmingham, Birmingham, AL; ⁴University of Alabama at Birmingham, Birmingham, AL; ⁵University of Iowa Children's Hospital, Iowa City, IA; ⁶Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²UPMC Presbyterian, Pittsburgh, PA.

4:30 PM – 6:00 PM
CONCURRENT SESSION 24: Heart Failure: Prognostication and Outcomes (Marquette)
CHAIRS: TUVIA BEN GAL, MD AND DONNA M. MANCINI, MD

4:30 PM  (204) Does Access to Device Therapies Affect Transplant Outcomes for Adults with Congenital Heart Disease? Analysis of the United Network for Organ Sharing (UNOS) Database; M.D. Everitt,¹² A.T. Yetman,¹¹ A.E. Donaldson,¹ J. Stehlik,¹ H. Al-Hitt,¹ V. Melenovsky, J. Kettner, J. Kautzner.²¹ University of Minnesota, Minneapolis, MN.

4:45 PM  (205) Cardiac Resynchronization Therapy (CRT) Induced Cellular Reverse Cardiac Remodeling Similar to Left Ventricular Assist Devices; C.M. Orrego, J. Florez, K. Youker, G. Torre-Amione. The Methodist Hospital, Houston, TX.

**6:20 PM (214) Analysis of Impact of Post Transplant Neoplastic Disease on Long-Term Follow up Following Heart Transplant;** P. Totaro, M. Savasta, S. Nicolardi, N. Ippoliti, C. Pellegrini, C. Goggi, A.M. D’Armini, M. Vigano, IRCCS Foundation S Matteo, Pavia, Italy; 2University School of Medicine, Pavia, Italy.

**6:25 PM (215) Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Correlates with Kidney Dysfunction in Heart Allograft Recipients;** P. Przybylowski, J.M. Malyszko, J. Malyszko. 3Collegium Medicum, Jagiellonian University, Krakow, Poland; 2Medical University Białystok, Białystok, Poland.

**6:30 PM (216) Extra-Corporeal Membrane Oxygenation for Primary Graft Failure after Cardiac Transplantation. Six-Year Single Center Experience;** C. D’Alessandro, J.L. Golmard, S. Aubert, A. Julien, E. Barreda, P. Leprince, G. Iradj, P. Alain. 1La Pitie Hospital, Paris, France; 2La Pitie Hospital, Paris, France; 3La Pitie Hospital, Paris, France.

**6:35 PM (217) A High-Intensity Exercise Program Improves Peak VO2 and Reduces Markers of Systemic Inflammation in Cardiac Transplant Recipients: A Randomized Study;** C.H. Dall, S.B. Christensen, T. Hermann, E. Prescott, F. Gustafsson. 1Rigshospitalet, Copenhagen, Denmark; 2Bispebjerg Hospital, Copenhagen, Denmark.

**6:40 PM (218) The Use of Neurohormonal Antagonists Is Not Associated with Vasoplegia in Post-Orthotopic Heart Transplant Patients;** M.M. Patarroyo, C.A. Simbaqueba, R. Wong, D.O. Taylor, W.H.W. Tang, K. Shrestha. 3Cleveland Clinic Foundation, Cleveland, OH; 2Cleveland Clinic Foundation, Cleveland, OH; 1Cleveland Clinic Foundation, Cleveland, OH.

**6:45 PM (219) Conversion to Everolimus in Heart Transplant Patients with Calcineurininhibitor (CNI)-Associated Myopathy;** S. Meyer, M. Adam, A. v Stritzky, F.M. Wagner, T. Deuse, H. Reichenspurner, A. Costard-Jaeckle. 1University Heart Center, Hamburg, Germany; 2University Heart Center, Hamburg, Germany.

**6:50 PM (220) A Web-Based Pilot Study of Inter-Pathologist Reproducibility Using the ISHLT 2004 Classification System for Biopsy Diagnosis of Acute Cardiac Allograft Rejection: The European Experience on Behalf of the Transplant Working Group of the Association for European Cardiovascular Pathology;** A. Angelini, C. Andersen, G. Bartoloni, F. Black, P. Bishop, H. Doran, M. Fedrigo, J. Fries, M. Goddard, H. Goebel, D. Neil, O. Leone, A. Marzullo, M. Ortmann, F. Paraf, S. Rotman, N. Turhan, A.C. Frigo, F. Grigoletto, A. Gasparetto, R. Mencarelli, G. Thiene, M. Burke. 1Pathological Anatomy-Cardiocoronary Pathology, Padua, Italy; 2Frederik V’s vej 11, Copenhagen, Denmark; 3Settorato Int. via Palermo, 47, P.O. Garibaldi Nesima, Catania, Italy; 4Freeman Cardiorespiratory Centre, Newcastle upon Tyne NHS Hospitals Trust, Royal Victoria Infirmary, Queen Victoria Road, Newcastle, United Kingdom; 5Wythenshawe Hospital, UHSM, Southmoor Road, Manchester, United Kingdom; 6Wythenshawe Hospital, Manchester, United Kingdom; 7Pathological Anatomy-Cardiocoronary Pathology, Padua, Italy; 8Kerpener Strasse 62, Cologne, Germany; 9Papworth Everard, Cambridge, United Kingdom; 10Kerpener Strasse 62, Cologne, Germany; 11University Hospital Birmingham, Medical School, Edgbaston, Birmingham, United Kingdom; 12S.Osola-Malpighi Hospital, Bologna, Italy; 13University of Bari, Policlinico p.za G. Cesare 11, Bari, Italy; 14Kerpener Strasse 62, Cologne, Germany; 15Centre Hosp Univ Dupuytren, Limoges, France; 16Institut Universitaire de Pathologie de Lausanne, Lausanne, Switzerland; 17Yuksek Ihtisas Hospital, Ankara, Turkey; 18University of Padua, Padua, Italy; 19University of Padua, Padua, Italy; 20Azienda ULSS 18, Rovigo, Italy; 21Azienda ULSS 18, Rovigo, Italy; 22Pathological Anatomy-Cardiocoronary Pathology, Padua, Italy; 23Harefield, Middx, Harefield, United Kingdom.

6:15 PM (225) **Survival and Status Transition of Patients Initially Listed UNOS Status 2: The Effect of Physician Decisions**; T.E. Dardas, K.D. Aaronson, F.D. Pagani. 1Department of Internal Medicine, Division of Cardiology, Ann Arbor, MI; 2University of Michigan Health System, Ann Arbor, MI.


6:25 PM (227) **Novel Observations of Differences in Lung Inflammatory Gene Expression Profiles between Donation after Cardiac Death vs. Donation after Brain Death: Inflammation-Specific Microarray Study**; C.-H. Kang, M. Anraku, M. Cypel, J.C. Yeung, A.F. Pierre, M. de Perrot, T.K. Waddell, M. Liu, S. Keshavjee. 1Toronto General Hospital, University of Toronto, Toronto, ON, Canada; 2Seoul National University Hospital, Seoul National University, Seoul, Korea.


6:35 PM (229) **Activated Omental Stromal Cells Ameliorate Bleomycin Induced Acute Lung Injury**; A.A. Martin, B.K. Braun, M.G. Medina, S. Shah, P. Sethupathi, C. Wigfield, R.B. Love. 1Loyola University Medical Center, Maywood, IL; 2Loyola University Medical Center, Maywood, IL.


6:00 PM (233) **Impact-DCM: A Randomized, Controlled, Multi-Center Phase II Trial Utilizing Expanded Autologous Bone Marrow As Sole Therapy for Dilated Cardiomyopathy**; B.A. Bruckner, D. Bull, B. Hammond, G. Ali, B. Elmar, L. Matthias, R.J. Michael, L. Perryman, N. Smedira, O. Lattouf, R.R. Bunge, A. Patel. 1The Methodist Hospital DeBakey Heart and Vascular Center, Houston, TX; 2Aastrom Biosciences, Inc., Ann Arbor, MI; 3Baylor University Medical Center, Dallas, TX; 4The University of Utah School of Medicine, Salt Lake City, UT; 5Cleveland Clinic Heart and Vascular Institute, Cleveland, OH; 6Emory University Hospital Midtown, Atlanta, GA.

6:05 PM (234) WITHDRAWN

6:10 PM (235) **Strategies for Cardiac Xenotransplantation Provide Technologies for Improved Calcium Resistant Bioprosthetic Heart Valves**; C.G.A. McGregor, N. Lila, M. Vlasin, B.S. Wiseman, J.S. Logan, G.W. Byrne, 1Mayo Clinic, Rochester, MN; 2University College London, London, United Kingdom; 3University of Paris, Paris, France.

6:15 PM (236) **Immunosuppressive Agents Differently Suppress T Cell Subpopulations**; X. Hua, T. Deuse, H. Reichenspurner, R.C. Robbins, S. Schreper. 1University Heart Center Hamburg, Hamburg, Germany; 2University of Calgary, Calgary, Canada.

6:20 PM (237) **HGF or VEGF Gene Transfer Maximizes Mesenchymal Stem Cell-Based Myocardial Salvage after Acute Myocardial Infarction**; T. Deuse, P. Fedak, R.C. Robbins, H. Reichenspurner, S. Schreper. 1University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, CA.

6:25 PM (238) **Imaging of Transplanted Bone Marrow Derived Stem Cells for Therapy of Ischemic Cardiomyopathy**; B. Bruckner, A. Ghodsizad, C. Piechaczek, A. Ruhparwar, M. Karck, M. Loebe, G. Noon, M. Reardon, R. Basel, W. Jones, L. Morales, M. Donovan, B. Bunge, P. Jaksch, L. Perryman. 1The Methodist Hospital DeBakey Heart and Vascular Center, Houston, TX; 2University of Heidelberg, Heidelberg, Germany.

6:30 PM (239) **CD14 and CD36 Restrain Inducible T reg Generation and Prevent Costimulatory Blockade Ex-

6:40 PM (241) Risk Factors for Nontuberculous Mycobacterial (NTM) Infections in Heart and Lung Transplant Recipients; S.A. Longworth,1 C. Vinnard,1 I. Lee,2 T. Barton,1 K. Sims,1 M. Synnestvedt,2 E. Blumberg,1 1Hospital of the University of Pennsylvania, Philadelphia, PA; 2University of Pennsylvania School of Medicine, Philadelphia, PA.

6:45 PM (242) Pre-B-Cell Colony Enhancing Factor (PBEF) Is a Novel target in Hypoxia-Induced Murine Pulmonary Hypertension; R.F. Machado,1 L. Moreno-Vinasco,1 R. Zaidi,1 S. Sammani,1 J.G.N. Garcia.1 1University of Chicago, Chicago, IL; 2, Chicago, IL.

6:50 PM (243) Impact of Mechanical Unloading on Myocardial Endothelium and Microvasculature; S. Drakos1,2,3,4 E. Hammond,2,3 S. Clayson,1,3 M.P. Revelo,2,3 S. Stoker,1,3 A. McCormick,1,3 H. Smith,1,3 C. Selzman,2,3 D.R. Verma,1,2,3 D. Budge,1,3 J. Stehlik,2,3 D. Li,2 A. Kfouri.1,2,3 1Utah Artificial Heart Program, Intermountain Medical Center, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT; 3UTAH Cardiac Transplant Program, Salt Lake City, UT; 43rd Cardiology Department, University of Athens, Athens, Greece.

6:55 PM (244) Effect of Mechanical Unloading on Fibrosis and Hypertrophy during Cardiac Remodeling in Humans; S. Drakos,1,2,3 E. Hammond,2,3 B. Reid,1,2,3 S. Stoker,1,3 M.P. Revelo,2,3 B. Rasmusson,1,3 C. Selzman,2,3 R. Alharethi,1,3 A. McCormick,1,2 E. Gilbert,2,3 D. Miller,2 D. Li,2 A. Kfouri.1,2,3 1Utah Artificial Heart Program, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT; 3UTAH Cardiac Transplant Program, Salt Lake City, UT.

6:00 PM – 7:00 PM
MINI ORAL SESSION 9 (Marquette)

CHAIRS: CHRISTIAN BENDEN, MD AND KRISTINE GULESERIAN, MD

6:00 PM (245) Allomap Use in Cardiac Transplantation: Single Center Experience; I. Dumitru,1 S. Radio,2 D. Tayama.1 1UNMC, Omaha, NE; 2UNMC, Omaha, NE; 3XDX, Brisbane, CA.

6:05 PM (246) Switch to Sirolimus and Dose Reduced Calcineurin-Inhibitor after Cardiac Transplantation

6:10 PM (247) Relationship between Microvascular and Macrovascular Disease in Heart Transplant Recipients; M.S. Abu-Qaoud,1 D. Chen,2 J. Kerstetter,3 L.N. Stoltenyi,2 R.G. Pai,2 1Loma Linda University Medical Center, Loma Linda, CA; 2Loma Linda University Medical Center, Loma Linda, CA; 3Loma Linda University Medical Center, Loma Linda, CA.


6:20 PM (249) A Randomized, Open-Label Study To Compare the Safety and Efficacy of Conversion From a Calcineurin Inhibitor (CNI) to Sirolimus Versus Continued Use of a CNI in Cardiac Transplant Recipients with Mild to Moderate Renal Insufficiency; A. Zuckermann,1 A. Keogh,2 M.G. Crespo-Leiro,3 D. Mancini,4 F. Gonzalez-Vilchez,5 L. Almenar,6 S. Kushwaha.10 1AKH Wien, Vienna, Austria; 2St. Vincent's Hospital, Darlinghurst, NSW, Australia; 3Complexo Hospitalario Universitario A Coruña, Coruña, Spain; 4Columbia University Medical Center, New York, NY; 5Hospital Marques de Valdecilla, Santander, Cantabria, Spain; 6Hospital La Fe, Valencia, Spain; 7University of Pennsylvania, Philadelphia, PA; 8Drexel University College of Medicine, Philadelphia, PA; 9Wyeth Pharmaceuticals, Collegeville, PA; 10Mayo Clinic Rochester, Rochester, MN.

6:25 PM (250) Conversion to Everolimus in Persistent Cytomegalovirus or Herpes simplex Viremia Following Thoracic Organ Transplantation; S. Meyer,1 M. Adam,1 A. v Stritzky,1 F.M. Wagner,2 T. Deuse; H. Reichenspurner,A. Costard-Jaeckle.1 University Heart Center, Hamburg, Germany; 2University Heart Center, Hamburg, Germany.

6:30 PM (251) Surveillance HLA Antibody Screening Post Cardiac Transplant – A Single Center Pediatric Experience; S. Zangwill,1 G. Stendahl,1 K. Tillman,1 S. Berger,1 T. Ellis,2 K. Gandy,3 M. Mitchell,1 J. Tweddell.3 1Medical College of Wisconsin, Milwaukee, WI; 2Blood Center of Wisconsin, Milwaukee, WI; 3Medical College of Wisconsin, Milwaukee, WI.
6:35 PM  (252) The Successful Use of Oral Sildenafil in Right Ventricular Dysfunction and High Pulmonary Vascular Resistance after Pediatric Heart Transplantation; R.K. Singh,1 M. Richmond,1 T.B. Giblin,1 R. Rodriguez,1 J.M. Chen,2 L.J. Addonizio.11 Columbia University Medical Center, New York, NY; 2Columbia University Medical Center, New York, NY.


6:45 PM  (254) Lung Transplantation for Childhood Interstitial Lung Disease; M.G. Schecter,1 J.A. Rama,1 E.D. McKenzie,2 J.S. Heinle,2 D.L. Morales,2 G.B. Mallory,1 O. Elidemir,1 1Baylor College of Medicine, Houston, TX; 2Baylor College of Medicine, Houston, TX.

6:50 PM  (255) Rapid Reduction in Donor Specific Antibodies with Bortezomib in Pediatric Heart Transplant Recipients with Positive Crossmatch and Antibody Mediated Rejection; W.R. Morrow,1 E.A. Frazier,1 W.T. Mahle,2 H.O. Terry,1 S.E. Pye,1 R.L. Saylors,1 X. Garcia,1 R.D.B. Jaquiss.11 Arkansas Children’s Hospital, Little Rock, AR; 2Sibley Heart Center, Atlanta, GA.

6:55 PM  (256) Risk Factors for Renal Dysfunction in Pediatric Heart Transplantation: A Multi-Institutional Study; B. Feingold,1 J. Zheng,2 Y. Law,3 W.R. Morrow,4 T.M. Hoffman,5 K.B. Schechtman,2 C. Canter.61 Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA; 2Washington University, St. Louis, MO; 3Seattle Children’s Hospital, Seattle, WA; 4Arkansas Children’s Hospital, Little Rock, AR; 5Nationwide Children’s Hospital, Columbus, OH; 6Washington University, St. Louis, MO.
Friday, April 23, 2010

7:00 AM – 6:00 PM
Registration Desk Open (8th Street Registration)

7:00 AM – 6:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM
PULMONARY TRANSPLANTATION SCIENTIFIC COUNCIL MEETING (Waldorf)
HEART FAILURE AND TRANSPLANT MEDICINE SCIENTIFIC COUNCIL MEETING (Marquette)
PEDIATRIC TRANSPLANTATION SCIENTIFIC COUNCIL MEETING (Joliet)
NURSING, HEALTH SCIENCE, AND ALLIED HEALTH SCIENTIFIC COUNCIL MEETING (PDR-2)
BASIC SCIENCE SCIENTIFIC COUNCIL MEETING (tentative) (PDR-4)

8:15 AM – 10:15 AM
PLENARY SESSION
(IMPORTANT BALLROOM)

CHAIRS: JON KOBASHIGAWA, MD AND STUART JAMIESON, MD

8:15 AM INVITED LECTURE, Co-Stimulation Blockade: Lessons from Kidney Transplantation, Implications For Thoracic Transplantation, Christian P. Larsen, MD, Emory University, Atlanta, GA

8:35 AM (257) FEATURED ABSTRACT Determinants of Survival in Patients Bridged to Heart Transplantation with Continuous-Flow Versus Pulsatile-Flow Ventricular Assist Devices; J.N. Nativi, A.Y. Kucheryavaya, L.B. Edwards, D. Taylor, M.I. Hertz, J. Stehlik. University of Utah, Salt Lake City, UT; United Network for Organ Sharing (UNOS), Richmond, VA; Cleveland Clinic Foundation, Cleveland, OH; University of Minnesota, Minneapolis, MN.

8:45 AM INVITED DISCUSSANT, O. Howard Frazier, MD, Texas Heart Institute, Houston, TX


9:00 AM INVITED LECTURE, Organ Resuscitation of the Heart, Lung, and Liver, Shaf Keshavjee, MD, Toronto General Hospital, Toronto, Ontario, Canada

9:20 AM (259) FEATURED ABSTRACT Effect of Donor Associated Characteristics on Primary Graft Dysfunction and Outcome after Cardiac Transplantation; A.Z. Aliabadi.

9:30 AM INVITED DISCUSSANT, Bruce Rosengard, MD, Boston, MA

9:35 AM (260) FEATURED ABSTRACT Changes in the Causes of Heart Transplant Mortality over Two Decades: Successes, Failures and Opportunities; D.O. Taylor, J.K. Kirklin, D.C. Naftel, R.N. Brown, M.H. Drazner, T. Stevens, J.M. Herre, J. Stehlik, D.C. McGiffin. Cleveland Clinic, Cleveland, OH; University of Alabama at Birmingham, Birmingham, AL; University of Texas Southwestern Medical Center, Dallas, TX; Mid-America Heart Institute, Kansas City, MO; Sentara Cardiovascular Research Institute, Norfolk, VA; University of Utah, Salt Lake City, UT.

9:45 AM INVITED DISCUSSANT, Sharon A. Hunt, MD, Stanford University, Palo Alto, CA

9:50 AM INVITED LECTURE, Preventing Heart Graft Rejection and Ischemia Reperfusion Injury Using siRNA, Weiping Min, MD, PhD, University of Western Ontario, London, Ontario, Canada

10:00 AM – 5:00 PM
Press Office Open (Continental Foyer Office 1)

10:00 AM – 4:30 PM
Exhibit Hall Open (Southeast Exhibit Hall)
Internet Café Open (Southeast Exhibit Hall)
Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:45 AM
ANNUAL BUSINESS MEETING (International Ballroom)
ISHLT Members Only

10:15 AM – 10:45 AM
Coffee Break (Southeast Exhibit Hall)

10:45 AM – 12:15 PM
CONCURRENT SESSION 25: Cost Effectiveness and Long-Term Outcomes
(IMPORTANT BALLROOM)

CHAIRS: CARMELO A. MILANO, MD AND ROBERT F. PADERA, MD, PHD


10:45 AM – 12:15 PM

**CONCURRENT SESSION 26:**

**Assessing the Risk of Heart Transplantation** (Continental A/B)

CHAIRS: JOHN V. CONTE, MD AND PAUL J. MOHACSI, MD

10:45 AM (267) **Minimizing Infection and Rejection Death: Clues Acquired from 19 Years of Multi-institutional Cardiac Transplantation Data**; J.E. George, D.O. Taylor, E.D. Blume, J.K. Kirklin, D.C. Nafte, R.N. Brown, A.I. Dipchand, J.A. Tallaj. University of Alabama at Birmingham, Birmingham, AL; Cleveland Clinic, Cleveland, OH; Children’s Hospital, Boston, MA; Hospital for Sick Children, Toronto, ON, Canada.

11:00 AM (268) **Has the Risk Abated in the Current Era? A 15 Year Multi-institutional Analysis**; R.S.D. Higgins, P.P. Chang, R.C. Starling, G.A. Ewald, J.A. Tallaj, R.N. Brown, N.M. Kirklin. Rush University Medical Center, Chicago, IL; University of North Carolina at Chapel Hill, Chapel Hill, NC; Cleveland Clinic Foundation, Cleveland, OH; Washington University School of Medicine, St. Louis, MO; University of Alabama at Birmingham, Birmingham, AL.


11:30 AM (270) **BMI Is an Independent Risk Factor for Surgical Wound Complication in de-novo Heart Transplant Recipients (HTxR) Regardless of the Immunosuppressive Therapy**; M.J. Barten, J.M. Arizon, H. Dong, H. Eisen, J. Kobashigawa, H. Lehmkuhl, H. Ross, M. Vigano, S.-S. Wang, A. Zuckermann. University of Leipzig, Heart Center, Leipzig, Germany; Reina Sofia University Hospital, Cordoba, Spain; Novartis Pharmaceuticals Corporation, East Hanover; Drexel University College of Medicine, Philadelphia, PA; Cedars-Sinai Heart Institute, Los Angeles, CA; Deutsches Herzzentrum Berlin, Berlin, Germany; University Health Network, Toronto, ON, Canada; Universität degli Studi di Pavia, Pavia, Italy; National Taiwan University, Taipei, Taiwan; University of Vienna, Vienna, Austria.

11:45 AM (271) **QTc-Interval and Molecular Gene Expression Profiling Test Score in Cardiac Allograft Dysfunction after Heart Transplantation**; K. Shahzad, J. He, Q.A. Aziz, M. Cadeiras, F. Latif, A. Sinha, S. Auerbach, S. Mital, S. Restaino, C.C. Marboe, J.D. Adondonzio, M.C. Deng. Columbia University Medical Center, New York, NY; Cedars-Sinai Medical Center, New York, NY; University of Toronto, Toronto, ON, Canada.

12:00 PM (272) **Persistent Pulmonary Hypertension in Heart Transplant Patients: Is This a Recipe for Long-Term Failure?**; J. Patel, M. Kittleson, M. Share, M. Kawano, S. Davis, J. Moriguchi, A. Ardehali, J. Kobashigawa. David Geffen School of Medicine at UCLA; Cedars-Sinai Heart Institute, Los Angeles, CA.

10:45 AM – 12:15 PM

**CONCURRENT SESSION 27:**

**Bronchiolitis Obliterans Syndrome (BOS): Risk Factors and Prevention** (Boulevard Room)

CHAIRS: ANNETTE BOEHLER, MD AND ALLAN R. GLANVILLE, MD, FRACP

10:45 AM (273) **The Impact of Air Pollution on Bronchiolitis Obliterans Syndrome and Mortality after Lung Transplantation**; B. Vanaudenaerde, 1,2 T. Nawrot, R. Vos, 1,2 S. Verleden, L. Jacobs, C. Faes, P. Hoet, D. Van Raemdonck, L. Dupont, B. Nemery, G. Verleden, Université Ziekenhuis Gasthuisberg, Leuven, Belgium; Katholieke Universiteit Leuven, Leuven, Belgium; University Hasselt, Hasselt, Belgium.

11:00 AM (274) **Molecular Typing of Pseudomonas Aeruginosa Isolated from CF Lung Transplant Recipients: Implications for BOS Risk**; A. Nicholson, J.D. Perry, S. Pearse, A. Fisher, K.F. Gould. Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

11:30 AM (276) Epstein Barr Virus Reactivation in the Lung Allograft Is Inversely Associated with Histopathological Acute Rejection in the Current Era of Routine Antiviral Prophylaxis; D.T. Keating, A. Michaelides, G.P. Westall, G.I. Snell, T. Kotsimbos. The Alfred Hospital, Melbourne, Vic, Australia; The Alfred Hospital, Melbourne, Vic, Australia; University of Maryland School of Medicine, Baltimore, MD; University of Edinburgh, Edinburgh, Scotland, United Kingdom.


12:00 PM (278) 1-Year Results of the CeMyLungs Study, a 3-Year Randomised, Open Label, Multi-Centre Investigator-Driven Study Comparing De Novo Enteric Coated Mycophenolate Sodium with Delayed Onset Everolimus, Both Arms in Combination with Cyclosporin (Using C2 Monitoring) and Corticosteroids for the Prevention of the Bronchiolitis Obliterans Syndrome in Heart-Lung, Bilateral Lung and Single Lung Transplant Recipients; A.R. Glanville, A.C.I. Aboyn, W. Kleperko, H. Reichenspurner, H. Treede, E.A. Verschuuren, A. Boehler, C. Benden, P. Hopkins, P.A. Corris. St.Vincent's Hospital, Sydney, NSW, Australia; University of Vienna, Vienna, Austria; University Heart Center Hamburg, Hamburg, Germany; University Medical Centre, Groningen, Netherlands; University Hospital, Zurich, Switzerland; The Prince Charles Hospital, Brisbane, Australia; Newcastle University, Newcastle, United Kingdom.

10:45 AM – 12:15 PM CONCURRENT SESSION 29: Making a Better Breath (Continental C)

10:45 AM (279) The Effect of Ex-Vivo Perfusion on the Microbiological Profile of the Donor Lung; D.M. Karamanou, J. Perry, H.R. Walden, A.J. Simpson, P. Corris, K. Gould, A.J. Fisher, J.H. Dark. Newcastle University, Newcastle upon Tyne, United Kingdom; Freeman Hospital, Newcastle upon Tyne, United Kingdom; University of Edinburgh, Edinburgh, Scotland, United Kingdom.

11:00 AM (280) Post-Mortem and Ex-Vivo Carbon Monoxide (CO) Ventilation Reduces Ischemia-Reperfusion Injury (IRI) in Rat Lungs Transplanted from Non-Heart-Beating Donors (NHBDs); B. Dong, T. Egan. School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.


10:45 AM – 12:15 PM CONCURRENT SESSION 29: Pulmonary Hypertension: Innovative Therapy (Waldorf)

CHAIRS: REDA GIRGIS, MD, BCH AND PATRICIA A. UBER, PHARMD

10:45 AM (285) Waitlist Mortality among Young Patients with Idiopathic or Familial Pulmonary Hypertension Awaiting Lung Transplantation in the United States; M.P. Mullen, R.R. Thiagarajan, D. Boyer, T. Kulik, F. Fynn Thompson, G. Visner, K. Gauvreau, G. Piercy, C.S. Almond, Children's Hospital, Boston, MA; Children's Hospital, Boston, MA; Harvard Medical School, Boston, MA.

11:00 AM (286) Effect of 16 Weeks of Bosentan-Based Therapy on Cardiac MRI (cMRI) Derived Ventricular Function, 6-Minute Walk Test Distance (6MWD) and Borg Dyspnea Index (BDI) in Patients with Pulmonary Arterial Hypertension (PAH): Results from the COMPASS-3 Study; S. Murali, S.G. Lloyd, H. Gupta, F.J. Soto, M.H. Park, F. Torres, N. Frey, R.L. Benza. Allegheny General Hospital, Pittsburgh, PA; University of Alabama at Birmingham, Birmingham, AL; Prevea Health, Sheboygan, WI; University of Maryland School of Medicine, Baltimore, MD; University of Texas Southwestern Medical Center,
FRIDAY

11:15 AM (287) **Endothelin Receptor Antagonists Are a Effective Long Term Treatment Option in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease with or without Trisomy 21;** F. Kermeen,1 C. Franks,1 K. O’Brien,1 H. Scale,1 K. Hall,1 K. McNeil,1 D. Radford.2 1The Prince Charles Hospital, Brisbane, QLD, Australia; 2The Prince Charles Hospital, Brisbane, QLD, Australia.

11:30 AM (288) **Aldosterone Antagonism in Pulmonary Hypertension and Right Heart Failure;** J.A. Mazurek,2 A. Rabinovitz,2 R. Zolty.1 1Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; 2Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY.

11:45 AM (289) **Comparison of Aprotinin and Tranexamic Acid in Pulmonary Thromboendarterectomy Surgery – Review of 161 Consecutive Patients;** M. Berman,1 D. Cardone,2 K. Goldsmith,3 A. Vuylsteke,2 A. Klein,2 C. Gerrard,2 J. Dunning,1 S. Tsui,1 D. Jenkins.1 1Papworth Hospital, Cambridge, United Kingdom; 2Papworth Hospital, Cambridge, United Kingdom; 3Papworth Hospital, Cambridge, United Kingdom.

12:00 PM (290) **Impact of Aggressive Management on Outcome in Patients with idiopathic Pulmonary Arterial Hypertension Listed for Lung Transplantation;** M. de Perrot, J. Granton, A.F. Pierre, K. McRae, T.K. Waddell, K. Yasufuku, C. Whytehead, M. Hutcheon, C. Chaparro, L.G. Singer, S. Keshavjee. Toronto General Hospital, Toronto, ON, Canada.

10:45 AM – 12:15 PM

CONCURRENT SESSION 30:
Clinical Case Dilemmas in Thoracic Transplantation
(Marquette)

CHAIRS: LORRIANA E. LEARD, MD AND DANIEL F. DILLING, MD

10:45 AM **Introduction,** Lorriana E. Leard, MD,
University of California, San Francisco, CA

10:50 AM **Challenges in Lung Transplantation**
CASE PRESENTER: Basar Sareyyupoglu, MD,
University of Pittsburgh Medical Center, Pittsburgh, PA
MODERATOR: Daniel F. Dilling, MD, Loyola University Medical Center, Maywood, IL
PANELISTS: Robert B. Love, MD, Loyola University Medical Center, Maywood, IL and Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

11:05 AM **Challenges in Heart Transplantation**
CASE PRESENTER: Oscar Kolsrud, MD, Sahlgrenska University Hospital, Gothenburg, Switzerland

MODERATOR: David W. Markham, MD, University of Texas Southwestern Medical Center, Dallas, TX
PANELISTS: Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD and Leslie W. Miller, MD, Washington Hospital Center & Georgetown University Hospital, Washington, DC

11:20 AM **Infectious Disease Challenges in Thoracic Transplantation**
CASE PRESENTER: Sonia Vishin, MD, University of Alabama at Birmingham, AL

MODERATOR: Cynthia J. Gries, MD, MSc, University of Washington, Seattle, WA
PANELISTS: Aimee Zaas, MD, MHS, Duke University Medical Center, Durham, NC and Kate Gould, FRC-Path, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

11:35 AM **Challenges in Pulmonary Hypertension**
CASE PRESENTER: Kathleen Tong, MD, University of California at San Francisco, CA

MODERATOR: Pali D. Shah, MD, Vanderbilt University Medical Center, Nashville, TN
PANELISTS: Teresa De Marco, MD, FACC, University of California, San Francisco, CA and Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA

11:50 AM **Challenges in Pediatric Thoracic Transplantation**
CASE PRESENTER: Joseph W. Rossano, MD, Baylor College of Medicine, Houston, TX

MODERATOR: Lorriana E. Leard, MD, University of California, San Francisco, CA
PANELISTS: Cynthia S. Herrington, MD, Children’s Hospital Los Angeles, CA and Lori J. West, MD, D.Phil, University of Alberta, Edmonton, Alberta, Canada

12:15 PM – 2:15 PM
Lunch Break

12:30 PM – 2:00 PM
JHLT EDITORIAL BOARD LUNCHEON MEETING (Joliet)

SCIENTIFIC COUNCIL CHAIRS LUNCHEON MEETING (PDR-4)

1:15 PM – 2:15 PM
2011 PROGRAM COMMITTEE MEETING (Lake Erie Room)

2:30 PM – 4:00 PM
CONCURRENT SESSION 31:
The Menu: Which Device When? (Continental A/B)
IL-17 Producing T-Lymphocytes in Acute and Lymphocytic Bronchiolitis Is Associated with T exas Heart Institute, Houston, TX. B.B. Reid, D. Budge, S.E. Verleden, E.K. Verbeken, B.M. Vanaudenaerde, S. Hodge, S. Schueler, R. Hetzer, A. Hoffmeier, D. Duveau, Hannover Medical School, Hannover, Germany; 2St Vincenz Hospital, Sydney, Australia; 3Medical University Vienna, Vienna, Austria; 4Royal Perth Hospital, Perth, Australia; 5Heart Center NRW, Bad Oeynhausen, Germany; 6Harefield Hospital, Harefield, United Kingdom; 7Freeman Hospital, Newcastle, United Kingdom; 8German Heart Center, Berlin, Germany; 9University Hospital Münster, Münster, Germany; 10Hospital Guillaume, Nantes, France.

Concept of a Catheterization-Lab Implanted Long-Term Circulatory Assist Device: Acute Animal Study Hemodynamic Data; R. Delgado, F. Raissi Shabari, Texas Heart Institute, Houston, TX.

Differential Impact on Post-transplant Outcomes between HeartMate XVE and HeartMate II Left Ventricular Assist Devices; P.A. Ventura, B.B. Reid, B.D. Horne, N.O. Mason, S. Stoker, R. Alharethi, D. Budge, B. Rasmusson, J. Doty, S.E. Clayson, A.G. Kfoury. Intermountain Medical Center, Salt Lake City, UT.

Design and Feasibility Testing of a Miniaturized Transapical Mechanical Circulatory Support Device: MVAD; M.S. Slaughter, G.A. Giridharan, S. Aggarwal, M. Sobieski, D. Tamez, J. LaRose, L. Sherwood, S.C. Koenig. University of Louisville, Louisville, KY; 2University of Louisville, Louisville, Ky; 3University of Louisville, Louisville, Ky; 4University of Louisville, Louisville, Ky; 5HeartWare International, Inc., Framingham, MA; 6HeartWare International, Inc., Framingham, MA; 7University of Louisville, Louisville, Ky; 8University of Louisville, Louisville, KY.

A Single Center Experience with the DuraHeart™ Mag-Lev Centrifugal Left Ventricular Assist System; M.J. Morshuis, L. Arusoglu, M. Schonbrodt, J. Boergermann, J. Gummert. Heart and Diabetic Center North Rhine Westfalia, Bad Oeynhausen, NRW, Germany.


Mechanisms of Inflammation and Repair in the Lung Allograft Airway (Boulevard)


Lymphocytic Bronchiolitis Is Associated with Inadequate Suppression of Blood T-Cell Granzyme B, IFN7 and TNFa; C.-L. Liew, G. Hodge, S. Hodge, D. Chambers, R. Hopkins, P.N. Reynolds, M.D. Holmes. 1, 2 Royal Adelaide Hospital, Adelaide, Australia; 3The Prince Charles Hospital, Brisbane, Australia; 4SA Lung Transplant Service, Adelaide, Australia.

A Novel Approach to the Assessment of Lymphocytic Bronchiolitis – The ‘B’ Score; D.C. Chambers, S. Hodge, G. Hodge, F. Kermeen, P. Reynolds, M. Holmes, P. Hopkins. 1, 2, 3 The Prince Charles Hospital, Brisbane, QLD, Australia; 4Hanson Institute, Adelaide, South Australia, Australia.

Lung Resident Mesenchymal Stem Cells Are Involved in Bronchiolitis Obliterans; S. Aharinejad, M. Salama, O. Andrukhova, S. Taghavi, W. Klepetko, P. Jaksh. 1, 2 Medical University of Vienna, Vienna, Austria; 3Medical University of Vienna, Vienna, Austria.
2:45 PM (304) Alemtuzumab Induction Facilitates Steroid-Free Immunosuppression in Human Cardiac Transplantation: Two Year Outcomes; M.A. Shullo,1 R. Zomak,2 J.K. Bham,3 C. Bermudez,2 D.M. McNamara,3 M. Navoney,2 R.L. Kormos,2 Y. Toyoda,2 J. Teuteberg,3 1University of Pittsburgh, Pittsburgh, PA; 2University of Louisville School of Medicine, Louisville, KY; 3University of Pittsburgh School of Medicine, Pittsburgh, PA.

3:00 PM (305) Mid-Term Results of Campath Induction and Steroid-free Maintenance Immunosuppression in Cardiac Transplantation; S. Aggarwal,1 K. Luftman,1 R. Bowles,1 K. McCants,2 S. Prabhu,2 R.D. Dowling,1 M.S. Slaughter.1 1University of Pittsburgh Medical Center, Pittsburgh, PA; 2University of Pittsburgh, Pittsburgh, PA; 3University of Pittsburgh, Pittsburgh, PA.

3:15 PM (306) Steroid Minimization Is Associated with Improved Survival in Patients with Diabetes after Heart Transplant; P. Zymek,1 L.J. Teuteberg,1 M.A. Shullo,2 C. Bermudez,3 R.L. Kormos,3 J.K. Bham,3 Y. Toyoda,2 D.M. McNamara,1 1University of Pittsburgh Medical Center, Pittsburgh, PA; 2University of Pittsburgh, Pittsburgh, PA; 3University of Louisville School of Medicine, Louisville, KY.

3:30 PM (307) The Effectiveness of a Standardized Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies (cPRA) in Sensitized Heart Transplant Candidates: Does It Make Sense To Desensitize?; J. Patel,1 M. Kirtleson,2 E. Reed,1 Q. Zhang,1 R. Rajalingam,1 A. Velleca,2 E. Stimpson,2 C. Burch,1 M. Kawano,2 S. Davis,2 J. Moriguchi,2 A. Ardehali,1 J. Kobashigawa.2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

3:45 PM (308) Lower Incidence of New Onset Diabetes after Cardiac Transplant with Alemtuzumab Induction; R. Jones,1 M.A. Shullo,2 R. Zomak,2 C. Bermudez,2 C. Newman,3 M. Rebel,2 C. Yost,2 M. Navoney,2 D.M. McNamara,3 Y. Toyoda,2 R.L. Kormos,2 J. Teuteberg.1 1University of Pittsburgh Medical School, Pittsburgh, PA; 2University of Louisville School of Medicine, Louisville, KY; 3University of Pittsburgh School of Medicine, Pittsburgh, PA.

2:30 PM – 4:00 PM
CONCURRENT SESSION 34: Healing My Broken Heart (Waldorf)

CHAIRS: GABOR B. SZABO, MD, PHD AND VALLUVAN JEEVANANDAM, MD

2:30 PM (309) Extended Myocardial Preservation by Polyphtarmaceutical Supplementation of Celsior; A.J. Watson,1,2 L. Gao,1 J. Tsun,1 L. Sun,1 A. Jabbour,1,2 M. Hicks,3 P.S. Macdonald.1,2 1Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; 2St Vincent’s Hospital, Sydney, NSW, Australia; 3Cedars-Sinai Heart Institute, Los Angeles, CA.
2:45 PM (316) **Minimal (A1) Acute Rejection Episodes are Independent Risk Factors for the Development of Bronchiolitis Obliterans Syndrome in Pediatric Lung Transplant Recipients;** O. Elidemir,¹ N.P. Varghese,¹ E.O. Smith,¹ G.B. Mallory,¹ E.D. McKenzie,² J.S. Heinele,² D.L. Morales,² M.G. Schecter.¹ ¹Baylor College of Medicine, Houston, TX; ²Baylor College of Medicine, Houston, TX.

3:00 PM (323) **Alloimmune Responses to Mismatched MHC Class I Antigens Induces Immune Responses to Self Antigens Leading to Chronic Rejection;** V. Tiriveedhi,¹ D.H. Brand,² D. Saini,¹ S. Ramachandran,¹ R. Hachem,³ E.P. Trulock,¹ G.A. Patterson,¹ T. Mohanakumar.¹ ¹Washington University School of Medicine, St. Louis, MO; ²University of Tennessee, Memphis, TN; ³Washington University School of Medicine, St. Louis, MO.

3:15 PM (324) **De Novo Formation of Lymphoid Tissue in the Lung Evolves Post Transplant Obliterative Airway Disease;** D. Wagnetz,¹ M. Sato,¹ J. Yeung,¹ S. Hirayama,¹ T. Waddell,¹ M. Liu,² S. Keshavjee.¹ ¹Toronto General Hospital, Toronto, ON, Canada; ²Latner Thoracic Research Laboratories, Toronto, ON, Canada.

3:30 PM (325) **cKit and MHC Class-I Expression in the Tolerizing Inoculum Dictates Donor-specific Tolerance vs Third-Party Cardiac Allograft Acceptance in a Neonatal Tolerance Model;** M. Jeyakanthan,¹ K. Tao,¹ L.J. West. University of Alberta, Edmonton, AB, Canada.

3:45 PM (326) **Allogeneic CD4+CD25+ T Cells Regulate Rejection of Bronchus Transplants in Porcineized Mice;** A.-K. Knoefel,¹ N. Madrahimov, G. Warnecke,¹ M. Avsar, K. Dreckmann, M. Strueber, A. Haverich.¹ ¹Hannover Medical School, Hannover, Germany.

4:00 PM – 4:30 PM Coffee Break (Southeast Exhibit Hall)

4:30 PM – 11:59 PM Exhibit Hall/Poster Hall Strike (Southeast/Southwest Exhibit Halls)

4:30 PM – 6:00 PM CONCURRENT SESSION 37: Heart Transplantation Clinical Challenges (Continental A/B)

**CHAIRS:** RAY E. HERSHBERGER, MD AND GONZALO V. GONZALEZ-STAWINSKI, MD

4:30 PM (327) **Gender Does Matter – Gender Specific Outcome Analysis of 1000 Heart Transplants at a Single Centre;** L. Kaczmarek, S. Eifert, S. Kofer, B. Meiser, B. Reichart. Grosshadern University Hospital, Munich, Germany.

4:45 PM (328) **Increased LV Mass and Concentricity as Associated with Increased Mortality in Cardiac Transplant Recipients;** P.C. Patel,¹ S.C. Reimold,¹ F.G. Araj,¹ P.A. Kaiser,¹ R.M. Peshock,¹ C.W. Yancy,² W.S. Ring,³ S. Gupta,¹ J.D. Mishkin,¹ P.P. Mammen,¹ D.W. Markham,¹ M.H. Drazner.¹ ¹University of Texas Southwestern Medical
Primary Graft Dysfunction Does Not Lead to Increased Cardiac Allograft Vasculopathy in Surviving Patients; S. Wong,1 J. Moriguchi,2 M. Kawano,2 J. Kobashigawa,2 R. Shemin,1 M. Kwon.1 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

Blood Product Requirements during Heart Transplantation Are Significantly Higher in Patients Bridged with Continuous Flow Devices Compared to Pulsatile Flow Devices; N. Uriel,1 S.-W. Pak,2 E.M. Sutton,1 Y. Naka,3 U.P. Jorde,4 D. Mancini.1 1Columbia University, New York, NY; 2Columbia University, New York, NY.

The Slope of Renal Function in De Novo HTxR. Can We Improve?; J. Kobashigawa,1 J. Arizon,2 G. Dong,3 H.J. Eisen,4 G. Junge,5 H. Schwende,5 A. Zuckermann,5 H.B. Lehmkuhl.3 1Cedars-Sinai Heart Institute, Los Angeles, CA; 2Hospital Universitario, Cordoba, Spain; 3Novartis Pharmaceuticals Corporation, East Hanover; 4Temple University, Philadelphia; 5Novartis Pharma, Basel, Switzerland; 6Medical University of Vienna, Vienna, Austria; 7Deutsches Herzzentrum Berlin, Berlin, Germany.

Lung Transplantation in Patients with Scleroderma: A Single Center Experience; M.M. Crespo,1 D. Zaldonis,2 M.P. George,1 Y. Toyoda,2 B. Johnson,1 C. Bermudez,2 S.S. Haider,1 J.K. Bhana,2 M.R. Morell,1 J.M. Pilewski.1 1University of Pittsburgh Medical Center, Pittsburgh, PA; 2University of Pittsburgh Medical Center, Pittsburgh, PA.

Lung Transplantation in Patients with Scleroderma: Does Bilateral Versus Single Lung Transplantation Improve Long Term Survival for Patients with Pulmonary Fibrosis?; S.D. Force,1 A. Pelaez,2 D.C. Neujahr,1 P.D. Kilgo,1 A.M. Ramirez,2 D.L. Miller,1 A. Pickens,1 F.G. Fernandez,1 C. Lawrence.2 1Emory University, Atlanta, GA; 2Emory University, Atlanta, GA.

Impact of the UNOS Lung Allocation Scoring System on Lung Transplantation for Interstitial Lung Disease; S. Osaki,1 J. Maloney,1 R.D. Cornwell,2 K.C. Meyer,3 N.M. Edwards,4 N.C. De Oliveira.1 1University of Wisconsin, Madison, WI; 3University of Wisconsin, Madison, WI.

Pre-Obese and Obese Patients with Idiopathic Pulmonary Fibrosis Are at High Risk for Early Mor-

Anti-Apoptotic Role of IL-16 Associated with Attenuation of Acute and Chronic Cardiac Rejection; N. Kimura,1 S. Ito,2 J.B. Vellota,1 O.P. Palmer,1 H. Kossuge,2 S. Nakae,3 H. Kornfeld,4 R.C. Robbins,1 M.P. Fischer,1 1Stanford University, School of Medicine, Palo Alto, CA; 2Stanford University, School of Medicine, Palo Alto, CA; 3University of Tokyo, The Institute of Medical Science, Tokyo, Japan; 4University of Massachusetts, Medical School, Worcester, MA.

IL-6 Plays a Crucial Role in the Induction of Autoimmunity and Development of Chronic Rejection; S. Ramachandran,1 N. Fukami,1 N. Benshoff,1 T. Mohanakumar.12 1Washington University in St Louis, St. Louis, MO; 2Washington University in St Louis, St. Louis, MO.

Explaining the Bronchiolitis Obliterans Syndrome (BOS) Phenotype – Epithelial-Mesenchymal Transition (EMT) Occurs More Readily in Small Airways Epithelium; B. Banerjee,1 A. Kicic,3,4 M.M. Musk,1 S.M. Stick,3,4 D.C. Chambers,1 1University of Western Australia, Crawley, Western Australia, Australia; 2University of Western Australia Lung Transplant Unit, Royal Perth Hospital, Perth, Western Australia, Australia; 3Telethon Institute of Child Health Research, Subiaco, Western Australia, Australia; 4Princess Margaret Hospital for Children, Subiaco, Western Australia, Australia; 5Queensland Centre for Pulmonary Transplantation Vascular Disease, Brisbane, QLD, Australia.

Obliterative Airway Disease (OAD) Induced by Antibodies to MHC- Class I Is B Cell Dependent: An Obligatory Role for Antibodies to Self-Antigens in the
**Pathogenesis of OAD;** S. Ramachandran,¹ N. Fukami,¹ D. Saini,¹ T. Mohanakumar,¹ ²Washington University in St Louis, St. Louis, MO; ³Washington University in St Louis, St. Louis, MO.


**5:45 PM (344) A Novel Approach To Generate Regulatory T Cells Using CD103 Depletion;** S.D. Moffatt-Bruce, N. Zikri, E. Schumer, D. Bobek, G. Hadley. The Ohio State University, Columbus, OH.

**4:30 PM – 6:00 PM**

**CONCURRENT SESSION 40:**

*Expert Consensus Definitions in Cardiothoracic Transplantation and Mechanical Circulatory Support Infections (Waldorf)*

**CHAIRS:** STEPHAN SCHUELER, MD, PHD AND JOSE G. MONTOYA, MD

This session will present a summary of the completed consensus document on infections in cardiac transplantation and mechanical circulatory support, which will form the basis for a set of international standardized variables for entry of infection data into the ISHLT Registry and for future research.

**4:30 PM**

*Definitions of Infection in Mechanical Circulatory Support,* Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

**5:00 PM**

*Definitions of Infection in Heart and Lung Transplantation,* Martha L. Mooney, MD, Sentara Norfolk Transplant Center/EVMS, Norfolk, VA

**5:30 PM**

*Panel Discussion with Taskforce Members:* Shahid Husain, MD, MS, Toronto General Hospital, Toronto, Canada; Frauke Mattner, MD, Hannover Medical Center, Germany; Lara Danziger-Isakov, MD, MPh, Cleveland Clinic Foundation, Cleveland, OH; John V. Conte, MD, Johns Hopkins Hospital, Baltimore, MD; Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle, United Kingdom; Robert F. Padera, MD, PhD, Brigham and Women’s Hospital, Boston, MA

**6:00 PM – 7:00 PM**

*NEW ISHLT BOARD MEMBER ORIENTATION MEETING (PDR-4)*

**8:00 PM – 10:00 PM**

*GALA ANNIVERSARY RECEPTION (Grand Ballroom)*
Saturday, April 24, 2010

7:00 AM – 10:30 AM
Registration Desk Open (8th Street Registration)

7:00 AM – 9:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 6:
Linking Outcomes and Quality of Life After Lung Transplant
(Boulevard)
CHAIRS: SELIM M. ARCASOY, MD AND MARTIN P. IVERSEN, MD, MPH

There has been a major focus on survival and physical outcomes after lung transplant. This has, however, underestimated the importance of quality of life assessment of outcomes. It is important that the wider lung transplant community recognize the value of quality of life assessment and its impact on outcomes after lung transplant. This session will investigate the associations between patient quality of life and outcomes after lung transplant.

7:00 AM Interventions to Improve Adherence After Thoracic Organ Transplantation, Fabienne Dobbels, MSc, PhD, University Hospital Leuven, Belgium

7:15 AM Integrated Survival and Quality of Life Outcomes in Lung Transplantation, Roger D. Yusen, MD, MPH, Washington University School of Medicine, St. Louis, MO

7:30 AM Patient-Reported Outcomes in Lung Transplantation, Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Ontario, Canada

7:45 AM Integrating Palliative Care in Lung Transplantation, Annette J. DeVito Dabbs, RN, PhD, University of Pittsburgh School of Nursing, Pittsburgh, PA

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 7:
Crossing the Lines (Continental C)
CHAIRS: REYNOLDS M. DELGADO, MD AND MARGARET M. HANNAN, MD

7:00 AM Central Lines Infections In Cardiothoracic Transplantation, Jose G. Montoya, MD, Stanford University School of Medicine, Stanford, CA

7:20 AM VAD Infections – Going Into the Future and Learning From the Past, Aly El Banayosy, MD, Penn State Hershey Medical Center, Hershey, PA

7:40 AM Definitions of VAD Infections, Drive-Line Infections, Pocket Infections, and Device Infections, and their Application into Databases for Future Research, William L. Holman, MD, University of Alabama at Birmingham, AL

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 8:
Disasters Early After Lung Transplant (Waldorf)
CHAIRS: THOMAS M. EGAN, MD, MSC AND JOHN DARK, MB FRCS

Unexpected events and early disasters continue to challenge all centres, with a range of possible responses. A range of acute surgical and medical problems and specific solutions to these problems will be discussed.

7:00 AM Unexpected PGD 1 Hyperacute Rejection, Duane Davis, MD, Duke University Medical Center, Durham, NC

7:10 AM Unexpected PGD 2 Left Heart Failure, David C. McGiffin, MD, University of Alabama at Birmingham, AL

7:20 AM Kinked PA/PV, Joshua Sonett, MD, Columbia Presbyterian Medical Center, New York, NY

7:30 AM Unexpected Donor Anatomy, Martin Strueber, MD, Hannover Medical School, Hannover, Germany

7:40 AM Technical Aspects of ECMO, Clemens Aigner, MD, Medical University of Vienna, Austria

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 9:
Tough Cases in the Management of the Sensitized Patient Case Presentations (Marquette)
CHAIRS: JACQUELINE LAMOUR, MD AND ELAINE F. REED, PHD

This symposium will address a practice gap in the diagnosis and management of the patient who has evidence of anti-HLA antibodies undergoing transplantation. There is a significant amount of controversy in surrounding the appropriate management of the highly sensitized patient and this symposium will allow participants to understand the state-of-the-art thinking in the field. This symposium will use a practical case-based approach to highlight the issues raised in the transplantation of the highly sensitized patient undergoing heart or lung transplantation.

INVITED DISCUSSANTS, Linda J. Addonizio, MD, Columbia Presbyterian Medical Center, New York, NY and Stephan M. Ensminger, MD, PhD, University of Erlangen-Numberg, Germany

7:00 AM Treatment of the Sensitized Lung Transplant Patient, Susan D. Moffatt-Bruce, MD, PhD, Ohio State University Medical Center, Columbus, OH

7:15 AM Discussion

7:20 AM Rising Donor Specific Antibodies after Transplant despite Excellent Graft Function: To Treat or Not to Treat, Jeffrey G. Gossett, MD, Children’s Memorial Hospital, Chicago, IL

7:35 AM Discussion
Cardiac Transplantation in a Highly Sensitized Pediatric Patient with Congenital Heart Disease, Chesney D. Castleberry, MD, Medical College of Wisconsin, Wauwatosa, WI

Discussion

PLENARY SESSION (Continental A/B)

INVITED LECTURE, New Therapies for Sensitized Renal Allograft Recipients, Patrick G. Dean, MD, Mayo Clinic Transplant Center, Rochester, MN

FEATURED ABSTRACT Are DCD Lungs Superior? Excellent Intermediate Results from a Donation after Cardiac Death Lung Transplant National Collaborative; B. Levvey, M. Harkess, D. Chambers, E. Granger, I. Ahmed, P. Hopkins, A. Glanville, G. Snell. The Alfred Hospital, Melbourne, Vic, Australia; St. Vincent’s Hospital, Sydney, NSW, Australia; Prince Charles Hospital, Brisbane, QLD, Australia.

INVITED DISCUSSANT, Andres Varela, MD, Hospital Universitaria Puerta de Hierro

FEATURED ABSTRACT Cardiac Resuscitation Following Circulatory Arrest in the Organ Donor Is Associated with Excellent Functional and Metabolic Recovery: Implications for Clinical Heart Transplantation; A.A. Ali, B. Xiang, P. White, S. Tsui, E. Ashley, S.R. Large, T.W. Lee, R. Arora, G. Tian, D.H. Freed. Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom; University of Manitoba, Winnipeg, MB, Canada; Stanford University Medical Center, Palo Alto, CA.

INVITED DISCUSSANT, Carmelo A. Milano, MD, Duke University Medical Center, Durham, NC

INVITED LECTURE, Stem Cell Tissue Engineering, Prof. Dr. Thomas Eschenhagen, University Hospital Hamburg-Eppendorf, Hamburg, Germany

FEATURED ABSTRACT United States Lung Allocation Score Predicts Hospital Charges Post-Transplant; G.J. Arnaoutakis, J.G. Allen, C.A. Merlo, W.A. Baumgartner, J.V. Conte, A.S. Shah. The Johns Hopkins Hospital, Baltimore, MD; The Johns Hopkins Hospital, Baltimore, MD.

INVITED DISCUSSANT, Edward R. Garrity, Jr., MD, University of Chicago Medical Center, Chicago, IL

FEATURED ABSTRACT Serum IgA Deficiency Is Common in Lung Transplantation and Is Independently Associated with Bronchiolitis Obliterans Syndrome (BOS); D.C. Chambers, B. Davies, S. Yerkovich, P.M. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia.

INVITED DISCUSSANT, Andrew J. Fisher, MD, Institute of Cellular Medicine, Newcastle Upon Tyne, United Kingdom

AWARDS PRESENTATIONS

DEBATE: Mechanical Circulatory Support is IN, Heart Transplantation is OUT

PRO: O. Howard, Frazier, MD, Texas Heart Institute, Houston, TX

CON: Mandeep R. Mehra, MD, University of Maryland School of Medicine, Baltimore, MD

Press Office Open (Continental Foyer Office 1)

Coffee Break (Registration Area)

CONCURRENT SESSION 42: Blood, Clots and Antibodies (Continental A/B)

CHAIRS: DARREN H. FREED, MD, PHD, FRCSC AND ROLAND HETZER, MD, PHD

Morbidity and Mortality Due to Thrombotic and Haemorrhagic Complications in Children Receiving Mechanical Cardiac Support Using the Berlin Heart Device; T. Biss, J. Cassidy, A. Hasan, P. Kesteven. Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Trust, Newcastle, Tyne and Wear; Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Trust, Newcastle, Tyne and Wear.

Patients in Critical Status Due to High Risk of Thromboembolism under Mechanical Circulatory Support Benefit More from Urgent Heart Transplantation than Other Candidates; T. Komoda, T. Drews, H.B. Lehmkuhl, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.


Desensitization Therapies Are Ineffective and May Increase Infection Rates in VAD Patients; E. Feller, E. Sorensen, B. Griffith. University of Maryland, Baltimore, MD; University of Maryland, Baltimore, MD; University of Maryland, Baltimore, MD.
11:30 AM (359) **Highly Sensitized Patients on VAD Support Avoiding Heart Transplant on a Ventricular Assist Device (VAD) Appear To Have a Less Robust Immune Response Compared to Non-VAD Patients;** M. Kittleson, J. Moriguchi, M. Kwon, E. Reed, S. Davis, M. Kawano, C. Burch, A. Velleca, E. Stimpson, J. Patel, A. Ardehali, J. Kobashigawa, David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.

11:45 AM (360) **In Vivo Assessment of Thrombogenicity of the Penn State Pediatric Ventricular Assist Device;** W.J. Weiss, E.L. Carney, J.B. Clark, T. Cooper, R. Peterson, T.P. Nifong, C. Siedlecki, B. Lukic, G. Rosenberg. Penn State Milton S. Hershey Medical Center, Hershey, PA.

10:30 AM – 12:00 PM

CONCURRENT SESSION 43: Lung Transplantation Complications (Boulevard)

CHAIRS: MARC A. STERN, MD AND PETER M. HOPKINS, FRACP

10:30 AM (361) **Retinoid Therapy Is Ineffective in Preventing Cutaneous Malignancy Complicating Lung Transplantation;** T. Tse, D.C. Chambers, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia.

10:45 AM (362) **PTLD after Lung Transplantation – Influence of CMV Prophylaxis on Incidence – Multicentre Centre Analysis and Review of the Literature;** P. Jaksch, J. Gottlieb, C. Geltner, A. Simon, J. Ankersmit, W. Klepetko. Medical University Vienna, Vienna, Austria; LKH Natter, Innsbruck, Austria; Medical University Hannover, Hannover, Germany; Medical University Hannover, Hannover, Germany.


11:15 AM (364) **Posterior Reversible Encephalopathy Syndrome after Lung Transplantation;** L. Haros-Agya, A. Scheed, M. Keplinger, P. Jaksch, W. Klepetko. Medical University of Vienna, Vienna, Austria; Medical University of Vienna, Vienna, Austria.

11:30 AM (365) **Ambulatory Muscle Strength Recovery Is Significantly Delayed When Compared to Improvements in Lung Function and Six Minute Walk Distance after Lung Transplantation;** J.R. Walsh, D.C. Chambers, R.J. Davis, H.E. Seale, N.R. Morris, F.D. Kermeen, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia; Griffith University, Gold Coast, QLD, Australia.


10:30 AM – 12:00 PM

CONCURRENT SESSION 44: Late Complications Post Heart Transplantation (Continental C)

CHAIRS: MARIAN ZEMBALA, MD, PHD, FESC AND DANIEL J. GOLDSTEIN, MD

10:30 AM (367) **Lung Cancer after Heart Transplantation: Incidence and Prognosis. Data from the Spanish Post-Heart-Transplant Tumour Registry;** M.G. Crespo-Leiro, N. Manito, G. Rabago, L. Almenar-Bonet, L.A. Alonso-Pulpon, S. Mirabet, J. Fernandez-Yanez, B. Diaz-Molina, F. Gonzalez-Vilchez, N. Romero, J.M. Arizon, J.F. Delgado, E. Roig, T. Blasco, D.A. Pascual-Figal, L. de la Fuente-Galan, J. Muniz. Hospital Universitario A Coruña, A Coruña, Spain; Hospital Universitario de Bellvitge, Barcelona, Spain; Clinica Universitaria de Navarra, Pamplona, Spain; Hospital Universitario La Fe, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Marques de Valdecilla, Santander, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital Universitario Reina Sofia, Cordoba, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clinics i Provincial, Barcelona, Spain; Hospital Virgen de la Arrixaca, Murcia, Spain; Hospital Clinico de Valladolid, Valladolid, Spain; Instituto de Ciencias de la Salud, A Coruña, Spain.

10:45 AM (368) **Outcomes after Chemotherapy for Post-Transplant Lymphoproliferative Disorder in Pediatric Heart Transplant Recipients;** M.E. Spornitz, M.E. Richmond, J.D. Dayton, M.A. Orjuela, J.M. Chen, L.J. Addonizio. Columbia University College of Physicians and Surgeons, New York, NY; Columbia University Medical Center, Children’s Hospital of New York-Presbyterian, New York, NY; Columbia University Medical Center, Children’s Hospital of New York-Presbyterian, New York, NY; Columbia University Medical Center, Children’s Hospital of New York-Presbyterian, New York, NY.


11:30 AM (371) First Angioplasty Does Not Appear To Alter Outcome in Heart Transplant Patients with Newly Diagnosed Transplant Coronary Artery Disease; M. Kittleson, J. Patel, B. Azarbal, J. Moriguchi, M. Kawano, S. Davis, A. Hage, A. Ardehali, J. Kobashigawa. David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.


10:30 AM – 12:00 PM
CONCURRENT SESSION 45: Transplantation for Pediatric Cardiomyopathies (Waldorf)

CHAIRS: KIMBERLY L. GANDY, MD, PHD AND CHARLES E. CANTER, MD

This symposium will provide important information about the specific outcomes of heart transplantation in children with different classes of cardiomyopathies. This information will be used to provide clinicians with a better understanding of the risks and benefits of transplantation in children with pediatric cardiomyopathies. This symposium will review the indications and outcomes of transplantation in patients with all forms of cardiomyopathy.

10:30 AM Classification of Cardiomyopathies and Impact of Genetic Diagnosis on Prognosis, Jeffrey A. Towbin, MD, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

10:45 AM Indications and Outcomes of Listing for Transplantation in Pediatric Cardiomyopathies, Daphne Hsu, MD, Children’s Hospital at Montefiore, Bronx, NY

11:00 AM Which Patients, What Device, and When to Use Mechanical Assist Support in Pediatric Cardiomyopathies? Robert D. B. Jaquiss, MD, Arkansas Children’s Hospital, Little Rock, AR

11:15 AM Outcomes of Transplantation in Patients With Dilated Cardiomyopathy, Richard Kirk, MA FRCP, FRCPCCH, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

11:30 AM Outcomes of Transplantation in Patients With Restrictive Cardiomyopathy, Steven D. Zangwill, MD, Children’s Hospital of Wisconsin, Milwaukee, WI

11:45 AM Outcomes of Transplantation in Patients With Hypertrophic Cardiomyopathy, Robert J. Gajarski, MD, CS Mott Children’s Hospital, Ann Arbor, MI

10:30 AM – 12:00 PM
CONCURRENT SESSION 46: What's Hot! Best Abstracts from Mechanical Circulatory Support, Heart Transplantation, Lung Transplantation (Marquette)

CHAIRS: RICHARD N. PIERSON, III, MD AND HERMANN REICHENSPURNER, MD, PHD

This session provides summaries of the best, most compelling abstracts presented earlier in the week during the ISHLT 2010 Annual Meeting.

10:30 AM What’s Hot, What’s Cool in Clinical Thoracic Transplantation and Cardiopulmonary Support, Bartley P. Griffith, MD, University of Maryland, Baltimore, MD

11:00 AM What’s Hot! Best Abstracts from Stem Cell Transplantation and Tissue Engineering, Sonja Schrepfer, MD, PhD, University Heart Centre Hamburg, Germany

11:30 AM What’s Hot! Best Abstracts from Experimental Solid Organ Transplantation, Paul Fedak, MD, PhD, FRCSC, Foothills Medical Center, Calgary, Canada

12:15 PM – 1:15 PM
COUNCIL REPORTS TO THE MEMBERSHIP AND BOARD (Continental C)

1:30 PM – 5:30 PM
ISHLT BOARD OF DIRECTORS MEETING (Lake Erie Room)
Wednesday • Thursday • Friday
April 21 – 23, 2010
SOUTHWEST EXHIBIT HALL

(373) Does Race Mismatch Have an Impact on Outcome after Heart Transplantation?; S. Montgomery,2 M. Kawano,2 D. Lockhart,2 A. Velleca,2 C. Burch,1 J. Patel,2 S. Davis,2 M. Kittleson,2 J. Moriguchi,2 A. Ardehali,1 J. Kobashigawa.2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

(374) The Threat of Medication Miscommunication in Non-English Speaking Heart Transplant Recipients; A. Velleca,2 C. Burch,1 S. Montgomery,2 D. Lockhart,2 J. Patel,2 M. Kittleson,2 M. Kawano,2 S. Davis,2 J. Moriguchi,2 A. Ardehali,1 J. Kobashigawa.2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

(375) Impact of Ventricular Assist Device (VAD) Implantation on Clinical and Economic Outcomes of Heart Transplantation (HT) in the United States (US) from 2001-2006; H.K. Song,1 B. Diggs,1 F. Mcneil,1 K. Caddell,1 M. Slater,1 F. Tibayan,1 S. Guyton,1 E. Adler,1 A. Kim.2 1Oregon Health and Science University, Portland, OR; 2Oregon Health and Science University, Portland, OR.

(376) Trends in the Functional Outcomes and Quality of Life of Cystic Fibrosis Patients following Lung Transplant; M. Loadman, J. Holman, K. Jackson, J. Weinkauf, N. Roland, A. Kapasi, D. Lien, University of Alberta, Edmonton, AB, Canada.

(377) Children’s Conceptions of Their Parent’s Lung Transplant; T.M. Leisfield,1 K. Wiggins,1 P. Fulbrook.2 1The Prince Charles Hospital, Brisbane, QLD, Australia; 2The Prince Charles Hospital, Brisbane, QLD, Australia.

(378) Factors Modifying Immunosuppression-Related Symptom Experiences in Heart Transplant Recipients; C. Kugler, P. Stiefe, D. Malehsa, M. Strueber, A. Simon, U. Tegtbur, A. Haverich, C. Bara, Hannover Medical School, Hannover, Germany; Hannover Medical School, Hannover, Germany.

(379) Improved Bloodcompatibility of a Poly-4-Methyl-1-Pentene Gas Exchange Membrane by Endothelialization; B. Wiegmann,1 C. Hess,1 A. Hilfiker,1 A. Haverich,1 S. Fischer.1 1Hannover Medical School, Hannover, Germany; 2Leibniz Research Laboratories for Biotechnology and Artificial Organs, Hannover, Germany.
(380) Non-Volume-Loaded Heart Provides a More Relevant Heterotopic Transplantation Model; K.R. Tang-Quan,1,2 J. Bartos,2 T. Deuse,1,2 R.C. Robbins,2 H. Reichenspurner,1 S. Schrepfer,1,2 1University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, CA.

(381) The Effect of Gastro-Duodenal Contents on Tracheal Mucosa: There Is More to It than Acid; V. Mertens,1 R. Farre,1 K. Blondeau,1 A. Pauwels,1 D. Sifrim,1,2 L. Dupont,3,4 1University Hospital Gasthuisberg, Leuven, Belgium; 2Barts and The London School of Medicine and Dentistry, University of London, London, United Kingdom; 3Katholieke Universiteit Leuven, Leuven, Belgium; 4University Hospital Gasthuisberg, Leuven, Belgium.

(382) Reduced Transplant Arteriosclerosis after Treatment with MMF and MMF in Combination with Ganciclovir in a Mouse Aortic Transplant Model; J. Hoffmann, M. Bohm, S. Abele-Ohl, M. Weyand, S.M. Ensminger, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.

(383) MyD88-Independent Signaling Pathway Is Involved with Lung Ischemic Preconditioning; A. Shimamoto,1 Y. Yajima, S. Shomura, M. Takao, H. Shimpo. Mie University Graduate School of Medicine, Tsu, Japan.

(384) Egfl7 Prevents Coronary Endothelial ICAM-1 Expression in Response to Calcineurin Inhibition; M.V. Badiwala, L.C. Tumiati, A. Ghashghai, J.M. Joseph, V. Rao. Toronto General Hospital, Toronto, ON, Canada.

(385) Expression of a Stabilized Hypoxia Inducible Factor-1a Reduces Cardiomyocyte Apoptosis and Prevents Cardiac Allograft Vasculopathy; M.A.I. Keranne,1 A.I. Nykanen,1 R. Krebs,1 K. Pajusola,2 K. Alitalo,2 K.B. Lemstrom,1,2 1University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 2Biomedicum Helsinki, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

(386) Contribution of Pre-Existing Vascular Disease to Allograft Vasculopathy in Mice; A. Zaki, J. Jordan, G. Hirsch, B. Ross, T. Lee. Dalhousie University, Halifax, NS, Canada.

(387) The Role of Plaque Haemorrhage in Progression of Coronary Allograft Vasculopathy; C. Castellani,1 A. Angelini,1 O. de Boer,2 C. van der Loos,2 M. Pedrigo,1 A. Gambino,3 G. Gerosa,3 G. Thiene,1 A.C. van der Wal,2 1University of Padua, Padua, Italy; 2Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands; 3University of Padua, Padua, Italy.


(389) The Indirect Alloimmune Response Causes Endothelial Dysfunction without Endothelial Replacement after Cardiac Transplantation; Y. Xu, A. McCormack, A. Chester, B. Hariri, P. Sarathchandra, M.L. Rose. Imperial College London, London, United Kingdom.

(390) Impact of Topically-Applied Preservation Solutions on Mucociliary Clearance and Tracheal Ischemic Injury in Rats; A.E. de Azevedo-Pereira,1 K.A. Oliveira,1 R. Pazeretti,1 J. Saka,1 M. Cстанавли,2 P.M. Pego-Fernandes,1 E.B. Jatene.1 1Heart Institute, University of São Paulo Medical School, São Paulo, Brazil; 2Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.

(391) T-Bet Deficiency Alters Murine Obliterative Airway Disease Immunopathology and Is Associated with Both Type 1 and Type 17 Effector T Cell Responses; E.A. Lendermon,2 E.R. John,1 H. Miller,1 P.D. Shah,1 J.B. Orens,1 A.C. Myers,2 J.F. McDyer.1 1Johns Hopkins, Baltimore, MD; 2Johns Hopkins, Baltimore, MD.

(392) Interaction between a-1-Antitrypsin (AAT) and A-Defensins in Regulating Immune Responses Leading to Chronic Rejection Following Human Lung Transplantation; D. Saini,1 S. Ramachandran,1 N. Stewart,1 A. Aloush,1 R. Hachem,1 E. Trulock,1 A. Patterson,1 T. Mohamedakumar,1,2 2Washington University in St Louis, St. Louis, MO; 3Washington University in St Louis, St. Louis, MO.

(393) The Gender Divide: Does Donor Gender Matter for Mesenchymal Stem Cell Transplantation?; C. Palichmann,1 K.R. Tang-Quan,1,2 M. Yamada,2 T. Deuse,1,2 R. Robbins,2 H. Reichenspurner,1 S. Schrepfer,1,2 1University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, Germany.

(394) The Role of CCR4 during the Pathogenesis of Murine Obliterative Bronchiolitis Post-Transplantation; V. Palchevskiy,1 Y.Y. Xue,1 R. Kern,1 S.S. Weigt,1 S. Hu,1 A. Derhovanessian,1 S.X. Song,2 A. Gregson,1 R. Elashoff,1 J.P. Lynch,1 J.A. Belperio.1 1University of California, Los Angeles, Los Angeles, CA; 2University of California, Los Angeles, Los Angeles, CA; 3University of California, Los Angeles, Los Angeles, CA.

(396) Coronary Intervention in Lung Transplant Candidates – Does It Impact Survival?; C. Chaparro, W. Karolak, C. Volling, L. Daniel, D. Delgado, F. Chen, M. Cypel, C. Guiterrez, C. Whytehead, L.G. Singer, M. Hutcheon, C.-W. Chow, K. McRae, V. Rao, R.J. Cusimano, M. de Perrot, T. Waddell, A. Pierre, K. Yasufuku, S. Keshavjee. 1Toronto General Hospital, University of Toronto, Toronto, ON, Canada; 2Toronto General Hospital, University of Toronto, Toronto, ON, Canada; 3Toronto General Hospital, University of Toronto, Toronto, ON, Canada; 4Toronto General Hospital, University of Toronto, Toronto, ON, Canada.

(397) Post Lung Transplant Cardiovascular Complications – Role of Cardiovascular MRI; H. Seethamraju, D. Shah, R. Kesavan, S. Bollineni, J. Estep, M. Loebe, G.P. Noon, A. Shah, S. Scheinin, S. Jyorhula, G. Torre. 1Bayler College of Medicine, Houston, TX; 2Methodist Debackey Heart and Vascular Center, Houston, TX.

(398) Reduction in Venous Thromboembolism Following Prophylaxis Modification in Lung Transplantation Patients; J.P. Gagermeier, C.G. Alex, D.F. Dilling, T. Patel, C.H. Wigfield, R.B. Love. 1Loyola University Medical Center, Maywood, IL; 2Loyola University Medical Center, Maywood, IL.


(400) Aggressive Skin Cancers Associated with Prolonged Voriconazole Therapy in 3 Lung Transplant Patients; S. Quetant, C. Saint-Raymond, A. Hugon, P. Bedouch, O. Epaulard, C. Pison, M.-T. Leccia. 1Grenoble University Hospital, Grenoble, France; 2Grenoble University Hospital, Grenoble, France; 3Grenoble University Hospital, Grenoble, France.

(401) Post Transplant Neoplastic Disease Following Lung Transplant: 17-Years Single Centre Experience; P. Totaro, C. Pellegrini, M. Savasta, S. Nicolardi, T. Oggionni, G. Orlandoni, A.M. D’Armini, M. Vigano. 1IRCCS Foundation S Matteo, Pavia, Italy; 2IRCCS Foundation S Matteo, Pavia, Italy; 3University School of Medicine, Pavia, Italy.


(403) The Incidence of Oropharyngeal Dysphagia and Associated Risk Factors Following Double Lung Transplantation: A Retrospective Study; S.A. Skorer, M. Graham, G. Kamitomo, R. Martino. 1University of Toronto, Toronto, ON, Canada; 2University of Alberta Hospital, Edmonton, AB, Canada; 3Toronto Western Research Institute, Toronto, ON, Canada.


(405) Peri-Operative Hyperglycemia and Acute Cellular Rejection 12 Months after Lung Transplantation; S. Indacochea, A. DePorre, D.F. Dilling, N.V. Emanuele, J.P. Gagermeier, C.H. Wigfield, C.G. Alex, R.B. Love, M.A. Emanuele. 1Loyola University Medical Center, Maywood, IL; 2Loyola University Medical Center, Maywood, IL; 3Loyola University Stritch School of Medicine, Maywood, IL.

(406) The Clinical Relevance of Mannose-Binding Lectin (MBL) in Long Term Survival of Lung Transplant Recipients; J.M. Kwakkel-van Erp, E.A. van de Graaf, A.W.M. Paantjens, D.A. van Kessel, J.M.M. van den Bosch, J.C. Grutters, H. Otten. 1Universitary Medical Center Utrecht, Utrecht, Netherlands; 2Universitary Medical Center Utrecht, Utrecht, Netherlands; 3Antonius Hospital, Nieuwegein, Netherlands.

(407) Comparison of Outcome Following Heart/Lung Transplantation for Chronic Thromboembolic Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension; R.V. Venkateswaran, D. Jenkins, J. Dunning, S. Tsui, J. Wallwork, J. Parmar. Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.

(408) Benefits of a Structured Lung Transplant Curriculum in Pulmonary/Critical Care Fellowship; D. Hayes, R. Berger, E. Diaz-Guzman, T.W. Mullett, S.S. Kramer. 1University of Kentucky College of Medicine, Lexington, KY; 2University of Kentucky College of Medicine, Lexington, KY; 3University of Kentucky College of Medicine, Lexington, KY.

(409) Minimizing Post Operative Ventilation Times in Lung Transplant Recipients; J.D. Maloney, S. Osaki, H. Thomas, R.D. Cornwell, K.C. Meyer, N.C. De Oliveira. 1University of Wisconsin, Madison, WI; 2University of Wisconsin, Madison, WI.
(410) Outcome of Lung Graft Volume Reduction for Oversized Donors during Pulmonary Transplantation; S. Shanmuganathan, B. Tanveer, S. Clark. The Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom.


(412) Antibiotic Desensitization in Cystic Fibrosis Patients with a History of Hypersensitivity Undergoing Lung Transplantation Is Not Mandatory; T. Tse, P.M.A. Hopkins, M.W. France, P.J. Masel, S.C. Bell, F.D. Kermeen, D.C. Chambers. The Prince Charles Hospital, Brisbane, QLD, Australia; The Prince Charles Hospital, Brisbane, QLD, Australia.


(419) Significant Side Effect Burden of Voriconazole Curtails Clinical Utility in Lung Transplantation; C.A. Beck, D.C. Chambers, F.D. Kermeen, T. Tse, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia.

(420) The Impact of Repeat HLA Mismatch on Pulmonary Retransplantation; A. Zeevi, D. Zaldonis, K. Spichy, A. Girmita, J. Howe, L. Jelinek, J. Lomago, M. Crespo, J. Pilewski, C. Bermudez, Y. Toyoda. University of Pittsburgh, Pittsburgh, PA; University of Cincinnati Academic Health Center, Cincinnati, OH.


(422) First Year Body Mass Index Trajectory Predicts Subsequent Survival in Lung Transplant Recipients; J.L. McMillan, P.M.A. Hopkins, S.T. Yerkovich, K.M. Herd, D.C. Chambers. The Prince Charles Hospital, Brisbane, QLD, Australia.


(424) Impact of Pharmacokinetics on the Anticipated Duration of Calcineurin Inhibition after Inhalation of Cyclosporine Solution; R.W. Niven, T.E. Corcoran.

(426) The Combined Australian Experience with Human Swine Influenza H1N1 in Lung Transplant Recipients; B.I.H. Ng,1 A.R. Glanville,2 J. D’Costa,3 G. Snell,4 M. Musk,4 M. Holmes,4 D.C. Chambers,4 P.M.A. Hopkins.1 1The Prince Charles Hospital, Chermside, QLD, Australia; 2St Vincent’s Hospital, Darlinghurst, NSW, Australia; 3The Alfred Hospital, Melbourne, Vic, Australia; 4Royal Perth Hospital, Perth, Western Australia, Australia; 4Royal Adelaide Hospital, Adelaide, South Australia, Australia.

(427) Reduced Survival in Lung Transplant Recipients with Bile Acids Aspiration Despite Azithromycin Therapy; V. Mertens,1 K. Blondeau,1 B. Vanaudenaerde,2 R. Vos,2 A. Pauwels,2 G. Verleden,2,3 D.E. Van Raemdonck,3 D. Sifrim,14 L.J. Dupont,23 1University Hospital Gasthuisberg, Leuven, Belgium; 2Katholieke Universiteit Leuven, Leuven, Belgium; 3University Hospital Gasthuisberg, Leuven, Belgium; ‘Barts and The London School of Medicine and Dentistry, University of London, London, United Kingdom.

(428) Initial Experience with Concomitant Surgery of Lung Transplantation and Tricuspid Valve Repair for Patients with Severe Pulmonary Hypertension; N. Shigemura,1 B. Sareyyupoglu,1 S. Tabata,1 T. Horai,1 P. Bonde,1 M. Crespo,2 B. Johnson,2 J. Pilewski,2 J. Bhamra,1 S. Gilbert,1 C. Bermudez,1 Y. Toyoda,1 1University of Pittsburgh Medical Center, Pittsburgh, PA; 2University of Pittsburgh Medical Center, Pittsburgh, PA.

(429) Long Term Outcome of Lung Transplantation in Previous Intravenous Drug Users with Talc Lung Granulomatosis; J.G. Weinkauf,2 R. Nador,1 A. Kapasi,1 K. Jackson,2 K. LaBranche,2 L. Puttagunta,1 K.C. Stewart,4 J. Mullen,4 D.L. Modry,4 D.C. Lien.1 1University of Alberta, Edmonton, AB, Canada; 2University of Alberta, Edmonton, AB, Canada; 3University of Alberta, Edmonton, AB, Canada; 4University of Alberta, Edmonton, AB, Canada.


(432) Near-Infrared Spectroscopy in Lung Transplant Patients: Correlation with Invasive Hemodynamic Measurements; A.N. Ibrahimiiye,1 G. Singh,1 H. Kim,1 A. Irirbarne,1 R. Sladen,2 J. Sonett,1 M. Bacchetta,1 1Columbia University College of Physicians and Surgeons, New York, NY; 2Columbia University College of Physicians and Surgeons, New York, NY.


(434) Statin Therapy Is Associated with Reduced Pulmonary Artery Pressures in Lung Transplant Candidates with COPD; R.M. Reed, R. Girgis. Johns Hopkins University School of Medicine, Baltimore, MD.

(435) Pulmonary Artery Hypertension: Endothelial Dysfunction and Statin Treatment; E.M. Bader,1 R. Zolty.2 1Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; 2Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(436) Mortality and Readmission Rates in Hypoan-tremic Patients with Pulmonary Hypertension and Right Ventricular Failure; A. Rabinovitz,1 R. Zolty.1 1Jacobi Medical Center, Bronx, NY; 2Montefiore Medical Center, Bronx, NY.


(439) Does Diastolic Dysfunction Contribute to Pulmonary Hypertension in Patients with Advanced COPD Awaiting Lung Transplantation?; N. Selimovic, B. Andersson, M. Lomsky, G.C. Riise, B. Rundqvist. Sahlgrenska University Hospital, Gothenburg, Sweden.

(440) Secondary Pulmonary Hypertension Does Not Affect Survival but Impacts Short and Long Term Outcome Measures Following Lung Transplantation; J.G. Weinkauf,2 R.G. Nador,1 K.B. Jackson,2 A.M. Kapasi,1 K. LaBranche,2 S.R. Meyer,1 D.L. Modry,3 J.C. Mullen,3 D.C. Lien.1 1University of Alberta, Edmonton, AB, Canada; 2University of Alberta Hospital, Edmonton, AB, Canada; 3University of Alberta, Edmonton, AB, Canada.

(441) Predictors of Right Ventricular Function in Lung Transplant Candidates; N. Selimovic, B. Andersson, M. Lomsky, G.C. Riise, B. Rundqvist. Sahlgrenska University Hospital, Gothenburg, Sweden.
(442) Lower Weight Related to Elevated Liver Enzymes in Pulmonary Hypertension Patients Treated with Bosentan; E.A. Kobashigawa,1 J.B. Schwarz,1 W.-C. Hsueh,1 N. Bendjilali,1 A. Wu,2 T. De Marco.1 1University of California San Francisco, San Francisco, CA; 2San Francisco General Hospital, San Francisco, CA.

(443) WITHDRAWN

(444) Severe Hypoxia in Eisenmenger Syndrome Does Not Preclude Safe Performance of the Six Minute Walk Test; R.J. Davis,1 K. Hall,1 J.R. Walsh,1 H.E. Scale,1 J.E. Harris,1 D.J. Radford,2 F.D. Kermeen.1 1The Prince Charles Hospital, Brisbane, QLD, Australia; 2The Prince Charles Hospital, Brisbane, QLD, Australia.

(445) Lack of Sensitivity of Morphological Features for the Detection of Antibody-Mediated Rejection on Monitoring Endomyocardial Biopsies; M. Fedrigo,1 A. Gambino,2 E. Benazzi,3 F. Poli,3 F. Tona,3 A. Caforio,3 C. Castellani,1 M. Valente,1 G. Gerosa,2 G. Thiene,1 A. Angelini.1 1University of Padua, Padua, Italy; 2University of Padua, Padua, Italy; 3IRCCS Fondazione OMP MARE, Milano, Italy.

(446) Quantitative Analysis of Nerve Density across Airway Anastomosis in Lung Transplant Recipients; A.G. Duarte,1 G.A. Campbell,1 V.G. Valentine,1 A.C. Myers.2 1University of Texas Medical Branch, Galveston, TX; 2Johns Hopkins University, Baltimore, MD.

(447) Quilty Is a Risk Factor for Microvasculopathy in Biopsy Following Heart Transplantation – Evidence from a Prospective Clinical Study; N.E. Hiemann,1 E. Wellhofer,1 H.B. Lehmkuhl,1 C. Knosalla,2 R. Hetzer,1 R. Meyer.1 1Deutsches Herzcentrum Berlin, Berlin, Germany; 2Deutsches Herzcentrum Berlin, Berlin, Germany.

(448) Tissue Plasminogen Activator Is the Most Important Component of a Novel Thrombosis/Activation (TA) Score for Predicting Cardiac Allograft Vasculopathy Following Heart Transplantation; C.A. Labarrere,1 J.R. Woods,1 J.W. Hardin,2 G.L. Campana,1 M.A. Ortiz,1 B.R. Jaeger,3 B. Reichart,4 L.A. Baldridge,5 J.M. Bonnin,5 A. Currin,5 S.K. Cosgrove,6 P.C. Kirlin,6 J.A. O’Donnell,7 D.A. Hormuth,6 T.C. Wozniak.6 1Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; 2University of South Carolina, Columbia, SC; 3Dr Stein und Kollegen, Mönchengladbach, Germany; 4Ludwig-Maximilians-Universität, Munchen, Germany; 5Indiana University School of Medicine, Indianapolis, IN; 6Clarian Health Partners, Indianapolis, IN; 7Kranzner Institute of Cardiology, Indianapolis, IN.

(449) Relating Microarray Results from 105 Heart Allograft Biopsies to Pathology and Function: Molecular Phenotypes of Myocardial Inflammation and Injury Correlate with Impaired Function and Histological Signs of Microcirculation Injury; M. Mengel,1 J. Chang,1 D. Kim,2 B. Sis,1 J. Burton,2 W. Tymchak,2 P. Halloran,1 1University of Alberta, Edmonton, Canada; 2University of Alberta, Edmonton, Canada.

(450) Characterization of IgM and Complement within CAV Lesions; E.L. Moseley,1 M.J. Goddard,1 J. Wallwork,3 C. Arkinson.2 1Papworth Hospital NHS Trust, Cambridge, United Kingdom; 2Medical University of South Carolina, Charleston; 3Papworth Hospital NHS Trust, Cambridge, United Kingdom.


(452) Differential Leukocyte Gene Expression in Cardiac Transplant Recipients Receiving Tacrolimus Compared to Cyclosporine; J. Patel,1 A.J. Hicks,1 T. Rowe,2 S.R. Hankins,1 H.J. Eisen.1 1Drexel University College of Medicine, Philadelphia, PA; 2Hahnemann University Hospital, Philadelphia, PA.

(453) Does a Difference in Molecular Diagnostic Test Results Exist between Proliferation Signal Inhibitors and Mycophenolic Acid in Cardiac Allograft Recipients?; J. Patel,1 G. Mwandia,1 T. Rowe,2 S.R. Hankins,1 H.J. Eisen.1 1Drexel University College of Medicine, Philadelphia, PA; 2Hahnemann University Hospital, Philadelphia, PA.

(454) Lack of Association between Pre-Transplant MICA Antibodies and Cardiac Allograft Dysfunction; M.A. McDonald,1 J. Braga,1 P. Billia,1 S. Tapiawala,2 H.J. Ross,1 K.J. Tinckam.2 1University Health Network, Toronto, ON, Canada; 2University Health Network, Toronto, ON, Canada; 3, Edmonton, AB.


(456) Heart Transplant Therapy in United States Veterans: 16-year Experience at A Single Center; D.R. Murray,1 S. Osaki,2 J. Kobashigawa,1 M. Hamilton,2 D. Gjertson,1 J. Gomez Abraham,1 H. Laks,1 A.
(474) Interaction of CMV Prophylaxis and Pre-emptive Strategies with Immunosuppressive Therapy: Potential Antiviral Effect of Everolimus; L. Potena,1 C. d’Agostino,2 D. Abate,4 G. Magnani,1 F. Baccollini,3 T. Ionico,1 F. Grigioni,1 A. Gambino,6 D. Sgarabotto,1 G. Toscano,1 A. Branzi,1 G. Gerosa,3 1University of Bologna, Bologna, Italy; 2University of Padua, Padua, Italy; 3University of Bologna, Bologna, Italy; 4University of Padua, Padua, Italy; 5University of Padua, Padua, Italy; 6University of Padua, Padua, Italy.

(475) Graftvasculopathy: Have We Learned Something after All These Years?; S.L. Mahr, A.Z. Aliabadi, D. Dunkler, F. Eskandary, M. Grommer, D. Zimpfer, G. Laufer, A.O. Zuckermann. Medical University of Vienna, Vienna, Austria.

(476) Acute Kidney Injury in Heart Transplant Patients Assessed by RIFLE, A/KIN, and Delta-Creatinine: Implications on Outcome; A. Schiferez,1 D. Hutschala,1 D. Dunkler,2 M. Hiesmayr,3 A. Zuckermann,4 E. Tschernko,1 1Medical University of Vienna, Vienna, Austria; 2Medical University of Vienna, Vienna, Austria; 3Medical University of Vienna, Vienna, Austria.

(477) Levosimendan for Primary Graft Failure after Heart Transplantation: A Three-Year Follow up; A. Beiras-Fernandez,1 F. Weis,2 L. Kaczmarek,1 M. Weis,2 P. Uberfuhr,1 F. Kur,1 B. Reichart.1 1LM-University, Munich, Germany; 2LM-University, Munich, Germany.

(478) Late Gadolinium Enhancement Patterns on Cardiac Magnetic Resonance Images in Heart Transplant Patients; C. Vittori,1 M. Cipriani,1 P. Pedrotti,1 S. Dellegrattorraglie,7 S. Pedretti,1 G. Bruschi,1 A. Roghi,1 M. Frigerio,1 1Niguarda Ca’ Granda Hospital, Milano, Italy; 2Federico II University, Napoli, Italy.


(480) Feasibility of Alikiren for Treatment of Refractory Arterial Hypertension in Heart Transplant Recipients; M. Adam,1 S. Meyer,1 F.M. Wagner,2 T. Deuse,2 H. Reichenspurner,2 A. Costard-Jaeckle,1 1University Heart Center, Hamburg, Germany; 2University Heart Center, Hamburg, Germany.


(482) Prevalence of Kidney Function in Heart Transplant Recipients Using New CKD-EPI Formula; P. Przybylowski,1 J.M. Małyszko,2 J. Małyszko.1 1Collegium Medicum, Jagiellonian University, Krakow, Poland; 2Medical University Bialystok, Bialystok, Poland.

(483) Significance of Pre Transplant Donor Specific HLA Antibodies and Post Transplant Cardiac Allograft Vasculopathy; M.J. Gandhi,1 S.R. De Goey,1 N. Periera,2 S. Kushwaha,2 B. Edwards,2 S. Park,2 A. Clavell,2 J. Schirger,2 R. Rodeheffer,2 R. Frantz,2 R.C. Daly.2 1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN.


(485) Inadequate Blood Pressure Control in Orthotopic Heart Transplant Recipients (OHT); P. Przybylowski,1 J. Małyszko,2 J.M. Małyszko.1 1Collegium Medicum, Jagiellonian University, Krakow, Poland; 2Medical University Bialystok, Bialystok, Poland.

(486) The Influence of VAD Bridging in Different Gender on Outcome Following Heart Transplantation; S. Klotz, H. Welp, J.R. Sindermann, H.H. Scheld. University Hospital Muenster, Muenster, Germany.


(488) The Etiology of Allograft Vasculopathy; M.H. Hart-Maryas,1 S. Nejat,1 B.M. Ross,2 G.M. Hirsch,1 T.D.G. Lee,1,2,3 1Dalhousie University, Halifax, NS, Canada; 2Dalhousie University, Halifax, NS, Canada; 3Dalhousie University, Halifax, NS, Canada.


(491) Everolimus for the Prevention of Microvasculopathy in Biopsy in Cardiac Transplant Recipients: Preliminary Results from Re-Evaluation of the RAD B253 Trial; N.E. Hiemann,1 C. Bara,2 J. Segovia,1 S. Simonsen,3 M. Crespo-Leiro,5 H. Eiskjaer,5 J. Vanhaecke,7 A. Poncelet,5 P. Przybylowski,5 M. Frigerio,10 1Clinic, Rochester, MN.
H.B. Lehmkuhl,1 R. Meyer,1 1Deutsches Herzzentrum Berlin, Berlin, Germany; 2Medizinische Hochschule Hannover, Hannover, Germany; 3Hospital Puerta de Hierro Majadahonda, Madrid, Spain; 4Oslo University Hospital, Rikshospitalet, Oslo, Norway; 5Hospital Universitario Juan Canalejo, La Coruna, Spain; 6Aarhus University Hospital, Skejby, Denmark; 7University Hospital Gasthuisberg, Leuven, Belgium; 8Cliniques Universitaires Saint-Luc, Brussels, Belgium; 9Jagiellonian University, John Paul II Hospital, Krakow, Poland; 10Az. Ospedaliera Ospedale Niguarda-Ca’ Granda, Milan, Italy.

(492) Incidence of Tacrolimus-Associated Hyperammonemia in a Cohort of Lung Transplant Recipients; J. Rusinak,1 E. Greenhalgh,1 D.F. Dilling,2 C.H. Wigfield,3 J.P. Gaggermeier,2 R.B. Love,3 C.G. Alex.1 1Loyola University Medical Center, Maywood, IL; 2Loyola University Medical Center, Maywood, IL; 3Loyola University Medical Center, Maywood, IL.

(493) Reduced Dose-Adapted MMF Exposure under Proton Pump Inhibitor Co-Medication in Stable Heart Transplant Recipients; A.O. Doesch,1 S. Mueller,1 S. Celik,1 M. Konstandin,1 A. Kristen,1 L. Frankenstein,1 P. Ehlermann,1 F.-U. Sack,2 H.A. Katus,1 T.J. Dengler.1 1University of Heidelberg, Heidelberg, Germany; 2University of Heidelberg, Heidelberg, Germany.

(494) Anti-Thymocyte Globulin Preserves Renal Function in Heart Transplantation; A.B. Cochrane,1 M.C. Chu,2 S.E. Fedson.2 1Univ of Chicago, Chicago, IL; 2Univ of Chicago, Chicago, IL.

(495) Everolimus Prevents Endomyocardial Remodeling after Heart Transplantation; N.E. Hiemann,1 H.B. Lehmkuhl,1 E. Wellnhof,2 C. Knosalla,1 R. Hetzer,1 R. Meyer.1 1Deutsches Herzzentrum Berlin, Berlin, Germany; 2Deutsches Herzzentrum Berlin, Berlin, Germany.

(496) Tacrolimus Versus Cyclosporine in Pediatric Lung Transplantation; O. Eflimtori,1 S.M. Moonnumakal,1 E.D. McKenzie,2 J.S. Heinle,2 D.L. Morales,2 J.A. Rama,1 E.O. Smith,1 G.B. Mallory,1 M.G. Schechter.1 1Baylor College of Medicine, Houston, TX; 2Baylor College of Medicine, Houston, TX.

(497) Cardiac MRI in the Assessment and Management of Heart Failure; D. Arumugam, R. Slaughter, M. Brown, G. Javorsky, D. Platts. The Prince Charles Hospital, Brisbane, QLD, Australia.

(498) WITHDRAWN

(499) Impact of Baseline RV Structural and Functional Abnormalities on the Presence of Cardiac Dyssynchrony: Insight from the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) TRIAL; H. Prylutksa,1 B. Thibault,1 F. Harel,1 M. White,1 A. Fortier,2 P.G. Guerra,1 A. Ducharme,1 1Montreal Heart Institute, Montreal, QC, Canada; 2Montreal Heart Institute Coordinating Center, Montreal, QC, Canada.

(500) The Impact of Baseline Cardiac Structural and Functional Abnormalities on Exercise Capacity: Insight from the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) Trial; A. Ducharme,1 M. White,1 H. Prylutksa,1 J. Graham,1 F. Harel,1 A. Fortier,2 P.G. Guerra,1 B. Thibault,1 1Montreal Heart Institute, Montreal, QC, Canada; 2Montreal Heart Institute Coordinating Center (MHICC), Montreal, QC, Canada.

(501) Efficacy of Immunoabsorption as Bridge-to-Transplant Therapy in Patients with Idiopathic Dilated Cardiomyopathy and Evidence of Beta-1 Adrenoceptor Autoantibodies; M. Dandel,1 G. Wallukat,2 A. Englert,1 H.B. Lehmkuhl,1 R. Hetzer.1 1Deutsches Herzzentrum Berlin, Berlin, Germany; 2Max Delbrück Centrum für Molekulare Medizin, Berlin, Germany.

(502) Geographic Changes in Waitlist Survival after Initiation of New Heart Allocation Policy; A. Iribarne,1 M.J. Russo,1 H. Takayama,1 M. Williams,1 A.S. Stewart,1 M. Argenziano,1 D.M. Mancini,2 Y. Naka.1 1Columbia University Medical Center, New York, NY; 2Columbia University Medical Center, New York, NY.


(504) The Effect of Ex-Vivo Perfusion on the Inflammatory Profile of the Donor Lung; D.M. Karamanou,12 H.R. Walden,2 S. Bean,2 M. Prabhu,2 S. Clark,1 A.J. Simpson,3 P. Corris,1,2 J.H. Dark,1,2 A.J. Fisher.1,2 1Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 2Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 3University of Edinburgh, Edinburgh, Scotland, United Kingdom.

(505) Retrograde Flush Is More Effective Than Heparinization in the Uncontrolled Non-Heart-Beating Donor; C. Van De Wauwer,1 A. Neyrinck,1 F. Rega,1 G.M. Verleden,1 T. Lerut,1 D. Van Raemdonck.1 1KU Leuven, Leuven, Belgium; 2KU Leuven, Leuven, Belgium; 3KU Leuven, Leuven, Belgium.

(506) Effect of N-Acetylcysteine on Acute Allograft Rejection after Lung Transplantation; B.V. Erne, W. Jungraithmayr, S. Arni, W. Weder, I. Inci. University Hospital Zurich, Zurich, Switzerland.
(507) Evidence of Progressive Inflammatory and Cardiac Stress Responses Following Brain Death; V.B. Dronavalli,1 A. Normandale,2 P. Gosling,2 C.A. Rogers,3,4 H. Thomas,4 N.R. Banner,3,6 R.S. Bonser,1,6 1Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; 2University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; 3Bristol Heart Institute, University of Bristol, Bristol, United Kingdom; 4NHS Blood and Transplant, Bristol, United Kingdom; 5Harefield Hospital, Royal Brompton and Harefield Hospital NHS Trust, Harefield, Middlesex, United Kingdom; 6On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, United Kingdom.


(510) Heparin and Thrombosis in Donor Lungs after Cardiac Death; H.B. Keshava,1 D.P. Mason,1 J.J. Yun,1 S.C. Murthy,1 N. Vakil,1 G.B. Pettersson,1 C.F. Farver.2 1Cleveland Clinic, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH.

(511) Impact of High Dose Inotropic Donor Support on Early Myocardial Necrosis and Outcome in Cardiac Transplantation; J.L. Nixon,1 K. Brunisholz,1 B. Horne,1 C. Myrick,1,2 D. Budge,1 A.G. Kfoury,1 M. Everitt,1 J. Stehlik,1 T.C. Schmidt,1,3 E.M. Gilbert,1 F. Bader,1 R. Alharethi,1 1UTAH Cardiac Transplant Program, Salt Lake City, UT; 2Intermountain Donor Services, Salt Lake City, UT.

(512) Increasing the Donor Pool by the Use of a Lung Donor Quality Score; J.M. Smits,1 W. van der Bij,2 D. van Raemdonck,1 A.O. Rahmel,1 1Eurotransplant, Leiden, Netherlands; 2UMCG, Groningen, Netherlands; 3Gasthuisberg, Leuven, Belgium.

(513) Tachycardia but Not T Wave Inversion or QTc Duration Is Associated with Donor Heart Injury; V.B. Dronavalli,1 J.N. Townend,1 C.A. Rogers,3,5 H. Thomas,4 N.R. Banner,2,5 R.S. Bonser,3,5 1Queen Eliza-

beth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; 2Royal Brompton and Harefield Hospital NHS Trust, Harefield, Middlesex, United Kingdom; 3Bristol Heart Institute, University of Bristol, Bristol, United Kingdom; 4NHS Blood and Transplant, Bristol, United Kingdom; 5On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, United Kingdom.

(514) The Effect of Direct Hemoperfusion with a Polymyxin B-Immobilized Fiber Column (DHP-PMX therapy) on Pulmonary Ischemia-Reperfusion Injury in a Canine Model; K. Oshima,1 T. Akao,2 K. Kobayashi,2 K. Matsumoto,3 I. Takeyoshi,2 1Gunma University Hospital, Maebashi, Gunma, Japan; 2Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan; 3CML Pathological Laboratory, Ebina, Kanagawa, Japan.

(515) Mitochondrial Behavior in Warm Pulmonary-Ischemia Reperfusion Injury; S.-P. Sommer,1 S. Sommer,1 V. Lange,1 I. Aleksic,1 B. Sinha,1 C. Schimmer,1 R.G. Leyh.1 1University Hospital Würzburg, Würzburg, Germany; 2University Hospital Würzburg, Würzburg, Germany.


(517) Dextrane Free Preservation Improves Early Graft Function in Porcine Single Lung Transplantation after 24 Hours of Cold Ischemia; B. Gohrbandr,1 M. Avsar,1 G. Warnecke,1 S.P. Sommer,2 A. Haverich,1 M. Strueber,2 1Hannover Medical School, Hannover, Germany; 2University Hospital of Wuerzburg, Wuerzburg, Germany.


(519) Predictors of Complications after Heart Transplantation in Pediatric Patients with Restrictive Cardiomyopathy; T. Shindo, J.C. Alejos, N. Halnon. David Geffen School of Medicine and Mattel Children’s Hospital, UCLA, Los Angeles, CA.

(520) Sudden Cardiac Death (SCD) in Pediatric Patients with Transplant Coronary Artery Disease (TCAD): Does Intravascular Ultrasound have a Role in Early Diagnosis of TCAD and Prevention of SCD in These Patients?; D.P. Bhat,2 C. Nasman,1 S. Worley,1 G.J. Boyle.1 Cleveland Clinic Children’s Hospital, Cleveland, OH; 2Metrohealth Medical Center, Cleveland, OH.
(521) **Evaluation of Safety and Efficacy of Exercise Stress Echocardiography To Screen for Coronary Allograft Vasculopathy in Pediatric Heart Transplant Recipients;** M.H. Chen, F.I. Lunze, T.P. Singh, L. Berghersen, L. Smoot, C.S. Almond, K. Gauvreau, T. Geva, S.D. Colan, K.E. Hall, E.D. Blume. Children's Hospital Boston, Boston, MA; Children's Hospital Boston, Boston, MA; Children's Hospital Boston, Boston, MA; Children's Hospital Boston, Boston, MA; Children's Hospital Boston, Boston, MA; Children's Hospital Boston, Boston, MA; Children's Hospital Boston, Boston, MA; Children's Hospital Boston, Boston, MA.

(522) **Pediatric Heart Transplant Recipients with Transplant Coronary Artery Disease Show a Show Increase in Filling Pressures over Time;** C. Tissot, B.A. Pietra, D.D. Ivy, M.B. Mitchell, D.N. Campbell, D.J. Gilbert, S.D. Miyamoto. The Children's Hospital, Aurora, CO.

(523) **Diagnosis, Treatment and Outcome of Hodgkin Like Post-Transplant Lymphoproliferative Disease after Pediatric Heart Transplantation: A Single Center Experience;** K. Behnke-Hall, H.-J. Wagner, J. Bauer, J. Thul, M. Horn, A. Reiter, D. Schranz. Children's University Hospital, Giessen, Germany.


(525) **Pre-Emptive Treatment for CMV in Paediatric Heart Transplantation- The Newcastle (UK) Experience;** R.K. Samuel. K. Gould. Freeman Hospital, Newcastle upon Tyne, United Kingdom.

(526) **Asymptomatic Rejection Diagnosed by Surveillance Endomyocardial Biopsy in Pediatric Heart Transplant Recipients: Do We Need To Treat?;** C. Tissot, B.A. Pietra, D.D. Ivy, D.N. Campbell, M.B. Mitchell, B.A. Diamond, S.D. Miyamoto. The Children's Hospital, Aurora, CO.

(527) **Daclizumab Is an Efficacious Induction Agent for Highly Sensitized Pediatric Heart Transplant Recipients;** S.R. Auerbach, D.N. Rosenthal, D. Bernstein, C. Chin. Stanford University, Palo Alto, CA.

(528) **The Doppler Derived Myocardial Performance Index (MPI) May Detect Patients with Coronary Allograft Vasculopathy (CAV) in Pediatric Heart Transplant Recipients;** S. Schubert, H.B. Lehmkuhl.

M. Yegitbasi, M. Huebler, N. Hiemann, R. Hetzer, F. Berger, Deutsches Herzzentrum, Berlin, Germany; Deutsches Herzzentrum, Berlin, Germany.

(529) **A Non-Invasive Assessment of Cardiac Output in Pediatric Heart Transplant Patients;** M.L. Likes, J.C. Alejos. Mattel Children's Hospital UCLA, Los Angeles, CA.

(530) **Postoperative Extracorporeal Membrane Oxygenation (ECMO) As a Bridge to Recovery in Infants Immediately after Heart Transplantation (HTX) 1999-2009;** R. Nubani, S. Kaushal, J.G. Gossett, K.L. Matthews, C.L. Backer, D. Wang, E. Pahl. Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago; Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago; Children's Memorial Research Center, Chicago.

(531) **Lobar Versus Conventional Whole Lung Transplantation for Children with Advanced Lung Disease;** K. Monegheetti, D.T. Keating, S. Marasco, J.H. Burton, M. Buckland, B. Levvey, C. Robertson, T.J. Williams, G.I. Snell, G.P. Westall, Alfred Hospital, Melbourne, Vic, Australia; Royal Children's Hospital, Melbourne, Vic, Australia.

(532) **Bilateral Bronchial Anastomosis Versus Tracheal Anastomosis with Bronchial Revascularization in Pediatric Lung Transplantation;** M.G. Schecter, S. Das, E.D. McKenzie, J.S. Heinle, D.L. Morales, G.B. Mallory, O. Elidemir, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX.

(533) **Recovery of Right Heart Function with Temporary Extracorporeal Membrane Oxygenation in Patients with Severe Biventricular Failure;** S. Saito, G. Matsumiya, T. Sakaguchi, S. Miyagawa, Y. Yoshikawa, T. Yamauchi, T. Kuratani, Y. Sawa. Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

(534) **Major Neurological Events after Ventricular Assist Device (VAD) Implantation Are Device Specific but Are Also Related to Pre-Implant Factors;** T. Horai, N.C. Ku, E.A. Genovese, C.A. Bermudez, J.K. Bahma, J.J. Teuteberg, S. Winovich, A. Weimer, G.C. O'Shea, Y. Toyoda, D.M. McNamara, R.L. Kormos, University of Pittsburgh, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA.

(536) Continuous Flow Ventricular Assist Devices Do Not Reverse the Gene Expression Program Typical of Heart Failure; A. Nair,1 A. Anyanwu,1 C. Nwasike,1 S. Pinney,1 E. Adler,2 1Mount Sinai Heart, New York City, NY; 2Oregon Health School of Medicine, New York City, NY.

(537) Creating a Safe and Effective Method for First Responders To Identify Mechanical Circulatory Support Patients in the Community Setting; D. Rivard, T. Elliott, C. Hanny Gilbert, A. Wolfe, T. Van de Bussche. Johns Hopkins Hospital, Baltimore; INOVA Fairfax, Fairfax; Washington Hospital Center, Washington, DC.

(538) Delayed Sternal Closure Following Left Ventricular Assist Device Implantation; Z.A. Hashmi,1 G.B. Pelz,1 R.J. Moraca,1 S. Murali,2 R.L. Benza,2 G.G. Sokos,2 A. Hopwood,1 S. Stutz,1 G.J. Magovern, Jr.,1 S.H. Bailey, D.A. Dean.1 1Allegheny General Hospital, Pittsburgh, PA; 2Allegheny General Hospital, Pittsburgh, PA.

(539) Characterization of Gastrointestinal Bleeding in HeartMate II Left Ventricular Assist Device Patients; N.O. Mason, B.B. Reid, G. Harmstan, J. Jones, S. Stoker, D. Budge, R. Alharethi, G. Thomsen, S.E. Clayson, W. Caine, A.G. Kfouri. Intermountain Medical Center, Salt Lake City, UT.


(541) Cardiac Performance in Patients without Early Native Aortic Valve Opening; O.H. Frazier, S.M. Parnis, R. Stainback, X. Quan, Z.T. Demirouz, W.E. Cohn, I. Gregoric. Texas Heart Institute, Houston, TX.

(542) Effect of Fibrosis at Implantation on Clinical Outcome in Patients with HeartMate II Ventricular Support; A.M. Segura, L.M. Buja, M.A. Elayda, S. Wang, O.H. Frazier. Texas Heart Institute, Houston.

(543) Long Term Outcome of Bridge to Recovery Versus Bridge to Transplantation; E.L. Birks,1 R.S. George,1 M. Noor,1 T. Bahrami,1 M. Amrani,1 J. Pepper,1 G. Dreyfus,1 M. Petrou,1 M.H. Yacoub,2 A. Khaghani,1 1Harefield Hospital, Harefield, Middlesex, United Kingdom; 2Harefield Hospital, Harefield, Middlesex, United Kingdom.


(545) Continuous Flow-Type VADs Induce Lower Levels of Unloading but Exert Similar Effects on Cellular Remodeling Compared to Pulsatile-Type VADs; L.J. Garcia, A.R. Trevino, K.A. Youker, B.A. Bruckner, M. Loeb, J.E. Estep, C. Orrego, G. Torremi. The Methodist Hospital, Houston, TX.

(546) Localization and Distribution of Micro-RNAs in the Myocardium of Heart Failure Patients before and after LVAD Support; J. Van Kuik, S. Lok, M.E.I. Schipper, H. Dullens, L. De Windt, P.A. Da Costa Martins, N. De Jonge, R.A. de Weger.1 University Medical Center Utrecht, Utrecht, Netherlands; 2University Medical Center Utrecht, Utrecht, Netherlands; 3Cardiovascular Research Institute Maastricht, Maastricht, Netherlands.

(547) Impact of Acute Renal Failure on Survival after HM II LVAD Implantation; J.A. Morgan,1 R.J. Brewer,1 H.W. Nemeh,1 S.E. Henry,1 J. Borgi,1 B. Czerska,2 C.T. Williams,2 D.E. Lanfear,2 C. Tita,2 C. Drost,2 C. Smith,1 J. Chernich,2 H.N. Sabbah,2 G. Paone.1 1Henry Ford Health System, Detroit, MI; 2Henry Ford Health System, Detroit, MI.

(548) Ventricular Assist Devices Rescue Patients in Cardiogenic Shock without Adversely Impacting the Complexity of Subsequent Heart Transplantation; P. Atluri,1 J.L. Howard,1 E.D. Kozin,1 B.W. Ullery,1 W. Hiesinger,1 J.R. Fitzpatrick,1 M. Jessup,2 M.A. Acker,1 R.J. Morris,1 Y.J. Woo.1 1University of Pennsylvania, Philadelphia, PA; 2University of Pennsylvania, Philadelphia, PA.

(549) Additional Procedure to Aortic Valve at LVAD Placement; A. Goda,1 H. Takayama,2 S.-W. Pak,2 U. Jorde,1 D. Mancini,1 Y. Naka,2 1Columbia University, New York, NY; 2Columbia University, New York, NY.

(550) Early Severe Post Operative Liver Dysfunction after Heartmate II® LVAD Placement: Incidence, Risk Factors, and Outcomes; E.A. Ziembba,1 J.M. Aho,1 K. Liao,1 M.A. Kuskowski,1 M.M. Colvin-Adams,1 P. Echman,2 M.R. Pritzker,2 R. John.1 1University of Minnesota, Minneapolis, MN; 2University of Minnesota, Minneapolis, MN; 3University of Minnesota, Minneapolis, MN; 4University of Pennsylvania, Minneapolis, MN; 5VA Medical Center, Minneapolis, MN; 6Chicago Medical School, Chicago, IL; 7VA Medical Center, Minneapolis, MN.

(551) Percutaneous LVAD Support in Refractory Cardiogenic Shock Rapidly and Disparately Modulates Serum Biomarkers of Apoptosis, Neurobormonal Activation, Inflammation, and Extracellular Matrix Remodeling; N.R. Shah,1 M.C. Bieniarz,1 P. Loyalka2 D.L. Mann,3 B. Kar.1,2 1Baylor College of Medicine, Houston, TX; 2Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX; 3Washington University School of Medicine, St. Louis, MO.
(552) **Use of Extracorporeal Membrane Oxygenation (ECMO) in Patients with Chronic Cardiomyopathy: A Word of Caution;** C. Bermudez,1 Y. Toyoda,1 F. Avila,1 S. Mulukutla,2 O. Marroquin,1 J. Teuteberg,2 R. Kormos.1 1University of Pittsburgh Medical Center, Pittsburgh; 2University of Pittsburgh Medical Center, Pittsburgh.

(553) **LVAD Support Results in a Significant Improvement in the Myocardial Sympathetic Nervous System, as Assessed by 123I-Metaiodobenzylguanidine (123I-MIBG), Independent of Ventricular Function:** R.S. George,1,2 M.H. Yacoub,2 A. Cheetham,3 A. Khaghani,1 E.J. Birks.1,2 1Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; 2Imperial College, Harefield, Middlesex, United Kingdom; 3Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

(554) **A Safe and a Cost-Effective Approach for Managing Patients with Levitronix CentriMag® Short Term Devices;** A. Firouzi,1 R.S. George,1 K. Absalom,1 S.M. Panther,1 H. Doyle,1 A. Bashford,2 C. Bindoff,3 A. Khaghani,1 E.J. Birks.1 1Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; 2Imperial College, Harefield, Middlesex, United Kingdom; 3Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

(555) **DNA-Methylation of the Human b1-Adrenergic Receptor Core Promoter Pre and Post VAD-Support and Its Putative Role for Gene Silencing in the Terminal Failing Myocardium;** A. Kassner,1 B. Bohms,1 M. Morshuis,2 S. Schulte-Eistrup,2 J. Gummert,2 H. Milting.1,2 1Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; 2Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany.

(556) **The SWAT Team Approach for Treating the Unstable Patient in Acute Cardiopulmonary Shock;** D. Jaroszewski,1 C. Pierce,1 R. Scott,2 E. Steidley,2 R. Gopalak,2 P. DeValeria,1 L. Lanza,1 F. Arabia.1 1Mayo Clinic, Phoenix, AZ; 2Mayo Clinic, Phoenix, AZ.

(557) **Improved Right Heart Function Secondary to Favorable Loading Conditions after Axial Flow Left Ventricular Assist Device Implantation;** R. Rasalingam,1 K.R. Bilhorn,3 S.N. Johnson,3 C.B. Kapa- dia,1 M. Makan,1 J.E. Perez,1 N. Moazami.1 1Washington University in St Louis, St. Louis, MO; 2Washington University in St Louis, St. Louis, MO; 3Barnes Jewish Hospital, St. Louis, MO.

(558) **The Effect of Continuous, Nonpulsatile Flow on Renal Function in Patients Supported by the HeartMate II Left Ventricular Assist Device;** Z.T. Demirozu, R. Radovancevic, O.H. Frazier. Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX.
**General Poster Session**

(566) Improved Outcomes after Ventricular Assist Device Implantation in Patients Requiring Intra-Aortic Balloon Pump; S. Osaki,1 N.M. Edwards,1 M.R. Johnson,2 M.A. Murray,1 A.K. Proebstle,1 L. Lozonschi,1 T. Kohmoto,1 1University of Wisconsin School of Medicine and Public Health, Madison, WI; 2University of Wisconsin School of Medicine and Public Health, Madison, WI.

(567) Single-Center Experience Using the Heartmate II Left Ventricular Assist Device as a Bridge to Decision; M. Toma,1 G.V. Gonzalez-Stawinski,2 D. Schmuhl,1 N.G. Smedira,3 R.C. Starling,1 M.M. Mounts.1 1The Cleveland Clinic Foundation, Cleveland, OH; 2The Cleveland Clinic Foundation, Cleveland, OH.


(570) Safety of EBV-DNA-Load Guided Pre-Emptive Reduction of Immunosuppression To Prevent PTLD; E.A. Verschuuren,1 M.E. Erasmus,2 B.L. Rottier,3 G.D. Nosent,1 W. van der Bij,1 1University Medical Centre Groningen, Groningen, Netherlands; 2University Medical Centre Groningen, Groningen, Netherlands; 3University Medical Centre Groningen, Groningen, Netherlands.

(571) Activity of Colistin Against Filamentous Fungi Isolated from Lung Transplant Recipients; G. Short,1 C. Rennison,1 K. Gould,1 A. Fisher.1 1Freeman Hospital, Newcastle upon Tyne, United Kingdom; 2Freeman Hospital, Newcastle upon Tyne, United Kingdom.


(573) Is Targeted Antifungal Prophylaxis Effective in Lung Transplants? S.M. Hosseini,1 L. Singer,1 C. Chapparo,2 M. Hutcheon,2 C. Rotstein,1 S. Keshavjee,1 S. Husain,1 1University Health Network, Toronto, ON, Canada; 2University Health Network, Toronto, ON, Canada.
## Exibiting Companies

<table>
<thead>
<tr>
<th>Alphabetical List of Exhibitors</th>
<th>Booth Numbers</th>
<th>Alphabetical List of Exhibitors</th>
<th>Booth Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abiomed Inc.</td>
<td>523</td>
<td>Lippincott, Williams &amp; Wilkins</td>
<td>322</td>
</tr>
<tr>
<td>Actelion Pharmaceuticals US, Inc.</td>
<td>316</td>
<td>Miller Pharmacal Group, Inc.</td>
<td>602</td>
</tr>
<tr>
<td>Argon Medical Devices, Inc.</td>
<td>218</td>
<td>Novartis Pharma AG</td>
<td>310</td>
</tr>
<tr>
<td>Astellas Pharma US</td>
<td>512</td>
<td>One Lambda, Inc.</td>
<td>612</td>
</tr>
<tr>
<td>Avalon Laboratories, LLC</td>
<td>317</td>
<td>Pulmonary Hypertension</td>
<td>222</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Association</td>
<td></td>
</tr>
<tr>
<td>Berlin Heart GmbH</td>
<td>304 &amp; 306</td>
<td>Quality Assured Services, Inc.</td>
<td>305</td>
</tr>
<tr>
<td>CardiacAssist, Inc.</td>
<td>421</td>
<td>Scanlan International, Inc.</td>
<td>606</td>
</tr>
<tr>
<td>Circulite, Inc.</td>
<td>610</td>
<td>Scholten Surgical Instruments, Inc.</td>
<td>221</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>604</td>
<td>SynCardia Systems, Inc.</td>
<td>405</td>
</tr>
<tr>
<td>Cylex Inc.</td>
<td>215</td>
<td>Terumo Heart, Inc.</td>
<td>204</td>
</tr>
<tr>
<td>Elsevier, Inc.</td>
<td>205</td>
<td>The Apothecary Shops</td>
<td>216</td>
</tr>
<tr>
<td>Essential Pharmaceuticals</td>
<td>323</td>
<td>Thoratec Corporation</td>
<td>407</td>
</tr>
<tr>
<td>Evaheart Medical</td>
<td>423</td>
<td>United Network for Organ Sharing</td>
<td>223</td>
</tr>
<tr>
<td>Genentech</td>
<td>313</td>
<td>United Therapeutics/Lung Rx</td>
<td>212</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>404</td>
<td>Vital Engineering</td>
<td>206</td>
</tr>
<tr>
<td>Heartware, Inc.</td>
<td>219</td>
<td>World Heart Corporation</td>
<td>321</td>
</tr>
<tr>
<td>ISHLT</td>
<td>613</td>
<td>XDX</td>
<td>502</td>
</tr>
<tr>
<td>ISHLT Registry</td>
<td>520</td>
<td>XVIVO Perfusion AB</td>
<td>307</td>
</tr>
<tr>
<td>Jarvik Heart, Inc.</td>
<td>319</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levitonix, LLC</td>
<td>522</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EXHIBITORS AND PRODUCT DESCRIPTIONS

Abiomed, Inc.
22 Cherry Hill Drive
Danvers, Massachusetts 01923
www.abiomed.com

Booth Number: 523
Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. Abiomed’s product portfolio stands from the surgical suite to the catheterization lab including the Impella® platform, Impella® 2.5, Impella® 5.0 and Impella® LD, AB5000™, BVS®5000 and the Abiocor, the world’s first completely self-contained replacement heart.

Actelion Pharmaceuticals US, Inc.
5000 Shoreline Court, Suite 200
So. San Francisco, California 94080
www.actelionus.com

Booth Number: 316
Actelion Pharmaceuticals is a biopharmaceutical company focusing on the discovery, development and commercialization of innovative treatments to serve unmet medical needs. Actelion is committed to research in cardiopulmonary disease, sleep disorders and immunology.

Argon Medical Devices, Inc. (USA)
1445 Flat Creek Road
Athens, Texas 75782
www.argonmedical.com

Booth Number: 218
Argon Medical Devices, Inc. manufacturer of Jawz™ Endomyocardial Biopsy Forceps and a full line of vascular access products including introducers, guide wires, thermodilution catheters and many kits specific to needs of cardiac transplantation centers. Ask about Argon’s line of Micro-Introducer kits for Biopsy IJ/Femoral access.

Astellas Pharma US, Inc.
Three Parkway North
Deerfield, Illinois 60015
www.us.astellas.com

Booth Number: 512
Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In the US, Astellas has an intense focus on six key therapeutic areas – Cardiology, Dermatology, Infectious Disease, Neuroscience, Transplant and Urology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate. For more information about Astellas Pharma US, Inc., please visit our web site at www.us.astellas.com

Avalon Laboratories, LLC
301 Michigan St. NE, Ste. 500
Grand Rapids, Michigan 49503
www.avalonlabs.com

Booth Number: 317
Avalon Laboratories is a leading manufacturer of wire-reinforced cardiopulmonary vascular cannula. Avalon Elite® is the company’s premium line of proprietary catheters providing new and unique solutions for patients receiving extracorporeal support. The Avalon Elite Bi-Caval Dual Lumen Catheter (DLC) is indicated for use as a single catheter for simultaneous venous drainage and reinfusion of blood via the internal jugular vein. With a wide range of sizes, the DLC is the world’s first wire-reinforced, veno-venous catheter available for both pediatrics and adults. The Avalon Elite line also features the high performing Multi-Port Venous Femoral Catheter and a Vascular Access Kit.
Berlin Heart
Wiesenweg 10
Berlin, Germany 12247
www.berlinheart.com

**Booth Number: 304 & 306**

Berlin Heart is the only company worldwide that develops, manufactures and distributes implantable and paracorporeal ventricular assist devices for patients for every age and body size.

EXCOR® is a paracorporeal pulsatile VAD for uni- or biventricular support in newborns, children, adolescents and adults. EXCOR® Pediatric is leading the worldwide market of pediatric VADs.

INCOR® is an implantable axial-flow LVAD for adults.

INCOR® is the only 3rd generation axial flow pump with CE-mark Approval.

INCOR® is not FDA approved. EXCOR® is approved for clinical investigation in pediatric patients in USA.

CSL Behring
1020 First Ave.
King of Prussia, Pennsylvania 19406
www.cslbehring-us.com

**Booth Number: 604**

CSL Behring is a global leader in the plasma protein biotherapeutics industry. CSL Behring manufacture and markets a range of safe and effective plasma-derived and recombinant products and related services.

The company’s products are used for organ transplantation, inherited emphysema, in the prevention of hemolytic diseases in the newborn, in cardiac surgery and in the treatment of burns and shock. Additional therapies are used in the treatment of hemophilia, von Willebrand disease, other bleeding disorders and immune deficiency disorders.

CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring-us.com.

Cylex, Inc.
8980 I Old Annapolis Road
Columbia, Maryland 21045
www.cylex.net

**Booth Number: 215**

Cylex is a global life sciences company focused on the development, manufacture and commercialization of In Vitro diagnostic products intended to illuminate immunity in the area of transplant medicine. The company has developed patented technology that provides an innovative platform to simply and reproducibly assess immune cell function, thus providing crucial insight for individualized transplant patient management. ImmuKnow®, the Company’s first FDA-cleared product, is used to effectively manage and optimize immunosuppression in organ transplant patients.

CircuLite, Inc.
250 Pehle Ave, Suite 403
Park 80 West
Saddle Brook, New Jersey 07663
www.circulite.net

**Booth Number: 610**

CircuLite is a cardiovascular device company that is transforming heart failure treatment with the development of minimally-invasive devices for long-term partial circulatory support (PCS). By enabling a proactive and lower-risk treatment approach by supplementing a patient’s native pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients and their families. CircuLite’s pipeline of PCS devices is lead by the Synergy® Pocket Micro-Pump, the world’s smallest implantable blood pump, currently in a CE Mark clinical trial. Next-generation Synergy micro-pumps include an endovascular system, a fully-implantable system and a pediatric system.
Genentech
1 DNA Way
South San Francisco  California, 94080
www.gene.com

Booth Number: 313
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a wholly owned member of the Roche Group, has headquarters in South San Francisco, California.

For additional information about the company, please visit http://www.gene.com.

Please visit our exhibit to learn more about CellCept, Valcyte and our ongoing commitment to transplantation.

Essential Pharmaceuticals
770 Newtown Yardley Road, Suite 212
Newtown, Pennsylvania  18940
www.essentialpharma.com
www.custodiol.com

Booth Number: 323
Essential Pharmaceuticals, LLC. is a specialty pharmaceutical company devoted solely to the development and sales of exclusive branded pharmaceutical products including Custodiol® HTK organ preservation solution. Custodiol® HTK, with its easy handling characteristics, water like viscosity and no need for additives or filters make it a preferred solution for many transplant centers.

Evaheart Medical USA, Inc.
880 William Pitt Way
Pittsburgh, Pennsylvania  15238
Web address: www.evaheart-usa.com

Booth Number: 423
The EVAHEART Left Ventricular Assist System (LVAS) is an implantable centrifugal Blood Pump designed to generate flow and pressure in cardiac transplant candidates with advanced heart failure and compromised left ventricular function. The Blood Pump contains a unique impeller fixed to a rotating shaft within a journal bearing and a mechanical seal, and a recirculating flushing system to reduce friction and extend the life of the pump. The current average duration of patient support in the Japanese trial is over 805 days. The EVAHEART LVAS is embarking on a bridge-to-transplant clinical trial in the United States.

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, California  94404
www.gilead.com

Booth Number: 404
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Heartware, Inc.
205 Newbury St.
Framingham, Massachusetts  07701
www.heartwareinc.com

Booth Number: 219
HeartWare, Inc. is developing a family of implantable mechanical circulatory support systems for the treatment of advanced heart failure. Through a cadence of progressively smaller devices implanted using less invasive techniques, HeartWare expects to treat an increasing proportion of heart failure patients and to access them at an earlier stage of their disease progression. HeartWare’s lead device, the HeartWare® Ventricular Assist System, incorporates state-of-the-art peripherals and features the only full-output pump designed to be implanted less invasively in the pericardial space. The HeartWare® System has CE-Mark approval and is currently the subject of a 150-patient US IDE clinical trial.
ISHLT Thoracic Transplant Registry  
700 North 4th Street  
Richmond, Virginia  23219  
Website: www.help@ishlt.org

Booth Number: 520  
The ISHLT International Registry for Heart and Lung Transplantation was created to collect on-going, current information on the worldwide thoracic organ transplantation experience. Our registry is the only one of its kind. The data we maintain is utilized for scientific study and contributes to the body of knowledge regarding thoracic transplantation. Our goal is to identify overall and best practices for improving cardiothoracic patient care.  
This year the exhibit will make center-specific information available for review by ISHLT clients. In addition, clients can view data screens and receive guidance on participation in our registry, submission of data and special data request services.

Jarvik Heart, Inc.  
333 West 52nd Street  
New York, New York  10019-6238  
www.jarvikheart.com

Booth Number: 319  
Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure.

Levitronix  
45 1st Avenue  
Waltham, Massachusetts  02451  
www.levitronix.com

Booth Number: 522  
Levitronix designed, developed and produces the CentriMag, PediMag and PediVAS circulatory support devices. In the United States, the CentriMag pump is approved for up to 30 days of use for patients requiring right ventricular support, and is undergoing clinical trials to treat patients in cardiogenic shock as a bridge to decision. The PediVAS is optimized to provide circulatory support for neonatal and pediatric patients, and is currently only available outside the United States. The PediMag pump is available in the United States for use in a cardiopulmonary circuit for up to 6 hours. CentriMag and PediVAS systems are both CE Mark approved for use for up to 30 days for use as a VAD or for ECMO.

Lippincott, Williams & Wilkins  
1578 Fordham St.  
Bolingbrook, Illinois  60490  
www.lww.com

Booth Number: 322  
Lippincott, Williams & Wilkins will have on display the latest textbooks, electronic media and journal publications in the fields of transplantation as well as general surgery.

Miller Pharmacal Group, Inc  
350 Randy Road, Ste #2  
Carol Stream, Illinois  60188  
www.mgplusprotein.com

Booth Number: 602  
“MG Plus Protein” is used at many transplant programs for the treatment and prevention of the hypomagnesemia caused by immunosuppressants, without causing the GI disturbances common with magnesium oxide. “MG Plus Protein” is: Well-tolerated, effective and inexpensive.

Novartis Pharma AG  
Postfach  
Basel, CH-4002  
Switzerland  
www.novartis.com

Booth Number: 310  
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group’s continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Scanlan International, Inc.
One Scanlan Plaza
Saint Paul, Minnesota  55107
www.scanlaninternational.com

**Booth Number: 606**

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, full line of VATS/MICS Thoracoscopic instruments including the Chitwood Clamp and Knot Pusher, D’Amico and Wolf Suction instruments, D’Amico and Harkin Clamps; SCANLAN® Super Cut™ Scissors and Rendina needle holder. Single-use products include: VASCU-STAT™ bulldog clamps, SCANLAN® Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument design modifications to meet your individual needs.

Pulmonary Hypertension Association
801 Roeder Road
Silver Spring, Maryland  20910
www.PHASassociation.org
www.PHAOnlineUniv.org

**Booth Number: 222**

Pulmonary Hypertension (PH) is an underdiagnosed illness that affects people of all ages and backgrounds. PHA is the voice of the medical community, patients and family members united against this illness. Visit PHA’s booth for complimentary information on PH, including PHA’s medical journal, Advances in Pulmonary Hypertension and a variety of educational tools like our Diagnosis CD-ROM and Cases DVD.

Scholten Surgical Instruments, Inc.
170 Commerce St, #101
Lodi, California  95240
www.bioptome.com

**Booth Number: 221**

Scholten Surgical Instruments is excited to be exhibiting here in Chicago at this year’s 30th Annual ISHLT meeting, debuting for the first time in the U.S. our new Novatome™ single-use endomyocardial biopsy forcep. In the tradition of the Scholten Bioptome trusted for its uncompromising quality and reliability the single-use Novatome™ is specially designed to acquire maximum sample size with the same precise feel, ease of placement and superior cutting force, expected from Scholten Products. Our biopsy forceps have been proven by over 30 years of successful clinical experience, and we are excited to continue setting the standard worldwide.

Quality Assured Services, Inc.
30 Keller Road
Ste. 100B
Orlando, Florida  32810
www.qualityassuredservices.com

**Booth Number: 305**

QAS is the only company in the US providing services to outpatients in both equipment and dressing supplies for a ventricular assist device and for patient self-testing of INR.
Booth Number: 405

The SynCardia temporary Total Artificial Heart (TAH-t) is the only FDA, Health Canada and CE approved device that provides circulatory restoration in morbidly ill patients with irreversible bi-ventricular failure, providing a life-saving bridge until a donor human heart becomes available. In 2006, the EXCOR® TAH-t mobile driver was granted a CE mark, enabling European hospitals to discharge stable TAH-t patients to return home while they are awaiting a transplant. Visit our booth for updates on upcoming clinical studies for the Freedom™ driver, the 50cc TAH-t and the pediatric VAD.

Booth Number: 407

With more than 14,000 patient implants and three decades of experience, Thoratec® Corporation offers the broadest portfolio of mechanical circulatory support devices. Thoratec’s product line includes the CentriMag® Acute Circulatory Support Device, HeartMate® LVAS, Thoratec PVAD™ and IVAD™. Now the HeartMate II® is FDA approved for both Bridge to Transplantation and Destination Therapy.

United Network for Organ Sharing (UNOS)

United Network for Organ Sharing (UNOS) is a 501(c) 3 not-for-profit, scientific, educational and charitable Richmond-based Virginia membership corporation that manages the national Organ Procurement and Transplantation Network. Its mission is to advance organ availability and transplantation by uniting and supporting its communities for the benefit of patients through education, technology and policy development. UNOS also plays a major role in the ongoing development and operation of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Through its subsidiary, Tii Informatix Group specializes in the design and operation of clinical registries in transplantation, Mechanical Circulatory Support and immunosuppressive therapies. Tii developed and has operated the ISHLT Thoracic Registry since 2001.

Booth Number: 223

UNOS is a 501(c) 3 not-for-profit, scientific, educational and charitable Richmond-based Virginia membership corporation that manages the national Organ Procurement and Transplantation Network. Its mission is to advance organ availability and transplantation by uniting and supporting its communities for the benefit of patients through education, technology and policy development. UNOS also plays a major role in the ongoing development and operation of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Through its subsidiary, Tii Informatix Group specializes in the design and operation of clinical registries in transplantation, Mechanical Circulatory Support and immunosuppressive therapies. Tii developed and has operated the ISHLT Thoracic Registry since 2001.

Booth Number: 212

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Lung Rx LLC, a wholly-owned subsidiary of United Therapeutics Corporation, is a biotechnology company focused on unmet medical needs in pulmonary medicine and pulmonary delivery of innovative therapeutic products.
Booth Number: 206

Vital Engineering provides training and educational programs for physicians and other health care providers as well as on-site training and technical support prior to, during and following device implantation. Vital Engineering has the knowledge and resources to improve patient care from surgery through discharge planning and outpatient care. Our clinical experience equips the artificial organ industry with the ultimate product quality improvement from emerging to experienced companies. Vital Engineering offers many partnership benefits to patients, clinicians, hospitals and industry.

Booth Number: 307

XVIVO Perfusion AB (Part of the Vitrolife Group) manufactures and markets solutions and equipment for transplantation and thoracic surgery, designed to preserve organs and tissues prior to transplantation. Our main two solutions are Perfadex® for hypothermic flushing and transportation of transplant lungs and STEEN Solution™ for normothermic ex vivo evaluation (approved in US for research purposes only).

XVIVO aims to:

- minimize ischemic reperfusion injuries by improving the solutions used for extra corporeal preservation of organs and tissues.
- extend the safe extra corporeal preservation time for organs and tissues prior to transplantation.
- increase the organ availability and transplantation success rates by introduction of new transplantation concepts and techniques.

Booth Number: 321

WorldHeart’s focus is to develop the innovative rotary Levacor™ VAD based on proprietary maglev technology. The IDE application for the Levacor VAD to start a pivotal BTT trial in the USA was unconditionally approved by the FDA in January 2010, and two implants followed shortly thereafter.

The Levacor VAD builds on a quarter-century of support provided by the long-term implantable pulsatile Novacor® LVAS to more than 1,800 patients worldwide with life-threatening heart failure. Utilizing its maglev technology platform, WorldHeart is also developing a miniaturized, partial-support MiVAD™ for less-sick heart failure adults, and a PediaFlow™ VAD for neonates and infants.

Booth Number: 502

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to aid in the management of heart transplant patients.
Working Together to Enhance Patient Care

We are pleased to bring you the Transplant Experience program. Transplant Experience works to provide essential education, valuable advice, and support materials throughout the transplant process.

- Materials designed to meet your patients’ specific needs
- Motivational messages extend the support reach beyond the transplant center
- Ongoing communications create dialogue about long-term health
- Welcome kit gets patients immediately involved in helping to manage their health—including a treatment journal, a pill box, and an informational and inspirational video
- Award-winning website offers patients an instant connection to transplant information, education, resources, and more

Join today to begin receiving sample materials to share with your patients.

Call 1-877-382-7627 or visit www.TransplantExperience.com.